EULAR Online Courses

NEW EULAR Online Course on Systemic Lupus Erythematosus
2nd EULAR Online Course on Imaging in RMDs
4th EULAR Online Course for Health Professionals
5th EULAR Online Course in Paediatric Rheumatology
7th EULAR Online Introductory Ultrasound Course
8th EULAR Online Course on Systemic Sclerosis
10th EULAR Online Course on Connective Tissue Diseases
13th EULAR Online Course on Rheumatic Diseases

Individual course cost: EUR 150; reduced prices available for EULAR School of Rheumatology members and low, middle income countries.

esor.eular.org
# TABLE OF CONTENTS

_All information listed in this programme is at the status of 1 May 2019_

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Welcome Message</td>
<td>2</td>
</tr>
<tr>
<td>Organising Committees</td>
<td>5</td>
</tr>
<tr>
<td><strong>GENERAL INFORMATION</strong></td>
<td>7</td>
</tr>
<tr>
<td>Information about your participation</td>
<td>7</td>
</tr>
<tr>
<td>EULAR Corporate Social Responsibility Statement</td>
<td>10</td>
</tr>
<tr>
<td>Networking opportunities</td>
<td>10</td>
</tr>
<tr>
<td>Scientific information</td>
<td>11</td>
</tr>
<tr>
<td>Information on industry related activities</td>
<td>11</td>
</tr>
<tr>
<td><strong>SCIENTIFIC PROGRAMME</strong></td>
<td>15</td>
</tr>
<tr>
<td>Congress at a Glance:</td>
<td>15</td>
</tr>
<tr>
<td>Wednesday, 12 June 2019</td>
<td>21</td>
</tr>
<tr>
<td>Scientific Programme</td>
<td>21</td>
</tr>
<tr>
<td>Thursday, 13 June 2019</td>
<td>35</td>
</tr>
<tr>
<td>Scientific Programme</td>
<td>35</td>
</tr>
<tr>
<td>Friday, 14 June 2019</td>
<td>55</td>
</tr>
<tr>
<td>Scientific Programme</td>
<td>55</td>
</tr>
<tr>
<td>Saturday, 15 June 2019</td>
<td>74</td>
</tr>
<tr>
<td>Scientific Programme</td>
<td>74</td>
</tr>
<tr>
<td><strong>PAEDIATRIC RHEUMATOLOGY (PReS)</strong></td>
<td>83</td>
</tr>
<tr>
<td>Programme</td>
<td>83</td>
</tr>
<tr>
<td><strong>HEALTH PROFESSIONALS IN RHEUMATOLOGY (HPR)</strong></td>
<td>88</td>
</tr>
<tr>
<td>Programme</td>
<td>88</td>
</tr>
<tr>
<td><strong>PARE</strong></td>
<td>94</td>
</tr>
<tr>
<td>Programme</td>
<td>94</td>
</tr>
<tr>
<td><strong>EULAR</strong></td>
<td>100</td>
</tr>
<tr>
<td>Related Meetings</td>
<td>100</td>
</tr>
<tr>
<td><strong>PARTNER PROGRAMME</strong></td>
<td>102</td>
</tr>
<tr>
<td>Company Profiles</td>
<td>102</td>
</tr>
<tr>
<td>Acknowledgements</td>
<td>117</td>
</tr>
<tr>
<td>Exhibitors’ List</td>
<td>118</td>
</tr>
<tr>
<td>Exhibition Plan</td>
<td>119</td>
</tr>
<tr>
<td>Congress Venue Overview Plan</td>
<td>120</td>
</tr>
</tbody>
</table>

The acronym ‘PARE’ used in the programme stands for ‘People with Arthritis/Rheumatism in Europe’

The acronym ‘HPR’ used in the programme stands for ‘Health Professionals in Rheumatology’

The acronym ‘PReS’ used in the programme stands for ‘Paediatric Rheumatology European Society’
Dear Colleagues,

Welcome to the Annual Scientific Congress of EULAR in Madrid. The EULAR Congresses comprise the major event in the calendar of world rheumatology. Madrid 2019 will again provide an unique event for the exchange of scientific, clinical and patient focussed information on a global basis. This year we celebrate our close cooperation with paediatric colleagues and our congress is jointly organised with the paediatric rheumatology society (PReS).

We will offer a platform to facilitate interaction between physicians, scientists, patients of all ages and their families, health professionals and professionals representing the pharmaceutical industry, from across Europe and around the world. Moreover, we will proudly disseminate the latest progress in our exciting and increasingly diverse array of EULAR and PReS supported activities, all focussed on improving the well-being of people with, or affected by, rheumatic musculoskeletal diseases.

EULAR Congresses arouse tremendous interest in terms of participation reflected by the remarkable quality of contributions. Possibilities for new treatments as well as the impact, burden and cost of rheumatic and musculoskeletal diseases for the individual and society are our focus. This year’s EULAR Congress will address once again a wide range of topics including innovation in population, health service, clinical, translational and basic science. Sessions dedicated to People with Arthritis and Rheumatism in Europe (PARE), Health Professionals in Rheumatology (HPR) will feature prominently! High quality health care industry sessions providing in-depth and focussed insights will again be offered.

Our poster presentations and poster tours will offer a highly interactive exchange of knowledge and solutions amongst participants. Our programme increasingly reflects the participation of the EULAR EMEUNET organisation of young rheumatologists that continues to attract young colleagues to the meeting and thus offers an exciting vision for our discipline. Finally, the unique opportunity to create our congress together with PReS, enabling interaction and stimulation of both fields is especially stimulating. Paediatric rheumatology encompasses many fascinating recently-recognised auto-inflammatory diseases that directly inform (adult) rheumatologists. Mutual knowledge exchange is assured and will be of undoubted benefit to all!

We are very happy to visit the City of Madrid again. In recent years, we have enjoyed this vibrant city with its remarkable history, architecture, galleries, museums (consider the breathtaking Prado, Museo Nacional Centro de Arte Reina Sofia and Museo Thyssen-Bornemisza), ambience (Plaza de Cibeles, Puerta del Sol, Plaza Mayor) and delicious food, all of which will once again provide an excellent background for clinical exchanges, international collaborations and renewal of friendships. We will take great pleasure in welcoming physicians, including our paediatric colleagues, patients, their families, health professionals and representatives of the pharmaceutical industry to EULAR 2019, and hope that your stay in Madrid will be informative, educational and thoroughly enjoyable.

Johannes W. J. Bijlsma
EULAR President
It is with the greatest pleasure that I invite you to join us at the upcoming joint EULAR/ PReS European League Against Rheumatism (EULAR) / Paediatric Rheumatology European Society (PReS) meeting in Madrid; this is a special moment for paediatric rheumatology.

In Lisbon in 2018 we celebrated the 25th PReS conference and launched a new mission and strategic programme: PReS 2025. Together, we, healthcare professionals, scientists, patient and parent groups, took a commitment to the following common goal: To advance the care and improve the health and wellbeing of children and young people with rheumatic conditions.

We are not alone in this commitment. Through the years, EULAR has been our natural partner, and for a good reason: Our patients also need the best possible care after their 18th birthday. Our efforts today are intended to offer our patients the very best chance to follow their dreams and aspirations tomorrow – and beyond. To achieve our common objective, our adult colleagues are our strongest allies. Since the first PReS congress took place 25 years ago, EULAR PReS has held joint conferences to share and exchange knowledge. Because of the importance of our alliance, this year EULAR and the PReS council have decided to take the joint congress to a next level: This year, we will build a truly integrated programme. It will be the opportunity to say goodbye to the old and welcome the new: Paediatric rheumatology will be visible and integrated throughout the full EULAR Congress programme. ENCA (European Network for Children with Arthritis) and PARE (People with Arthritis / Rheumatism in Europe) as well as Young PARE; Emeunet (EMerging EULAR NETwork) and Emerge (EMErging RheumatoloGists and rEsearchers) and scientists and health professionals from both EULAR and PReS – we all will be meeting and working together with a simple common goal: To make a difference to our patients.

This offers exceptional possibilities for our visitors, for together, EULAR/PReS is stronger. We can learn from each other and get inspired by new perspectives offered by our colleagues.

All this in the magical city of Madrid: The city of Velazquez, Cervantes and Lorca. Madrid, the city of a brand-new and inspirational EULAR/PReS 2019 Congress. I am looking forward to welcoming you to Madrid.

Berent J. Prakken
PReS President

Michael Beresford
Chair of the PReS scientific committee
The EULAR Strategic Objectives 2018 – 2023

**QOC**

By 2023, EULAR will deliver pre-eminent comprehensive quality of care (QOC) frameworks for the management of people with RMDs.

**ESOR**

By 2023, EULAR will be the leading provider of education in rheumatic and musculoskeletal diseases (RMDs).

**CONGRESS**

By 2023, EULAR will provide the foremost RMD congress experience, building on the heritage of our outstanding annual meeting.

**ADVOCACY**

By 2023, EULAR’s activities and related advocacy will have increased participation in work by people with RMDs.

**GOVERNANCE, INFRASTRUCTURE, FINANCIALS**

By 2023, EULAR will have established governance, workflows and infrastructure to deliver the EULAR strategic objectives.

**RESEARCH**

By 2023, EULAR will have established a European centre for RMD research to advance high quality collaborative research.
ORGANISING COMMITTEES

EULAR EXECUTIVE COMMITTEE
President
Prof. Johannes W. J. Bijlsma, Netherlands
President-Elect
Prof. Iain B. McInnes, United Kingdom
Past President
Prof. Gerd R. Burmester, Germany
Vice-President representing national PARE organisations
Mr. Dieter Wiek, Germany
Vice-President representing the Health Professionals in Rheumatology
Prof. Tanja Stamm, Austria
Treasurer
Prof. Annamaria Iagnocco, Italy
General Secretary
Prof. Ruxandra Ionescu, Romania
Editor in Chief of the ‘Annals of the Rheumatic Diseases – The EULAR Journal’
Prof. Josef Smolen, Austria
Editor in Chief of ‘RMD Open’
Prof. Bernard Combe, France
Liaison to EMEUNET
Dr. Alessia Alunno, Italy
* Liaison to the American College of Rheumatology ACR
Prof. Désirée van der Heijde, Netherlands
* Liaison Officer, EU Public Affairs
Mr. Neil Betteridge, United Kingdom
* Liaison to the FOREUM Foundation
Prof. Steffen Gay, Switzerland
* President UEMS Section of Rheumatology
Dr. Jean Dudler, Switzerland
* Executive Director
Dr. Julia Rautenstrauch, Switzerland

EULAR STANDING COMMITTEE CHAIRPERSONS
(ex officio members of the EULAR Executive Committee)
Investigative Rheumatology
Prof. Timothy Radstake, Netherlands
Clinical Affairs
Prof. Ulf Müller-Ladner, Germany
Education and Training
Prof. Nemanja Damjanov, Serbia

Epidemiology and Health Services Research
Prof. Laure Gossec, France
Musculoskeletal Imaging
Dr. Xenofon Baraliakos, Germany
Paediatric Rheumatology
Prof. Berent Prakken, Netherlands
PARE
Mrs. Nele Caeyers, Belgium
Health Professionals in Rheumatology
Dr. Rikke Helene Moe, Norway

CONGRESS PROGRAMME COMMITTEE
Scientific, Health Professionals, PARE
The EULAR Executive Committee Members
(excluding functions marked with*)
The EULAR Standing Committee Chairs
Chair of the Scientific Programme Committee
Prof. Thomas Dörner, Germany
Chair of the Abstract Selection Committee
Prof. John Isaacs, United Kingdom
Past-Chair of the Scientific Programme Committee
Prof. Robert B. M. Landewé, Netherlands
Prof. Joan Bathon, United States
Prof. Francis Berenbaum, France
Dr. Michael Beresford, United Kingdom
Prof. Loreto Carmona, Spain
Prof. Piet Geusens, Netherlands
Prof. Martin Herrmann, Germany
Prof. Eduardo Mysler, Argentina
Dr. Caroline Ospelt, Switzerland
Prof. Hendrik Schulze-Koops, Germany
Dr. Daniel Prieto-Alhambra, United Kingdom
Dr. Yeliz Prior, United Kingdom
Dr. Sofia Ramiro, Netherlands
Prof. Alexander So, Switzerland
Prof. Lai-Shan Tam, Hong Kong (SAR)
Prof. Angela Tincani, Italy
Prof. Filip van den Bosch, Belgium
Prof. Jaap van Laar, Netherlands
Dr. Tonia Vincent, United Kingdom
Dr. David Walsh, United Kingdom
Prof. Kazuhiko Yamamoto, Japan

* These functions are not included in the Congress Programme Committee
CONGRESS VENUE: DATES AND LOCATION
The Annual European Congress of Rheumatology EULAR 2019 is held at:
IFEMA
Feria de Madrid
Avenida del Partenón
28042 Madrid, Spain
Website: www.ifema.es
The congress opens on Wednesday, 12 June 2019 - 12:00 and closes on Saturday, 15 June 2019 - 15:00. The EULAR Congress Opening Plenary session takes place on Wednesday, 12 June 2019 from 13:00 to 14:00. A networking platform, for scientific exchange, is held in the evening of Wednesday, 12 June 2019 at the congress venue itself.
Set next to one of the most important business centres in the city, the Feria de Madrid is linked to major arteries, which makes it easily accessible for EULAR 2019 participants.
The Adolfo Suaréz Madrid-Barajas airport is just a few kilometres away from the IFEMA. Delegates can also make use of public transport, particularly thanks to the vast underground network, which links the venue to every point in the city.
The architecture of Feria de Madrid’s facilities and the versatile capacity of its various spaces make this complex one of the most modern, technologically best-designed and equipped venues in Europe.

REGISTRATION AREA OPENING HOURS
Tuesday 11 June 2019 17:00 - 20:00
Wednesday 12 June 2019 07:30 - 20:00
Thursday 13 June 2019 07:45 - 19:15
Friday 14 June 2019 07:45 - 19:15
Saturday 15 June 2019 08:30 - 15:00

SCIENTIFIC SECRETARIAT
EULAR Secretariat
Seestrasse 240
CH-8802 Kilchberg/Zurich
Switzerland
Tel: +41 44 716 3030
Fax: +41 44 716 3039
E-mail: eular@eular.org
Website: www.eular.org / www.congress.eular.org

ORGANISING SECRETARIAT
In charge of registration, abstract handling, partnership & investment opportunities and hotel reservations
EULAR 2019
c/o MCI Suisse SA
Rue du Pré-Bouvier 9
CH-1242 Satigny, Geneva
Switzerland
Tel: +41 22 33 99 590
Fax: +41 22 33 99 601
Email: eular@mci-group.com
Website: www.mci-group.com

LOCAL ORGANISING AGENCY
For social events, excursions, transfers and company events
MCI Spain / OVATION Spain
C/ Santa Engracia 151 1 1ª
28003 Madrid
Spain
Tel: +34 911 420 590
Email: eular2019.soc@ovationdmc.com
Website: www.ovationdmc.com/destinations/spain/
GENERAL INFORMATION

INFORMATION ABOUT YOUR PARTICIPATION

ADMITTANCE TO THE EULAR CONGRESS
In respect of Spanish and European laws and regulations, as well as due to current health and safety rules and legislation in effect, registration and/or admittance to the EULAR Congress shall be limited solely to participants who are 18 years of age or older. Registration by anyone who is under 18 is unauthorised and violation of these terms and conditions will automatically result in the forfeit of their registration. Identification is to be provided to congress staff upon request. Participants below 18 years of age will not be granted access to any part of the congress at any time.

This is also valid for children accompanied by their parents and for any other unregistered person. If access to the congress is needed and no registration is available, the person should contact the registration desk. The congress management will take a final decision.

CANCELLATION OF CONGRESS
It is mutually agreed that in the event of total or partial cancellation of the congress due to fire, strike, natural disaster (either threatened or actual), government regulations or causes which would prevent its scheduled opening or continuance, the contractual relationship between EULAR and the participant will be terminated immediately and EULAR shall determine an equitable basis for the eventual refund of a portion of the registration or other fees after due consideration of expenditures and commitments already made. Under no circumstances is EULAR responsible for any participant expenses (such as travel and lodging) or any other incidental or consequential damages.

DATA SCANNING SYSTEM
Congress badges will contain a barcode acting as an electronic business card and thus enable visitors to leave their contact details for exhibitors quickly and easily.

DRESS CODE
Dress will be informal throughout the congress. EULAR reserves the right to refuse access if it is deemed necessary for the comfort and safety of all delegates.

EULAR CONGRESS MOBILE APP
Since 2003, EULAR has offered a congress programme and guide for mobile devices, at that time pioneering in this upcoming technology. In recent years, we have also offered a planning tool, the internet based itinerary planner. Schedules made in the planner can be transferred easily to your smartphone or tablet on iOS, Android or WindowsPhone. Apart from general information, the app contains the complete congress programme with all sessions and lectures, all abstracts in full text and all symposia. Links between these elements allow for changes to content to be made easily. The location of session and meeting rooms is shown interactively so you know instantly where the next event takes place.

A support desk for mobile devices is located in the EULAR Village.

GENERAL INFORMATION

CHARGING STATIONS FOR SMARTPHONES AND MOBILE DEVICES
Charging stations for smartphones and other mobile devices are available in the registration area and exhibition hall.

CLIMATE
Madrid and its metropolitan area have a Mediterranean climate that borders on the continental climate with mild, cool winters and warm to hot summers. The average temperature in June is 21°C (70°F). During summer, days are longer and the city really begins to come alive in the evening.

CLOAKROOM
A cloakroom service for coats and reasonable-sized luggage is available during the opening hours of the registration area (Hall 2), near the south entrance. For security reasons, electrical items cannot be kept in the cloakroom.

CONGRESS DOCUMENTS AND BADGES
Name badges can be printed at the self-service stations, located at the registration area in Hall 2 for participants accessing IFEMA from the south entrance. Participants accessing IFEMA from the north entrance can use the shuttle service to commute to the south entrance. Alternatively, congress documents (including name badges) can be collected at the registration desks in Hall 2. Name badges must be worn visibly at all times during the congress and in the exhibition area.

CONGRESS EVALUATION
We would be grateful if you could take a few minutes to support the onsite staff member who may approach you to gain your opinion about the congress and the scientific programme. This will help us to continue to improve the congress in the future.

CREDIT CARDS
Major credit cards (Visa, American Express, Eurocard/ Mastercard, Diners Club) are accepted in most hotels, restaurants and shops. ATM/cash machines are available at the congress venue.
CURRENCY
The Spanish currency is the Euro (1 Euro = 100 cents).

CYBER CAFÉ
Two Cyber Cafés are located in the exhibition, Hall 10.

ELECTRICITY
The electricity power supply in Spain is 220 Volts with a European standard plug.

FOOD AND BEVERAGE
During official coffee breaks, complimentary coffee and tea will be served in the EULAR Village and exhibition/poster area, Hall 10. Lunch will be provided on Thursday and Friday and will also be served in the EULAR Village and exhibition/poster areas. Various self-service restaurants and sandwich bars are located in the congress venue.

MADRID & SPAIN (FACTS ABOUT)
Madrid is the capital of Spain.

Such a self-evident statement has a much wider-ranging underlying significance, whose multiple implications have moulded the city’s singular personality. Madrid is the decision-making centre of the Spanish government, the place where the different de facto national powers have their headquarters, and where the major companies, multinationals, banks and financial markets are located. It is also the geographic centre of the Iberian Peninsula (the exact centre is Cerro de los Angeles, 14 km outside Madrid), and the hub of all of Spain’s national highways and international throughways.

The diversity of its neighbourhoods and buildings reminds us at every step of the city’s dual role in the political and economic spheres. Its historic monuments are the heritage of a city that has wielded administrative power for more than four centuries. Alongside them, glass- and concrete-clad skyscrapers encase the heartbeat of an increasingly important local economy, whose weight is growing both at the Spanish and international levels.

Within the territory of the Madrid region, whose total surface area is approximately 8000 km², two other major local powers live side-by-side: the government of the Autonomous Region and the capital’s City Council. Madrid is one of the 17 autonomous regions into which Spain was divided under the Constitution of 1978; unlike most of the others, it has but one province. Its population tops 5 million, or 12% of the national total. Its surroundings and its location have shaped Madrid.

It is a city in the centre not only of the region, but also of the country. Perhaps this location is one of the determining factors in its status as the capital, as the political, business, economic and transport centre all which help to explain why this city has always been a potpourri of different people and interests, both historically and today.

Geographically, the Madrid region has a diversity that might astonish someone who only knows the city and its outskirts. The proximity of the Sierra de Guadarrama offers a variety of landscapes that break up the monotony of the Castilian meseta, and make Madrid a region of forests, hidden valley’s and peaks more than 2,500 m high, a surprising contrast to the great city and its far-flung suburbs.

Madrid boasts a unique historic and artistic heritage that coexists in harmony with creativity, embracing culture and gastronomy. The modern and cosmopolitan flare of the Spanish capital offers guests a variety of things to discover. The passionate and friendly character of the Madrileños also enhances the visitor experience.

GETTING AROUND IN MADRID
Metro
The underground (metro) is the fastest, most efficient and most affordable way to move around Madrid. The city has a vast metropolitan network, one of the most comprehensive in Europe, and covers almost all the points in the capital and many of the neighbouring areas.

Currently, there are twelve metro lines and three metro Ligero (tramway) lines.

The metro line number 8 or pink line (Nuevos Ministerios - Airport T4) connects the city to the Adolfo Suarez Madrid-Barajas airport, in approximately 12 minutes and to Madrid’s Trade Fair grounds (IFEMA). The metro stop at IFEMA is called “Feria de Madrid”, located at the South Entrance of the IFEMA.

Bus
Madrid has an extensive city bus network, run by the company Empresa Municipal de Transporte (EMT), which covers the whole city. All the vehicles are air-conditioned and equipped with WiFi. Madrid’s buses have special facilities for disabled access. Although main streets have dedicated bus lanes, buses can be slowed down during rush hours.

Line number 112 running from Mar de cristal to Barrio aeropuerto stops at the IFEMA. Get off at “Partenon - Campo de la Naciones”.

Taxis
Taxis in Madrid are white with a diagonal red band on their front door bearing the emblem of the city. They have a green light that is on when they are free. To hail a taxi all you need to do is raise your hand.

There are also several taxi ranks around the city, indicated by a blue sign with a white letter ‘T’. Taxis must be taken from the corresponding ranks at railway and bus stations and at the airport. Throughout the rest of the city they can be easily stopped on the street.

With over 15,600 taxis in Madrid, finding a free taxi on any of the city’s main streets is rarely difficult. Journeys are usually paid for in cash although more and more taxis accept credit cards.

Prices are quite reasonable, considering that a one-way trip from the city centre to the airport costs around 30 Euros.
HELP POINT FOR SMARTPHONES AND MOBILE
DEVICES
A help point for phones and other mobile devices as well
as charging options for such devices will be located in
the congress venue. The EULAR Mobile Congress App
can also be downloaded there.

INSURANCE AND LIABILITY
It is recommended that participants obtain adequate
cover for travel, health and accident insurance before
they depart from their countries. EULAR and MCI
as organisers accept no liability or responsibility for
personal injuries, or loss of, or damage to, private
property belonging to the congress participants.

LANGUAGES/OFFICIAL LANGUAGE
The official language in Madrid is Spanish, however
English is spoken in tourist areas. Catalan, Galician
and Basque are frequently spoken in some areas. The
official congress language is English. No simultaneous
translation is provided.

PRESS CENTRE
The press and media area is located in room Goya,
next to Hall 4. Facilities such as computers, telephone,
photocopier, and internet access are available for
registered press representatives.

SECURITY
Please pay special attention to your personal belongings,
especially when walking in the city centre or using
the public transportation system, but also inside the
congress venue. Any security problems or concerns
within the congress venue should be reported to a
member of the EULAR or MCI staff.

Security staff will handle any emergency situation and
everyone is required to follow instructions announced via
the public information system.

Emergency exits are marked with green exit signs.

SERVICES FOR THE DISABLED
All session rooms at the congress venue are fully
accessible to participants with disabilities. Quiet areas
are available throughout the congress venue, mainly in
the EULAR Village.

SHOPPING IN MADRID
Madrid is a very interesting city for shopping. International
brands mix with local shops which are open (normally
from 10:00 to 22:00), where you can find almost
everything: clothing, shoes, food, wines, souvenirs...
in very different styles, at very different prices.

SMOKING POLICY
Smoking is not permitted at the congress venue.

SOCIAL MEDIA
Share your best moments of EULAR on your social
media platforms by using the hashtag #EULAR2019.
Please also refer to the EULAR Social Media Policy
which can be downloaded at www.congress.eular.org.

SOCIAL MEDIA / PHOTOGRAPHY RULES AND
REGULATIONS AT EULAR 2019
The intention at EULAR 2019 is to facilitate the sharing
of content within the scientific, health professional and
patient communities while still respecting the copyrights
and intellectual property of the presenters. Picture-
taking/filming and/or live streaming for commercial use
and in the commercial area is not permitted. Recording or live streaming of congress presentations/sessions is not allowed in any way (neither image, nor sound). Presenters and chairs have the right to request no photographs during their presentation/session/activities. In compliance with Spanish laws on promotional activities for medical events and satellite symposia, published photographs should not include any ‘trade names’, ‘brand names’ and/or any product advertisement. At all times, when permitted, photographs must be taken in a non-disruptive manner. Full guidelines can be downloaded on www.congress.eular.org.

TELEPHONES
Please respect your fellow colleagues and friends by operating your mobile devices in silent mode in all session rooms and poster areas.

TIME
Spain follows Central European Time (CET) which is UTC +1 hour in winter and UTC + 2 in summer.

TIPPING
Locals in Madrid usually tip when they have received good service. In general, people tend to tip 10% in restaurants (restaurants do not charge extra on the bill). Tipping taxi drivers and hotel personnel is also customary in Madrid.

TRANSPORTATION
EULAR provides transportation passes to duly registered delegates who booked the accommodation through MCI, the official congress housing bureau, enabling them to travel on the public transportation network during the EULAR Congress within zone A.

EULAR CORPORATE SOCIAL RESPONSIBILITY STATEMENT
EULAR is aware of the environmental, economic and social impact of holding a large congress, and is working closely with its partners to ensure that environmentally, economically and socially friendly policies are in place.

For the Madrid congress, EULAR has made the following sustainable arrangements:

HEALTHY FOOD
All buffets for lunches and coffee breaks offer healthy options meaning that there is always a choice of fresh fruit or vegetables. A smaller selection of dietary offerings is also available. Local products have been prioritised.

PRINTING
EULAR is committed to ensuring that printing is kept to a minimum to reduce the amount of waste paper. Poster presentations are no longer included in the final programme but are available online and in the EULAR Congress App. In addition, the full texts of all accepted abstracts are available online as well as the preliminary programme for EULAR 2020. This will save printing about 25,680,000 pages.

LOCAL SUPPLIERS
EULAR wishes to have a positive local impact. When sourcing materials and supplies, EULAR gives priority to local partners to avoid a negative transportation impact and to positively impact the local economy.

SERVICES FOR THE DISABLED
EULAR wishes to make the congress experience comfortable for all attendees. All rooms and areas at the congress venue are fully accessible to participants with disabilities. Quiet areas are available throughout the congress venue, mainly within the EULAR Village.

NETWORKING OPPORTUNITIES

OPENING PLENARY SESSION
Wednesday, 12 June 2019 13:00-14:00 - Hall 6
The EULAR Congress Opening Plenary session will feature again inspiring talks and updates from EULAR and also includes the EULAR Awards.

NETWORKING PLATFORM
Wednesday, 12 June 2019 20:00-22:00
Esplanade in front of Hall 6
All registered participants are cordially invited to meet and greet old and new friends.

EULAR CONGRESS DINNER
Friday, 14 June 2019 20:30 - 23:00
La Quinta de Jarama
Price: EUR 95 per person
(not included in the registration fee)
EULAR 2019 welcomes you to La Quinta de Jarama, for the congress dinner held on Friday 14th June.
La Quinta de Jarama is an exclusive venue located only 30 minutes from Madrid city center.
The cocktail will be held in its beautiful space full of nature composed of gardens, olive trees and a fountain. After enjoying the cocktail in these awe-inspiring gardens, a dinner will be served in its elegant indoor spaces and porches.
The EULAR Congress Dinner is a great opportunity to dine and meet with friends and colleagues from around the world in a relaxed atmosphere, enjoying the unmatched charm and fascination of Madrid. Those who have shared this evening with us in previous years would not want to miss it. Come and join us!
**SCIENTIFIC INFORMATION**

**CERTIFICATE OF ATTENDANCE**
A certificate of attendance will be sent by email to all attendees who fill out the congress evaluation survey.

**CONTINUING MEDICAL EDUCATION (CME) CREDITS**
CME approval was still under review at the time of printing. Please consult the EULAR Website www.congress.eular.org or the EULAR App for further information.

**POSTERS**
The scientific posters and health professionals in rheumatology posters are displayed in the poster areas in the exhibition, Hall 10 from Thursday to Saturday. They are changed on a daily basis. PARE posters are displayed permanently on an ePoster station near the EULAR Village. Delegates interested in the EULAR projects have the possibility to browse posters of the different projects and working groups in the poster area.

Official poster viewing will take place at the following hours:

- **Thursday**
  - 13 June 2019
  - 11:45 - 13:30
- **Friday**
  - 14 June 2019
  - 11:45 - 13:30
- **Saturday**
  - 15 June 2019
  - 10:30 - 12:00

Guided poster tours on selected topics will take place during the official poster viewing times at dedicated ePoster stations.

**SCIENTIFIC SESSIONS (ACCESS TO)**
The meeting rooms for scientific sessions vary in size. Should the room be full, we invite you to use the overflow facilities located in the registration area, located in Hall 9 or to attend a different session. Neither EULAR nor MCI can be held responsible should a delegate be unable to attend a scientific session. The maximum capacity of the rooms are determined by the local safety and security regulations and must be respected by law.

**SPEAKERS’ PREVIEW ROOM**
The Speakers’ Preview Room, located in the Business Centre on the Mezzanine level above Hall 7, is open at the following hours:

- **Wednesday**
  - 12 June 2019
  - 08:00 - 20:00
- **Thursday**
  - 13 June 2019
  - 08:00 - 19:00
- **Friday**
  - 14 June 2019
  - 08:00 - 19:00
- **Saturday**
  - 15 June 2019
  - 08:00 - 14:30

The preview room is equipped with computers. All speakers are required to check in their presentation at least 2 hours before their session, or on the day before, for the early morning sessions.

**INFORMATION ON INDUSTRY RELATED ACTIVITIES**

**EXHIBITION**
During the congress, EULAR will present an attractive exhibition to the congress participants.

The abstract poster presentation areas are built within the exhibition. Coffee and other refreshments are available within the exhibition during official breaks.

The exhibition hours are as follows:

- **Wednesday**
  - 12 June 2019
  - 12:00 - 18:00
- **Thursday**
  - 13 June 2019
  - 08:00 - 17:15
- **Friday**
  - 14 June 2019
  - 08:00 - 17:15
- **Saturday**
  - 15 June 2019
  - 08:45 - 14:00

**EXHIBITION ACCESS (RESTRICTED)**
For medical conferences taking place in Europe, all participants as well as all contributors are subject to European laws, rules and regulations clarified by the ‘Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2011 on the Community code relating to medicinal products for human use’.

The relevant European laws, rules and regulations and their Spanish application clearly state that:

- Patients and patient advocates should have no access to the areas where prescription medicines are promoted and should not receive any materials containing product advertisements (irrespective of their nationality)

As such and in full respect of the applicable regulations, EULAR has decided to implement the following processes:

- The commercial and the non-commercial parts of the exhibition will be clearly identified
- Congress participants registered as PARE representatives or as patients will be clearly identified and will not have access to the commercial part of the exhibition and satellite symposia including brand advertisement. The access to all other official parts of the congress including the non-commercial part of the exhibition is unrestricted.

We kindly ask all registered participants to follow the specific instructions they will receive together with the congress documents. Onsite staff and dedicated signs are there to help participants navigate the exhibition halls.
PRIVATE EVENTS POLICY
All requests from companies/organisations to host private events during the congress must have been approved prior to the congress by the EULAR Secretariat.

SATELLITE SYMPOSIA (ACCESS TO)
The meeting rooms for satellite symposia vary in size. Neither EULAR nor MCI can be held responsible should a delegate be unable to attend a satellite symposium. The maximum capacity of the rooms are determined by the local safety and security regulations and must be respected by law.

Access to satellite symposia featuring product advertisement is restricted to healthcare professionals who are allowed to prescribe or supply (in the country where the professional is practicing its profession).

SATELLITE SYMPOSIA (TIMINGS)
A number of satellite symposia are organised during EULAR 2019 at the following times:

<table>
<thead>
<tr>
<th>Day</th>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wednesday</td>
<td>12 June 2019</td>
<td>18:15 - 19:45</td>
</tr>
<tr>
<td>Thursday</td>
<td>13 June 2019</td>
<td>08:15 - 09:45</td>
</tr>
<tr>
<td></td>
<td>13 June 2019</td>
<td>17:30 - 19:00</td>
</tr>
<tr>
<td>Friday</td>
<td>14 June 2019</td>
<td>08:15 - 09:45</td>
</tr>
<tr>
<td></td>
<td>14 June 2019</td>
<td>17:30 - 19:00</td>
</tr>
</tbody>
</table>

Further information is available in the satellite booklet, included in your congress bag.

Satellite symposia are governed by the EULAR Guidelines. All symposia and special events must be approved by EULAR. Other symposia are strictly prohibited during the official programme, as outlined in the EULAR Code of Practice.
## ALL DATES AND TIMES AT A GLANCE

<table>
<thead>
<tr>
<th>DATE</th>
<th>AREA</th>
<th>SPEAKERS PREVIEW</th>
<th>POSTER VIEWING</th>
<th>NET-WORKING</th>
<th>EXHIBITION</th>
<th>SATELLITE SYMPOSIA</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TUESDAY 11 JUNE 2019</strong></td>
<td>17:00–20:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>WEDNESDAY 12 JUNE 2019</strong></td>
<td>07:30–20:00</td>
<td>08:00–20:00</td>
<td></td>
<td>13:00–14:00 Opening plenary</td>
<td>12:00–18:00</td>
<td>18:15–19:45</td>
</tr>
<tr>
<td><strong>THURSDAY 13 JUNE 2019</strong></td>
<td>07:45–19:15</td>
<td>08:00–19:00</td>
<td>11:45–13:30</td>
<td></td>
<td>08:00–17:15</td>
<td>08:15–09:45 17:30–19:00</td>
</tr>
<tr>
<td><strong>FRIDAY 14 JUNE 2019</strong></td>
<td>07:45–19:15</td>
<td>08:00–19:00</td>
<td>11:45–13:30</td>
<td>20:30–23:00 EULAR Congress Dinner</td>
<td>08:00–17:15</td>
<td>08:15–09:45 17:30–19:00</td>
</tr>
<tr>
<td><strong>SATURDAY 15 JUNE 2019</strong></td>
<td>08:00–15:00</td>
<td>08:00–14:30</td>
<td>10:30–12:00</td>
<td></td>
<td>08:45–14:00</td>
<td></td>
</tr>
</tbody>
</table>

## FUTURE CONGRESS

Annual European Congress of Rheumatology 2020
Frankfurt am Main, Germany, 3-6 June 2020
## CONGRESS AT A GLANCE
**WEDNESDAY, 12 JUNE 2019**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>14:15–17:45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abstract session</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myositis and SSc: Clinical Highlights 2019</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abstract session</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bringing digital health care solutions to patients</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abstract session</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cartilage, synovium and bone</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abstract session</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rehabilitation; opening Pandora’s box</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abstract session</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Osteoporosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abstract session</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>When rheumatoid arthritis (RA) does not walk alone; new data on comorbidities in RA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abstract session</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tackling chronic pain; fibromyalgia and back pain</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:45–18:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Break</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area, Hall 2**

**Please refer to the satellite symposia booklet for further information**
In order to participate in a guided poster tour, please register at the poster tours & workshops desk, located in the registration area, Hall 2

**Please refer to the satellite symposia booklet for further information**

---

**CONGRESS AT A GLANCE**

**THURSDAY, 13 JUNE 2019**

<table>
<thead>
<tr>
<th>TIME</th>
<th>HALL 6</th>
<th>HALL 8</th>
<th>HALL 7A</th>
<th>HALL 7B</th>
<th>N103/N104</th>
<th>South Auditorium</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:15–09:45</td>
<td>Satellite symposium***</td>
<td>Satellite symposium***</td>
<td>Satellite symposium***</td>
<td>Satellite symposium***</td>
<td>Basic and Translational Science session From the cradle to the grave - what does paediatric disease teach us about adult disease?</td>
<td></td>
</tr>
<tr>
<td>09:45–10:15</td>
<td>COFFEE BREAK</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:15–11:45</td>
<td>What is New (WIN) / How to Treat (HOW) Advances in understanding and treating SLE</td>
<td>Abstract session Psoriatic arthritis: old and new drugs and how to deal with them?</td>
<td>Abstract session &quot;Rheumatoid arthritis – looking before, looking forward!&quot;</td>
<td>Abstract session SLE, Sjögren and APS: systemic autoimmunity in the real life</td>
<td>Abstract session Diagnostics and imaging procedures</td>
<td>Abstract session Vasculitis</td>
</tr>
<tr>
<td>11:45–13:30</td>
<td>LUNCH AND POSTER VIEWING</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00–15:00</td>
<td>GUIDED POSTER TOURS**</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30–15:00</td>
<td>What is New (WIN) / How to Treat (HOW) Spondyloarthritides - new perspectives on outcome</td>
<td>Clinical Science session Can imaging improve outcome in OA?</td>
<td>Challenges in Clinical Practice session Can drugs and surgery help people with joint pain increase activity?</td>
<td>From bench to bedside Different pathophysiological pathways in axial and peripheral disease: peripheral and axial spondyloarthritis: to split or to lump?</td>
<td>Clinical Science session My joints hurt and I'm overwhelming tired - fatigue in rheumatoid arthritis</td>
<td>Basic and Translational Science session Molecular fingerprinting</td>
</tr>
<tr>
<td>15:00–15:30</td>
<td>COFFEE BREAK</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30–17:00</td>
<td>What is New (WIN) How to Treat (HOW) Interstitial lung disease in rheumatic diseases and systemic sclerosis</td>
<td>Clinical Science session Diagnostic challenges in vasculitis</td>
<td>Challenges in Clinical Practice session How to manage and treat childhood onset lupus? A multidisciplinary point of view</td>
<td>From bench to bedside Radiographic progression in arthritides: still valid or a tale from the past?!</td>
<td>Clinical Science session Difficult to manage Sjögren’s syndrome and myositis</td>
<td>Basic and Translational Science session Anergy, exhaustion or post-activation in autoimmunity - facts and future consequences</td>
</tr>
<tr>
<td>17:30–19:00</td>
<td>Satellite symposium***</td>
<td>Satellite symposium***</td>
<td></td>
<td></td>
<td>Basic and Translational Science session Fighting and fixing: from initiation to resolution of inflammation</td>
<td></td>
</tr>
</tbody>
</table>
**In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area, Hall 2**

**In order to participate in a guided poster tour, please register at the poster tours & workshops desk, located in the registration area, Hall 2**

**Please refer to the satellite symposia booklet for further information**

### THURSDAY 13 JUNE 2019 | CONGRESS AT A GLANCE | 17

|-----------|-----------|-----------|-----------|-----------|-----------|-----------|

### COFFEE BREAK

- **PReS Abstract session**
  - Journeys from bench to bedside in paediatric rheumatology

- **HPR Abstract session**
  - Transformative care – the future

- **Abstract session**
  - Other orphan diseases

- **PARE/PReS Joint session**
  - From child to adult care - breaking down the barriers of transition

- **Abstract session**
  - Osteoarthritis: research in motion

- **Abstract session**
  - Systemic sclerosis, myositis and related syndromes - etiology, pathogenesis and animal models

- **Abstract session**
  - Genetics, epigenetics and immunity

### LUNCH AND POSTER VIEWING

### GUIDED POSTER TOURS**

- **PReS session**
  - Adults are just grown up children! Discuss

- **HPR session**
  - Exercise - more than a wonderdrug

- **Clinical Science session**
  - Getting a grip on the co-morbidities in gout

- **PARE/HPR Joint session**
  - Treatment is more than drugs

- **EULAR Projects**
  - Challenging projects in education and training

- **Practical skills session**
  - Crystal II

- **Practical skills session**
  - Ultrasound basic I

### COFFEE BREAK

- **Clinical Science session**
  - Fracture liaison service: an opportunity for rheumatologists to focus on secondary fracture prevention

- **HPR session**
  - How not to smoke like a chimney

- **Practical skills session***
  - Scientific data visualisation: focus on (poster) presentation

- **PARE session**
  - Should we worry about anything else – also young people have multi-morbidities

- **EULAR Projects in investigative rheumatology**
  - Big Data and the disruption of medical care

- **Practical skills session**
  - MRI

- **Practical skills session**
  - Ultrasound advanced I

- **Satellite symposium***

- **Satellite symposium***

- **Satellite symposium***

- **Satellite symposium***
## CONGRESS AT A GLANCE
FRIDAY, 14 JUNE 2019

<table>
<thead>
<tr>
<th>TIME</th>
<th>HALL 6</th>
<th>HALL 8</th>
<th>HALL 7A</th>
<th>HALL 7B</th>
<th>N103/N104</th>
<th>South Auditorium</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:15–09:45</td>
<td></td>
<td></td>
<td>Satellite symposium***</td>
<td>Satellite symposium***</td>
<td>Satellite symposium***</td>
<td>Basic and Translational Science session</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Seeing is believing: nanotechnologies in tissue imaging</td>
</tr>
<tr>
<td>09:45–10:15</td>
<td>COFFEE BREAK</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:15-11:45</td>
<td>What is New (WIN) / How to Treat (HOT)</td>
<td>Abstract session Rheumatoid arthritis - biological DMARDs</td>
<td>Abstract session How to treat SpA: choices and outcomes with biDMARDs</td>
<td>Abstract session SSC and myositis – novel therapeutic options</td>
<td>Abstract session SLE news</td>
<td>PReS Abstract session Tackling the challenges of autoimmune / autoinflammatory conditions in children and young people</td>
</tr>
<tr>
<td>11:45-13:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:50-13:30</td>
<td>LUNCH AND POSTER VIEWING</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30-15:00</td>
<td>What is New (WIN) / How to Treat (HOT)</td>
<td>Clinical Science session Immuno-suppression in SSC – a matter of timing!</td>
<td>Challenges in Clinical Practice session Predicting short-term fracture risk: can we foresee the (close) future?</td>
<td>From bench to bedside New insights in Lupus Nephritis (LN)</td>
<td>Clinical Science session Primary and secondary fibromyalgia; are they different?</td>
<td>Basic and Translational Science session Joint EULAR/EFIS session: Combating or harnessing ILC in the battle against autoimmunity</td>
</tr>
<tr>
<td>15:00–15:30</td>
<td>COFFEE BREAK</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30-17:00</td>
<td>What is New (WIN) / How to Treat (HOT)</td>
<td>Clinical Science session Overdiagnosis and overtreatment in inflammatory arthritis</td>
<td>Challenges in Clinical Practice session The multiple rheumatological faces of PsA (or PsA is more than just poly-arthritis? - consequences for management in daily practice)</td>
<td>From bench to bedside Cannabis for arthritis: hype or hope?</td>
<td>Clinical Science session Reproductive issues in rheumatology</td>
<td>Basic and Translational Science session The future of therapeutic strategies</td>
</tr>
<tr>
<td>17:30–19:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Basic and Translational Science session Complement and autoimmunity - emerging therapeutic opportunities</td>
</tr>
</tbody>
</table>

** In order to participate in a guided poster tour, please register at the poster tours & workshops desk, located in the registration area, Hall 2

*** Please refer to the satellite symposia booklet for further information
In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area, Hall 2

In order to participate in a guided poster tour, please register at the poster tours & workshops desk, located in the registration area, Hall 2

*** Please refer to the satellite symposia booklet for further information
In order to participate in a guided poster tour, please register at the poster tours & workshops desk, located in the registration area, Hall 2

*** Please refer to the satellite symposia booklet for further information.
WIN & HOT session
NEW AVENUES OF OA & OSTEOPOROSIS MANAGEMENT

Learning objectives:
- To provide insights into new strategies for the management incl. treatment options in osteoarthritis with particular focus on recent trial data (anti-NGF and others)
- Update on the active and passive role of cartilage in OA (remodelling enzymes and regenerative potency of cartilage) and the role of immune activation and pain
- To discuss current treatment of osteoporosis and fracture prevention, based on current evidence including the role of non-medical prevention measures
- Remaining medical need will be discussed providing the rational for new therapeutic targets and strategies

Chair(s):
Lianne S. Gensler (United States of America)
Philippe Carron (Belgium)

14:20 – ABSTRACT N° SP0001
Francis Berenbaum (France)
WIN in OA management

15:00 – ABSTRACT N° SP0002
Serge Ferrari (Switzerland)
HOT: Osteoporosis @2019

14:20 – ABSTRACT N° SP0003
Victoria Navarro-Compán (Spain)
NSAIDs – how to optimally use them? (safety of NSAIDs)

14:40
Pedro Machado (United Kingdom)
A critical look into treat-to-target in SpA

15:00 – ABSTRACT N° SP0004
Uta Kiltz (Germany)
Managing patients with axSpA: what are the quality standards?

15:20 – ABSTRACT N° OP0001
Olafur Palsson (Sweden)
J. Wallman, T. Love, M. Kapetanovic, P. Gunnarsson, B. Gudbjornsson
The prescription of NSAIDs for patients with inflammatory arthritis is associated with patient but not physician assessed disease activity measures and decreases with initiation of TNF inhibitor therapy

15:30 – ABSTRACT N° OP0002
Rebecca Adshead (United Kingdom)
H. Tahir, P. Knight, S. Donnelly
Early inflammatory back pain service – reducing time to diagnosis in patients with axial spondyloarthritis – the first 8 years
14:15 - 15:45  HALL 7A
Challenges in Clinical Practice session
HOW TO MAINTAIN REMISSION IN VASCULITIS

Learning objectives:
- To understand the alternatives in maintaining remission in vasculitis
- To learn the pros and cons of the different approaches

Chair(s):
Hendrik Schulze-Koops (Germany)
John H. Stone (United States of America)

14:20 – Weniko Care (France)
Case 1 presenter: Maintaining remission in the patient with AAV

14:30 – ABSTRACT N° SP0005
Loic Guillevin (France)
Case 1 discussant: Long-term efficacy of remission-maintenance regimens for AAV

15:00 – Lisa Christ (Switzerland)
Case 2 presenter: Maintaining remission in the patient with GCA

15:10 – ABSTRACT N° SP0006
Peter Villiger (Switzerland)
Case 2 discussant: Long-term efficacy of remission-maintenance regimens for GPA

14:15 - 15:45  N103/N104
Clinical Science session
COMORBIDITIES IN PSORIATIC ARTHRITIS

Learning objectives:
- To understand that psoriatic arthritis is a disease with extra-articular manifestations
- To understand the risk of cardiovascular disease and infection, and to consider vaccination strategy(ies)

Chair(s):
Philip Helliwell (United Kingdom)
Christopher T. Ritchlin (United States of America)

14:20 – ABSTRACT N° OP0003
Emilie Chotard (France)
A. Blanchard, G. Gailly, R. Vargas Poussou, A. Ostertag, H. Ea
Calcium pyrophosphate crystal deposition in a cohort of 52 patients with Gitelman syndrome

15:30 – ABSTRACT N° OP0004
Tristan Pascart (France)
C. Marzin, L. Norberciak, J. Legrand, F. Becce, J. Budzik
Is dual-energy computed tomography able to identify early-stage calcium crystal deposition in vivo? Initial clinical experience in 132 patients with and without knee chondrocalcinosis

14:15 - 15:45  HALL 7B
From Bench to Bedside
CPPD – A FORGOTTEN DISEASE THAT REQUIRES MORE ATTENTION??!!!

Learning objectives:
To update the audience on new pathophysiological and ultrasonographic concepts on CPPD

Chair(s):
Pascal Zufferey (Switzerland)
Hang Korng Ea (France)

14:20 – Frederic Lioté (France)
Pathophysiology of CPPD formation and deposition

14:40 – ABSTRACT N° SP0007
Georgios Filippou (Italy)
Is ultrasound a good tool to evaluate CPPD?

15:00 – ABSTRACT N° SP0008
Abhishek Abhishek (United Kingdom)
Management of CPPD disease

15:03 – ABSTRACT N° OP0006
Ashit Syngle (India)
N. Garg, P. Krishan on behalf of Innovators
Improvement of endothelial dysfunction and inflammation in psoriatic arthritis: improve - PsA study
PHARMACEUTICAL PIPELINE IN OA

Learning objectives:
- To know the most advanced targeted drugs for treating symptoms and structure degradation
- To know the benefits and the risks of sprifermin, Wnt inhibitors and anti-NGF

Chair(s):
Francis Berenbaum (France)
Philip G. Conaghan (United Kingdom)

Growth factors and cartilage: from mechanisms to DMOADs

Rik Lories (Belgium)
Manipulating signaling pathways for treating OA

Pascal Richette (France)
Biotherapies in OA: quest for the holy grail?

Cartilage thickness modification with sprifermin in knee osteoarthritis patients translates into symptomatic improvement over placebo in patients at risk of further structural and symptomatic progression: post-hoc analysis of the phase II FORWARD trial

Lars Erik Kristensen (Denmark)
Effect of liraglutide on body weight and pain in the treatment of overweight and knee osteoarthritis: a randomised, double-blind, placebo-controlled study

Resistant starch intake alleviates collagen-induced arthritis in mice by modulating gut microbiota and promoting SCFA production

High body mass index (BMI) in psoriatic arthritis (PsA) is associated with higher disease activity in weight and skin, impaired quality of life and more disability: results from the PsAbio study

Capturing the exposome

Capturing the exposome

Resistant starch intake alleviates collagen-induced arthritis in mice by modulating gut microbiota and promoting SCFA production
14:15 - 15:45  N105/N106

PARE session

WHAT'S NEW: LATEST NEWS ON BIOLOGICAL TREATMENT

Learning objectives:
To inform about the latest news on biologicals and the latest advances in treatment

Chair(s):
Johannes W. J. Bijlsma (Netherlands)
Jürgen Clausen (Germany)

14:33 – ABSTRACT N° SP0014
Jonathan Kay (United States of America)
The latest news on biosimilars treatment

14:51 – Tore K. Kvien (Norway)
To switch or not to switch?

15:09 – ABSTRACT N° OP0012
Marion Pons (France)
S. Chevret, K. Briot, M. d’Agostino, C. Roux, M. Dougdas, A. Moltó
Effectiveness of TNFI after a first switch is lower in patients with early axial spondyloarthritis: a longitudinal analysis of the DESIR cohort

15:27 – ABSTRACT N° OP0013-PARE
Laurence Carton (France)
C. Cardon, F. Alliot Launois, G. Chales, B. Liesse, L. Grange on behalf of PATIENT’s of AFLAR
AFLAR’s – French league against rheumatism – position and patient information action about biosimilar medicines in France

14:15 - 15:45  N115/N116

Health Professionals session

HEALTH PROFESSIONAL WELCOME SESSION

Learning objectives:
- To learn about recent EULAR HPR achievements
- To prepare for the congress sessions from different angles
- To outline collaboration with PreS

Chair(s):
Milena Gobbo Montoya (Spain)
Rikke H. Moe (Norway)

14:20 – Annette de Thurah (Denmark)
HPR news over the last year

14:40 – ABSTRACT N° SP0018
Maria Bergström (Sweden)
What you shouldn’t miss from the HPR programme as a clinician

15:00 – Marco Testa (Italy)
What you shouldn’t miss from the programme from a research perspective

14:15 - 15:45  N111/N112

The Young Rheumatologist

HOW TO PERFORM LOW-BUDGET HIGH-QUALITY RESEARCH

Learning objectives:
To give guidance and provide young rheumatologists with basic tools to organize small research units and perform quality research on a low budget

Chair(s):
Sebastian Rodriguez-Garcia (Spain)
Loreto Carmona (Spain)

14:20 – ABSTRACT N° SP0015
Laure Gossec (France)
How to organize a very small research unit

14:40 – ABSTRACT N° SP0016
Loreto Carmona (Spain)
Your very first steps on systematic review
WEDNESDAY 12 JUNE 2019 | SCIENTIFIC PROGRAMME | 25

14:15 - 15:45  N117/N118  EULAR Projects

EULAR PROJECTS IN PAEDIATRIC RHEUMATOLOGY

Learning objectives:
- Update on key EULAR Projects in Paediatric Rheumatology – progress and next steps. These will focus on the following:
  - Addressing the challenges of developing the next generation of translational scientists and leaders in paediatric rheumatology
  - Paediatric rheumatology faces many challenges across the globe. Tackling these to ensure equity of access to care is critical for children and young people affected by these disorders
  - Developing a robust evidence base to underpin advancements in care for children across the world faces specific challenges that as an international community we need to consider

Chair(s):
Angelo Ravelli (Italy)

14:20 – ABSTRACT N° SP0023
Anne-Kathrin Tausche (Germany)
Introductory talk on crystal analysis

Tutor(s):
Eleonora Norkuviene (Lithuania)
Francisca Sivera (Spain)
José Pimentao (Portugal)
Francesca Oliviero (Italy)

14:15 - 15:45  N109/N110

Practical skills session*

CAPILLAROSCOPY I

Learning objectives:
- Learners will be instructed on the normal and abnormal nonspecific morphology of the microvessels versus pathological conditions
- Learners will be informed about the most important risk factors that may induce the endothelial damage that start the Raynaud’s phenomenon
- The most common capillaroscopic patterns will be explained and explained how to be quantified, in addition the different tools available for the analysis will be described
- Links with other techniques investigating the skin sickness and the peripheral blood flow in scleroderma patients will be reported
- The predictive and prognostic role of capillaroscopy in scleroderma will be explained and documented
- Learners at the end of the session will have understood when a capillaroscopic pattern is pathologic and what to do
- Learners will observe on live patients how the nailfold capillaroscopic analysis is done and will discuss with the tutors the diagnosis

Chair(s):
Maurizio Cutolo (Italy)
Vanessa Smith (Belgium)

14:20 – ABSTRACT N° SP0024
Vanessa Smith (Belgium)
Standardisation of normal versus abnormal and pathological capillaroscopic images

14:30 – ABSTRACT N° SP0025
Ariane Herrick (United Kingdom)
Reliability in the last 10 years: capillaroscopic characteristics versus instrumental detection

---

* In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area, Hall 2
14:40 – Maurizio Cutolo (Italy)
Nailfold capillaroscopy realistically detect the links between progression of microvascular pathological damage and clinical symptoms

14:50 – ABSTRACT N° SP0026
Alberto Sulli (Italy)
Methods and tools for quantization of capillaroscopic morphological changes

15:00
Practical session: Tutors perform live practical analysis of patients by videocapillaroscope

15:45 - 16:15 EXHIBITION AND EULAR VILLAGE (HALL 10)
COFFEE BREAK

16:15 - 17:45 HALL 6
Abstract session
OPENING PLENARY ABSTRACT SESSION

Chair(s):
John Isaacs (United Kingdom)
Thomas Dörner (Germany)

16:15 – ABSTRACT N° OP0016
Lianne Kearsley-Fleet (United Kingdom)
R. Davies, J. Page, E. Baildam, M. Beresford, H. Foster, T. Southwood, W. Thomson, K. Hyrich
What to choose: a second TNFI or an alternative class of biologic for patients with JIA who have failed their first TNFI

16:25 – ABSTRACT N° LB0001
Bernard Combe (France)
Efficacy and safety of filgotinib for patients with rheumatoid arthritis with inadequate response to methotrexate: FINCH1 primary outcome results

16:35 – ABSTRACT N° OP0017
Oliver Distler (Switzerland)
K. Highland, M. Gahlemann, A. Azuma, A. Fischer, M. Mayes, G. Raghu, W. Sauter, M. Girard, M. Alves, E. Clerisme-Beaty, S. Stowasser, M. Kuwana, T. Maher on behalf of SENSCIS trial investigators
Nintedanib reduced decline in forced vital capacity across subgroups of patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial

16:45 – ABSTRACT N° OP0018
Mohit Kapoor (Canada)
H. Endisha, P. Datta, A. Sharma, S. Nakamura, E. Rossomach, C. Younan, G. Tavallaee, R. Gandhi
MiR-34A is a potential therapeutic target in osteoarthritis

16:55 – ABSTRACT N° OP0019-HPR
Jaspreet Kaur (United Kingdom)
B. Kundaki, G. Nakafro, A. Abhishek, M. Doherty, W. Zhang
A systematic review and meta-analysis assessing gastrointestinal, liver, renal and cardiovascular adverse events of paracetamol

17:05 – ABSTRACT N° OP0020
Ai Li Yeo (Australia)
J. Ong, K. Connelly, S. Le, R. Ptasznik, J. Ross, E. Morand, M. Leech
Less is more: analysing the impact of repeated antinuclear antibody testing

17:15 – ABSTRACT N° OP0021
Md Yuzaiful Md Yusof (United Kingdom)
Predicting severe infection in repeat cycles of rituximab and effects of hypogammaglobulinaemia for the treatment of rheumatic and musculoskeletal diseases

17:25 – ABSTRACT N° OP0022
Fenne Wouters (Netherlands)
X. Matthijssen, D. Boeters, R. ten Brinck, A. van der Helm - van Mil, E. Niemantsverdriet
Do MRI-detected erosions in patients with clinically suspect arthralgia predict progression to rheumatoid arthritis? A longitudinal study

17:25 – ABSTRACT N° OP0023
Xanthe Matthijssen (Netherlands)
E. Niemantsverdriet
ACPA-positive rheumatoid arthritis patients benefited more from advanced treatment strategies than ACPA-negative rheumatoid arthritis patients: 25-year results of a longitudinal cohort study

17:25 – ABSTRACT N° OP0024
Arani Vivekananatham (United Kingdom)
M. Belousov, L. Hassan, G. Nenadic, W. Dixon
Patient discussions of glucocorticoid-related side effects within an online health community forum
16:35 – ABSTRACT N° OP0025
Stanley Cohen (United States of America)
Fenebrutinib compared to placebo and adalimumab in patients with inadequate response to either methotrexate therapy or prior TNF therapy: phase 2 study

16:45 – ABSTRACT N° OP0026
Tsutomu Takeuchi (Japan)
A phase 3 study of the efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis who had an inadequate response to methotrexate

16:55 – ABSTRACT N° OP0027
Min Jung Kim (Korea, Rep. of (South Korea))
Y. Song, E. Lee, J. Park
Effect of short-term methotrexate discontinuation on the disease activity in patients with rheumatoid arthritis: posthoc-analysis of two randomized clinical trials

17:05 – ABSTRACT N° OP0028
Joel Kremer (United States of America)
Post-approval comparative safety study of tofacitinib and biologic DMARDs: five-year results from a US-based rheumatoid arthritis registry

17:15 – ABSTRACT N° OP0029
Mark C. Genovese (United States of America)
R. Fleischmann, R. Blanco, S. Hall, G. Thomson, F. van den Bosch, C. Zerbini, J. Enenosa, Y. Li, R. DeMasi, I. Song
Switching between the JAK1-selective inhibitor upadacitinib and adalimumab following initial non-response: clinical and functional outcomes among rheumatoid arthritis patients

17:25 – ABSTRACT N° OP0030
Gerd R. Burmester (Germany)
Randomized controlled 24-week trial evaluating the safety and efficacy of blinded tapering versus continuation of long-term prednisone (5 mg/d) in patients with rheumatoid arthritis who achieved low disease activity or remission on tocilizumab
17:15 – ABSTRACT N° OP0037
Santiago Rodrigues-Manica (Portugal)
A. Sepiano, S. Ramiro, R. B. M. Landewé, P. Claudepierre, A. Moltó, M. Dougados, M. van Lunteren, D. van der Heijde
Association between bone marrow edema and structural progression in the same quadrant in axial spondyloarthritis – 5-year data from the DESIR cohort

17:25 – ABSTRACT N° OP0038
Thomas Renson (Belgium)
A. De Craezer, A. Depicker, L. Deroo, M. de Hooge, N. Herregods, L. Jans, G. Varkas, K. Roelens, I. Dehaene, P. Carron, F. van den Bosch, D. Eliewaut
High prevalence of sacroiliac bone marrow edema on MRI in postpartum women: a temporary phenomenon

16:15 - 17:45
Hall 7B
Abstract session
SLE, SJÖGREN’S AND APS - TREATMENT
Chair(s):
Lai-Shan Tam (Hong Kong (SAR))
Ian N. Bruce (United Kingdom)

16:20 – ABSTRACT N° OP0039
Alan Baer (United States of America)
Efficacy and safety of abatacept in active primary Sjögren’s syndrome: results of a randomised placebo-controlled phase III trial

16:30 – ABSTRACT N° OP0040
Claudius Speer (Germany)
Modified immune cell therapy ameliorates murine lupus nephritis and induces regulatory cell subsets

16:40 – ABSTRACT N° OP0041
Ronald van Vollenhoven (Netherlands)
G. Tsokos, R. Gordon, K. Lo, Y. Gregan, K. Fei, S. Rose, B. Hahn
Maintenance of efficacy and safety and reduction of bilag flares with ustekinumab, an interleukin-12/23 inhibitor, in patients with active systemic lupus erythematosus (SLE): 1-year results of a phase 2, randomized placebo-controlled, crossover study

16:50 – ABSTRACT N° OP0042
Y. K. Onno Teng (Netherlands)
Long-term effects of synergetic B cell immunomodulation with rituximab and belimumab combination treatment in severe, refractory SLE: two year results

17:00 – ABSTRACT N° OP0043
Alexis Mathian (France)
M. Pha, J. Haroche, M. Hie, F. Cohen, D. Boutin-Le Thi Huong, M. Pineton de Chambrun, P. Cherin, H. Devilliers, Z. Amoura
Withdrawal of a low dose (5 mg) of corticosteroids in systemic lupus in remission for more than a year is at risk of relapse - the CORTICOLUP trial

17:10 – ABSTRACT N° OP0044
Shi-Nan Luong (United Kingdom)
A. Isaacs, F. Sin, I. Giles
A systematic review and meta-analysis of the gonadotoxic effects of cyclophosphamide and benefits of gonadotropin releasing hormone analogues in women of child-bearing age with autoimmune rheumatic disease

17:20 – ABSTRACT N° OP0045
Hendrika Bootsma (Netherlands)
Abatacept treatment of patients with early active primary Sjögren's syndrome - a randomized, double-blind placebo-controlled phase III-study (ASAP-III)

17:30 – ABSTRACT N° OP0046
Lorenza Maria Argolini (Italy)
Multicentric study comparing cyclosporine, mycophenolate mofetil and azathioprine in the maintenance therapy of lupus nephritis: 10 years follow up

16:15 - 17:45
Hall 7B
Abstract session
CRYSTALS
Chair(s):
Alexander So (Switzerland)
Mariano Andrés (Spain)

16:20 – ABSTRACT N° OP0047
Yusuke Kawamura (Japan)
A genome-wide association study identified novel loci associated with the progression from asymptomatic hyperuricemia to gout

16:30 – ABSTRACT N° OP0048
Hirotaka Matsuo (Japan)
Genome-wide meta-analysis revealed multiple novel loci associated with serum uric acid levels in Japanese
16:40 – ABSTRACT N° OP0049
Pascal Richette (France)
Factors associated with early flares when initiating urate lowering therapies. Post hoc analysis of clear 1,2 and crystal trials

16:50 – ABSTRACT N° OP0050
Mihaela Gamala (Netherlands)
J. Jacobs, S. Linn-Rasker, M. Nix, B. Hegglman, P. Pasker, J. van Laar, R. Klaassen
Additive value and diagnostic accuracy of dual-energy CT for the diagnosis of gout: a prospective study in subjects with unclassified mono or oligoarthritis

17:00 – ABSTRACT N° OP0051
Peter Lipsky (United States of America)
N. Schlesinger, N. Edwards, A. Yeo
Development of a multivariable improvement measure for gout

17:10 – ABSTRACT N° OP0052
Fernando Perez-Ruiz (Spain)
P. Richette, A. Stack, R. Karra, M. García de Yébenes, L. Carmona
Failure to reach serum urate target is associated with elevated mortality in gout

17:20 – ABSTRACT N° OP0053
Alexander So (Switzerland)
F. Mehl, N. Harris, V. Chobaz, H. Gallart-Ayala
Ceramides and dihydroceramides levels are associated with the inflammatory response in a murine model of gout

17:30 – ABSTRACT N° OP0054
Valgerdur Sigurdardottir (Sweden)
A. Svárd, L. Jacobsson, L. Schiöler, K. Torén, M. Dehlin
Occupational exposure to inorganic dust - a novel risk factor for incident gout?

16:40 - 17:45  SOUTH AUDITORIUM

JIA: FROM NEW HORIZONS OF TREATMENT TO PERSPECTIVES OF CURRENT ONES

Chair(s):
Dirk Foell (Germany)
Gabriella Giancane (Italy)

16:15 Introduction by Chairs
16:20 – ABSTRACT N° OP0062
Huiyi Zhu (China)
C. Wu, N. Jiang, Y. Wang, J. Zhao, D. Xu, X. Zeng, M. Li
Identification of six dermatomyositis subgroups using principal component analysis-based cluster analysis

16:30 – ABSTRACT N° OP0063
Serena Vettori (Italy)
R. Chieffo, M. Ciliento, V. Giacco, G. Scalise
Safety of mycophenolate mofetil treatment in systemic sclerosis in real life: report from a single center large cohort observational study

16:40 – ABSTRACT N° OP0064
Anna-Maria Hoffmann-Vold (Norway)
T. Maher, E. Philpot, A. Ashrafzadeh, O. Distler
Evidence-based consensus recommendations for the identification and management of interstitial lung disease in systemic sclerosis

16:50 – ABSTRACT N° OP0065
Silvia Bellando Randone (Italy)
The very early diagnosis of systemic sclerosis (VEDOSS) project: predictors to develop definite disease from an international multicentre study

17:00 – ABSTRACT N° OP0066
Maja Špiritovič (Czech Republic)
Effectiveness of specialized hand/face physical-occupational therapy in patients with systemic sclerosis - preliminary results of a one-year controlled study

17:10 – ABSTRACT N° OP0067
Masataka Kuwana (Japan)
C. Blair, J. Langley, T. Takahashi, G. Coghlan
Utility of risk stratification in predicting outcomes of initial monotherapy versus combination therapy in pulmonary arterial hypertension associated with connective tissue disease: a post-hoc analysis of the AMBITION study

17:20 – ABSTRACT N° OP0068
Dinesh Khanna (United States of America)
Abatacept in early diffuse cutaneous systemic sclerosis - results of a phase 2 investigator-initiated, multicenter, double-blind randomized placebo-controlled trial

17:30 – ABSTRACT N° OP0069
Robert Spiera (United States of America)
D. Khanna, N. Dgetluck, B. Conley, B. White
Performance of American College of Rheumatology (ACR) combined response index in diffuse cutaneous systemic sclerosis (CRISS) score in phase 2 trial of lenabasum in diffuse cutaneous systemic sclerosis (DCSS)
16:15 - 17:45 N111/N112

Abstract session
CARTILAGE, SYNOVIUM AND BONE

Chair(s):
Tonia Vincent (United Kingdom)
Felice Rivellese (Italy)

16:20 – ABSTRACT N° OP0071
Olivier Malaise (Belgium)
Y. Tachikart, M. Constantiniades, M. Mumme, D. Noël, J. Wang, C. Jorgensen, J. Brondello
Revealing the link between osteoarthritis development and mesenchymal stem cell senescence

16:30 – ABSTRACT N° OP0072
Vishal Deshmukh (United States of America)
Inhibition of CLK2 and Dyrk1A by SM04690 as a novel molecular regulator of Wnt signaling, chondrogenesis, and inflammation, a potential disease-modifying treatment for knee osteoarthritis

16:40 – ABSTRACT N° OP0073
Rocio Castro-Viñuelas (Spain)
C. Sanjurjo-Rodríguez, M. Piñeiro-Ramil, T. Hermida Gómez, I. Fuentes-Boquete, J. de Toro-Santos, F. Blanco, S. Díaz-Prado on behalf of Cell Therapy and Regenerative Medicine research group
Establishment of human induced pluripotent stem cell lines (iPSC) for in vitro modelling hand osteoarthritis

16:50 – ABSTRACT N° OP0074
Timo Gaber (Germany)
A. Brinkman, A. Damerau, M. Pfeifferberger, L. Ehlers, F. Buttgerieit, P. Hoff
Tofacitinib promotes fundamental processes of bone healing

17:00 – ABSTRACT N° OP0075
Carl Goodyear (United Kingdom)
K. McCulloch, C. Huesa, L. Dunning, R. van’t Hof, J. Lockhart
PAR2 accelerates osteoarthritis-like joint changes in a murine model of post-traumatic osteoarthritis

17:10 – ABSTRACT N° OP0076
Axel Hueber (Germany)
S. Adam, N. Simon, U. Steffen (née Harre), F. Andes, D. Müller, S. Culemann, D. Andreu, M. Hahn, C. Scholtysek, G. Schett, K. Krönke, S. Frey
JAK-inhibitors tofacitinib and baricitinib improve pathological bone loss in vivo

17:20 – ABSTRACT N° OP0077
Marije Koenders (Netherlands)
I. Di Ceglie, M. Broeren, C. Waterborg, D. Dorst, R. Thurlings, P. Laverman, F. van de Loo, P. van der Kraan, P. van Lent
Innovative translational models to study human synovial pathology: target validation and preclinical imaging

16:30 – ABSTRACT N° OP0078
Beatriz Rocha Loureda (Spain)
B. Cillero-Pastor, C. Ruiz-Romero, R. Heeren, F. Blanco
Linking lipid markers to synovial hyperplasia and vascularization in osteoarthritis by MALDI-MSI

16:15 - 17:45 N115/N116

Health Professionals session
REHABILITATION, OPENING PANDORA’S BOX

Learning objectives:
- State of the art of rehabilitation within the field of rheumatic and musculoskeletal diseases (RMDs)
- To obtain knowledge about the challenges of measuring the outcome of rehabilitation

Chair(s):
Mathilda Bjork (Sweden)
Eda Tonga (Turkey)

16:20 – ABSTRACT N° SP0031
Ann Breemander (Sweden)
News in the world of rehabilitation

16:35 – ABSTRACT N° SP0032
Alison Hammond (United Kingdom)
How to measure rehabilitation

16:50 – Turid Nygaard Dager (Norway)
How to organize interdisciplinary rehabilitation

17:05 – ABSTRACT N° SP0033
Thea Vliet Vlieland (Netherlands)
Rheumatological rehabilitation, what’s next

17:20 – ABSTRACT N° OP0079-HPR
Juliane Stöcker (Netherlands)
J. Spierings, M. Vonk, F. van den Hoogen, M. Nijhuis-van der Sanden, J. Staal, T. Satink, C. van den Ende on behalf of ARCH
Non-pharmacological care in systemic sclerosis: opening the black box
16:15 - 17:45  N117/N118

Abstract session

OSTEOPOROSIS

Chair(s):
Piet Geusens (Belgium)
Daniel Prieto-Alhambra (United Kingdom)

16:20 – ABSTRACT N° OP0080
Piet Geusens (Belgium)
S. Goemaere, N. Panacciuili, N. Lane, E. Lespessailles, O. Messina, R. Chapurlat, X. Yin, R. Wagman, J. van den Bergh

Effect of denosumab versus risedronate on cortical and trabecular bone microarchitecture by high resolution peripheral quantitative computed tomography (HR-PQCT) in glucocorticoid-treated individuals

16:30 – ABSTRACT N° OP0081
Anaïs Guiot (France)
P. Szulc, R. Chapurlat

Relationship between diffuse idiopathic skeletal hypertosostosis and fragility vertebral fracture – a prospective study in older men

16:40 – ABSTRACT N° OP0082
Giovanni Adami (Italy)

Temporal trends of bisphosphonate discontinuation and factors associated with alendronate discontinuation and restart at population level

16:50 – ABSTRACT N° OP0083
Núria Guañabens (Spain)

Prevalence of vertebral fractures in postmenopausal women with rheumatoid arthritis

17:00 – ABSTRACT N° OP0084
Miguel Guerra (Portugal)
S. Ganhão, F. Aguiar, R. Ferreira, T. Martins-Rocha, A. Águeda, G. Terroso, C. Vaz, L. Costa

Fragility hip fractures – does destination after hospital discharge have an impact on patient’s outcome?

17:10 – ABSTRACT N° OP0085
Bérengère Aubry-Rozier (Switzerland)
G. Liebich, D. Stoll, E. Gonzalez-Rodriguez, D. Hans, O. Lamy

Can we avoid the loss of bone mineral density one year after denosumab discontinuation? The ReoLaus bone project

17:20 – ABSTRACT N° OP0086
Frank Buttgereit (Germany)
G. R. Burmester, J. Nebesky, J. Devenport, M. Donath, M. John

Impact of glucocorticoid tapering on markers of bone metabolism in patients with rheumatoid arthritis who achieved low disease activity or remission on tocilizumab: exploratory analysis from a randomized controlled trial

17:30 – ABSTRACT N° OP0087
Shreyasee Amin (United States of America)
D. Bekele, A. Kearns, E. Atkinson

Trends in hip fracture incidence in women and men over 1980-2015 in Olmsted county, Minnesota, USA

16:15 - 17:45  N107/N108

Abstract session

WHEN RHEUMATOID ARTHRITIS (RA) DOES NOT WALK ALONE: NEW DATA ON COMORBIDITIES IN RA

Chair(s):
Adeline Ruyssen-Witrand (France)
Yeong Wook Song (Korea, Rep. of (South Korea))

16:20 – ABSTRACT N° OP0088
Vanessa Kronzer (United States of America)
C. Crowson, J. Sparks, E. Myasoedova, J. Davis

Comorbidities as risk factors for rheumatoid arthritis (RA) and accrual after RA diagnosis

16:30 – ABSTRACT N° OP0089
Bindee Kuriya (Canada)

Metabolic syndrome is common around the time of early rheumatoid arthritis diagnosis and associations vary by sex and menopausal status: results from the Canadian Early Arthritis Cohort

16:40 – ABSTRACT N° OP0090
Piero Ruscitti (Italy)
P. Cipriani, V. Liakouli, D. Iacono, I. Pantano, G. Destro Castaniti, N. Mariotti, D. Margiotta, L. Picciariello, F. Caso, R. Grembiale, F. Atzeni, R. Scarpa, F. Peroa, A. Aelfa, F. Cantatore, G. Guggino, F. Ciccia, R. Giamelli on behalf of GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale)

The occurrence of subclinical and clinical atherosclerosis in rheumatoid arthritis, results from the 3-year, multicenter, prospective, observational, GIRRCS study

16:50 – ABSTRACT N° OP0091
Núria Guañabens (Spain)

Prevalence of vertebral fractures in postmenopausal women with rheumatoid arthritis

17:00 – ABSTRACT N° OP0092
Miguel Guerra (Portugal)
S. Ganhão, F. Aguiar, R. Ferreira, T. Martins-Rocha, A. Águeda, G. Terroso, C. Vaz, L. Costa

Fragility hip fractures – does destination after hospital discharge have an impact on patient’s outcome?

17:10 – ABSTRACT N° OP0093
Bérengère Aubry-Rozier (Switzerland)
G. Liebich, D. Stoll, E. Gonzalez-Rodriguez, D. Hans, O. Lamy

Can we avoid the loss of bone mineral density one year after denosumab discontinuation? The ReoLaus bone project

17:20 – ABSTRACT N° OP0094
Frank Buttgereit (Germany)
G. R. Burmester, J. Nebesky, J. Devenport, M. Donath, M. John

Impact of glucocorticoid tapering on markers of bone metabolism in patients with rheumatoid arthritis who achieved low disease activity or remission on tocilizumab: exploratory analysis from a randomized controlled trial

17:30 – ABSTRACT N° OP0095
Shreyasee Amin (United States of America)
D. Bekele, A. Kearns, E. Atkinson

Trends in hip fracture incidence in women and men over 1980-2015 in Olmsted county, Minnesota, USA
16:50 – ABSTRACT N° OP0091
René Cordtz (Denmark)
L. Kristensen, A. Odgaard, S. Overgaard, L. Dreyer
Risk of medical complications following total hip or knee arthroplasty in patients with rheumatoid arthritis: a nationwide register-based cohort study

17:00 – ABSTRACT N° OP0092
Hsiu Yen Tung (United Kingdom)
S. Norton, F. Matcham, J. Galloway, M. Hotopf
Associations between clinical variables and psychological symptoms in rheumatoid arthritis: a network science perspective

17:10 – ABSTRACT N° OP0093
Shohei Anny (Japan)
The incidence and risk factor of new carotid plaques and the progression rate of carotid plaques in patients with rheumatoid arthritis in 6 years prospective case control study -TOMORROW study-

17:20 – ABSTRACT N° OP0094
Kiana Yazdani (Canada)
H. Xie, A. Aviña, Y. Zheng, M. Abrahamowicz, D. Lacaille
Secular trends in the incident risk of cerebrovascular accident in rheumatoid arthritis relative to the general population

17:30 – ABSTRACT N° OP0095
Ryoko Sakai (Japan)
Influence of periodontitis on disease activity, physical function, and safety in patients with rheumatoid arthritis: a observational study using the IORRA cohort

16:15 - 17:45 N109/N110
Abstract session

TACKLING CHRONIC PAIN; FIBROMYALGIA AND BACK PAIN

Chair(s):
David Walsh (United Kingdom)
Nidhi Sofat (United Kingdom)

16:20 – ABSTRACT N° OP0096
Stefan Dudli (Switzerland)
Dysregulated bone marrow stromal cells in modic type 1 changes

16:30 – ABSTRACT N° OP0097
Stefan Bergman (Sweden)
B. Drab, K. Alli, E. Haglund
Chronic pain and sick leave in a 21-year follow up

16:40 – ABSTRACT N° OP0098
Mohammad Adawi (Israel)
N. Bragazzi, D. McGonagle, A. Watad, H. Amital
Suicidal behaviour in fibromyalgia patients: meta-analysis and systematic review of the literature

16:50 – ABSTRACT N° OP0099
Ilknur Aktas (Turkey)
C. Bursali, F. Unlu Ozkan, M. Yilmaz Kaysin, N. Dortcan, D. Geler Kulcu
Effectiveness of repetitive transcranial magnetic stimulation in patients with failed back surgery syndrome

17:00 – ABSTRACT N° OP0100
Samar Abd Alhamed Tabra (Egypt)
M. Abu-Zaid, M. Aboelhawa, S. Elmorsy
The effect of combined pregabalin and duloxetine in functional status, quality of life and psychological status in fibromyalgia

17:10 – ABSTRACT N° OP0101
Blanca Gavilán Carrera (Spain)
Comparative effectiveness of land and water-based exercise on quality of life of patients with fibromyalgia: preliminary findings from the al-Ándalus randomised controlled trial

17:20 – ABSTRACT N° OP0102
Camille Daste (France)
S. Laclau, M. Boisson, F. Segretin, A. Feydy, M. Lefevre Colau, F. Rannou, C. Nguyen
Intervertebral disc therapies for non-specific chronic low back pain: a systematic review and meta-analysis

17:30 – ABSTRACT N° OP0103
Martin Badard (France)
M. Certain, F. Rannou, P. Ribinik, X. Dufour, F. Bailly, B. Fautrel, V. Foltz on behalf of French national public health insurance (CNAMTS), BVA, Rachis section, Therapeutic education section of French Society of Rheumatology, CEDR (Pain Center Study of Rheumatology)
Effects on a French mass media campaign on back pain beliefs and behaviors
18:15 - 19:45  SOUTH AUDITORIUM

Basic and Translational Science session

PERSONALISED MEDICINE IN RHEUMATIC DISEASE

Learning objectives:
- To see how patient stratification can improve clinical care
- To learn about examples where patient stratification was successfully applied

Chair(s):
Lucy Wedderburn (United Kingdom)
Aurelie Najm (France)

18:20 – ABSTRACT N° SP0034
John Isaacs (United Kingdom)
RA-MAP. Patient stratification in RA

18:38 – ABSTRACT N° SP0035
Yoshiya Tanaka (Japan)
Precision medicine in PsA

18:56 – ABSTRACT N° SP0036
Ian N. Bruce (United Kingdom)
MASTERPLANS - tailoring SLE for therapy

19:14 – ABSTRACT N° SP0037
Anne Barton (United Kingdom)
Using genetics in personalised medicine in rheumatic diseases

19:32 – ABSTRACT N° OP0104
Fiona Watt (United Kingdom)
C. Garriga, M. Goff, K. Leyland, E. Paterson, R. Hrusecka, B. Hamid, L. Honeyfield, K. Satchithananda, A. Lim, N. Arden, A. Judge, A. Williams, T. Vincent
The presence of blood in the joint and the immediate molecular response in synovial fluid are independently associated with worse clinical outcomes at 2 years after human knee injury

18:15 - 19:45  N105/N106

Health Professionals session

THE RIDDLE OF ADHERENCE

Learning objectives:
- To learn about adherence and important facilitating factors
- To obtain knowledge about screening tools and what to prioritise in clinical care

Chair(s):
Yeliz Prior (United Kingdom)
Fernando Estevez-Lopez (Spain)

18:20 – Robert Horne (United Kingdom)
Adherence and beliefs about medication

18:45 – Ailsa Bosworth (United Kingdom)
Patient perspectives on adherence to medication

19:10 – ABSTRACT N° SP0038
Bart van den Bemt (Netherlands)
Factors important for medical adherence

19:35 – ABSTRACT N° OP0105-HPR
Yomei Shaw (Switzerland)
D. Courvoisier, A. Scherer, A. Ciurea, T. Lehmann, V. Jaeger, U. Walker, A. Finckh
Do mobile apps improve shared decision making and disease management in the rheumatic diseases? An evaluation of apps in a Swiss rheumatology registry

20:00 - 22:00  ESPLANADE (HALL 6)

NETWORKING PLATFORM
SCIENTIFIC PROGRAMME
THURSDAY
13 JUNE 2019

07:45 - 19:15  REGISTRATION AREA (HALL 2)
Registration

08:15 - 09:45  SOUTH AUDITORIUM
Basic and Translational Science session
FROM THE CRADLE TO THE GRAVE - WHAT DOES PAEDIATRIC DISEASE TEACH US ABOUT ADULT DISEASE?

Learning objectives:
- To learn about common pathways activated in paediatric and adult rheumatic diseases
- To understand which pathways are active in paediatric monogenic auto-inflammatory diseases

Chair(s):
Helen J. Lachmann (United Kingdom)
Angelo Ravelli (Italy)

08:20 – Seza Özen (Turkey)
Monogenic auto-inflammatory diseases: defining new pathways in human innate immunity and inflammation

08:40 – Raphaela Goldbach-Mansky
(United States of America)
JAK1/2 inhibition in the treatment of auto-inflammatory interferonopathies

09:00 – Mike Briggs (United Kingdom)
Animal models of chondrodysplasia – what do these teach us about adult OA?

09:20 – ABSTRACT N° OP0106
Arinna Bertoni (Italy)
A novel knock-in mouse model of caps that develops amyloidosis: therapeutic efficacy of proton pump inhibitors

09:30 – ABSTRACT N° OP0107
Alice Lepelley (France)
Heterozygous mutations in COPA are associated with enhanced type I interferon signalling

09:45 - 10:15  COFFEE BREAK

10:15 - 11:45  HALL 6
WIN & HOT session
ADVANCES IN UNDERSTANDING AND TREATING OF SLE

Learning objectives:
- To update on the current understanding of the immunopathogenic mechanisms of SLE, including the role of interferons, activation of innate and adaptive immunity with an emphasis on recent discoveries with a potential to change therapeutic concepts
- To provide a state-of-the-art overview on the current treatment algorithms for renal and non-renal SLE beyond current EULAR Recommendations, discussing T2T approaches (LLDAS, remission) and outlook of new therapeutic advances

10:20 – ABSTRACT N° SP0039
Mary K. Crow (United States of America)
WIN: De-convoluting the complexities of SLE – recent insights into the pathogenesis

11:00 – ABSTRACT N° SP0040
Thomas Dörner (Germany)
HOT: Novel paradigms in the management of SLE
36 | SCIENTIFIC PROGRAMME | THURSDAY 13 JUNE 2019

10:15 - 11:45 HALL 8

Abstract session

PSORIATIC ARTHRITIS: OLD AND NEW DRUGS AND HOW TO DEAL WITH THEM?

Chair(s):
Laura C. Coates (United Kingdom)
Kurt de Vlam (Belgium)

10:20 – ABSTRACT N° OP0108
Christopher T. Ritchlin (United States of America)
Dual neutralisation of IL-17A and IL-17F with bimekizumab in patients with active PsA: overall and TNF-inhibitor-naïve population results from a 48-week phase 2B randomised study

10:30 – ABSTRACT N° OP0109
Philip J. Mease (United States of America)
D. Gladman, F. van den Bosch, M. Stanislavchuk, A. Rychlewiska-Hanczewska, C. Tasset, L. Meuleners, R. Besuyen, J. Gao, M. Trivedi, L. Coates, P. Helliwell
Efficacy of filgotinib vs placebo in active psoriatic arthritis: patient-level data from equator, a randomized, phase 2 study

10:40 – ABSTRACT N° OP0110
L Bruce Kirkham (United Kingdom)
C. Sesin, A. Sprabery, C. Lin, A. Gellett, A. Turkiewicz
Ixekizumab improves signs and symptoms of psoriatic arthritis in patients who have had inadequate response to 1 or 2 tumor necrosis factor inhibitors

10:50 – ABSTRACT N° OP0111
Philip J. Mease (United States of America)
D. Gladman, C. Collier, T. Ritchlin, P. Helliwell, L. Coates, V. Strand, L. Liu, G. Kricorian, J. Chung
A randomized, phase 3, double-blind trial examining methotrexate and etanercept as monotherapy or in combination for treating psoriatic arthritis: a comparison of the composite measures used to evaluate disease activity

11:00 – ABSTRACT N° OP0112
Tor Olofsson (Sweden)
C. Roseman, J. Wallman, A. Jöud, M. Schelin, J. Einarsson, E. Lindqvist, M. Kapetanovic, J. Lampa
Unacceptable pain despite inflammation control after start of a first anti-TNF therapy in patients with psoriatic arthritis and its relation to treatment response

11:10 – ABSTRACT N° OP0113
Alessandra Nerviani (United Kingdom)
G. Liiso Ribera, M. Boutet, K. Goldmann, S. Kelly, M. Bombardieri, M. Lewis, F. Humby, C. Pitzalis
Histological and molecular portrait of the synovial tissue in early treatment-naive psoriatic arthritis in comparison with rheumatoid arthritis

11:20 – ABSTRACT N° OP0114
Iain McInnes (United Kingdom)
M. Kormaksson, E. Pournara, G. Ligozio, L. Pricop, K. Abrams, B. Kirkham, K. Reich
Machine learning tools identify patient clusters and swollen and tender joint correlation patterns in a large database from the secukinumab psoriatic arthritis clinical development program

11:30 – ABSTRACT N° OP0115
Alexis Ogdie (United States of America)
General and sex-specific predictors of PsA among patients with psoriasis

10:15 - 11:45 HALL 7A

Abstract session

“RHEUMATOID ARTHRITIS – LOOKING BEFORE, LOOKING FORWARD!”

Chair(s):
Georg Schett (Germany)
George E. Fragoulis (Greece)

10:20 – ABSTRACT N° OP0116
Alf Kastbom (Sweden)
Joint erosions visible on ultrasound predict arthritis development in patients with ACPA and musculoskeletal pain but no swollen joints

10:30 – ABSTRACT N° OP0117
Georg Schett (Germany)
Micro-structural changes associated with anti-citrullinated vimentin autoimmunity in RA-at-risk individuals precipitate the onset of rheumatoid arthritis

10:40 – ABSTRACT N° OP0118
Matthew J. Loza (United States of America)
Discrete patterns of citrullinated peptide autoantibody reactivities emerge during progression from pre-disease state to diagnosis of rheumatoid arthritis

10:50 – ABSTRACT N° OP0119
Carles Ubeda (Spain)
The pre-treatment gut microbiome predicts early response to rheumatoid arthritis therapy
11:00 – ABSTRACT N° OP0120
Gloria Liiso Ribera (United Kingdom)
Baseline cellular and molecular characteristics of synovial tissue and relation with TNFI response. Results from the pathobiology of the early arthritis cohort (PEAC)

11:10 – ABSTRACT N° OP0121
Michaela Koehm (Germany)
U. Henkemeier, T. Rossmanith, K. Margenthal, J. Petersen, H. Burkhardt, F. Behrens on behalf of PANORA working group
Patient characteristics and incidence of signs of inflammation in patients with new onset of non-specific musculoskeletal symptoms and positive anti-citrullinated peptide point-of-care test in Germany - the PANORA trial

11:20 – ABSTRACT N° OP0122
Nancy Shadick (United States of America)
Exploring heterogeneity in rheumatoid arthritis: patient profiling through principal component and cluster analysis of the BRASS registry

11:30 – ABSTRACT N° OP0123
Ruth Costello (United Kingdom)
M. Haris, J. Humphreys, J. Sergeant, F. Stirling, K. Raza, D. van Schaardenburg, I. Bruce
Symptoms in first degree relatives of patients with rheumatoid arthritis: evaluation of data from the symptoms in persons at risk of rheumatoid arthritis questionnaire

11:00 – ABSTRACT N° OP0125
Nadia Howard Tripp (United Kingdom)
B. Hargreaves, J. Tarn, D. Lendrem, W. Ng
Real world longitudinal data using EULAR outcome assessment tools for primary Sjögren’s syndrome (pSS) patients in a UK clinic

10:30 – ABSTRACT N° OP0126
Soledad Retamozo (Argentina)
Lymphoma arising at the time of diagnosis of primary Sjögren syndrome: a highly-active systemic subset of the disease

10:40 – ABSTRACT N° OP0127
Lucia Campos (Brazil)
Disease presentation of 1,312 childhood-onset systemic lupus erythematosus: influence of ethnicity

10:50 – ABSTRACT N° OP0128
Richard Furie (United States of America)
Systemic lupus erythematosus disease characteristics associated with the type I interferon gene signature: baseline data of the SLE prospective observational cohort study (SPOCS)

11:00 – ABSTRACT N° OP0129
Marc Pineton de Chambrun (France)
A. Mathian, A. Combes, C. Luyt, Z. Amoura on behalf of Registre SAPHIR
CAPS criteria fail to identify most severe patients with antiphospholipid syndrome admitted to the intensive care unit with a new thrombotic manifestation
11:00 – ABSTRACT N° OP0136
Kyungh Ann Lee (Korea, Rep. of (South Korea))
S. Lee, H. Kim
Diagnostic value of ultrasound in calcium pyrophosphate deposition disease of the knee joint

11:10 – ABSTRACT N° OP0137
Sarah Kennedy (United States of America)
C. Swearingen, J. Tambiah, P. Conaghan
Optimizing subject selection in knee osteoarthritis clinical trials by radiographic joint space width: post-hoc clinical response analysis from a phase 2B trial of Wnt pathway inhibitor, SM04690

11:20 – ABSTRACT N° OP0138
Laura Barrio Nogal (Spain)
C. Bohórquez, A. Abbasi, L. Ruiz, A. Pérez Gómez, A. Castelló, M. Álvarez de Mon
The role of ultrasound in the diagnosis of primary Sjögren syndrome and its concordance with salivary gland biopsy

10:15 - 11:45
SOUTH AUDITORIUM
Abstract session

DIAGNOSTICS AND IMAGING PROCEDURES

Chair(s):
Lene Terslev (Denmark)
Xenofon Baraliakos (Germany)

10:20 – ABSTRACT N° OP0132
Yousra Dakkak (Netherlands)
A. Boer, D. Boeters, M. Reijnierse, A. van der Helm - van Mil
How accurate is physical joint examination of the MTP-joints, and what can we learn from additional magnetic resonance imaging on forefoot involvement in early arthritis?

10:30 – ABSTRACT N° OP0133
Kresten Krarup Keller (Denmark)
J. Thomsen, K. Stengaard-Pedersen, J. Therkildsen, A. Nielsen, B. Schiøttz-Christensen, L. Svendsen, M. Graakjær, P. Petersen, B. Unger, G. Kjær, B. Langdahl, E. Hauge
One-year progression of erosive disease evaluated with high-resolution peripheral quantitative computed tomography in patients with anti-citrullinated peptide antibodies and arthralgia

10:40 – ABSTRACT N° OP0134
Ulf Sundin (Norway)
Ultrasound in the management of early rheumatoid arthritis: MRI outcome data from the ARCTIC randomized controlled strategy trial

10:50 – ABSTRACT N° OP0135
Sin Ngai Ng (Hong Kong (SAR))
M. Bjørndal Axelsen, M. Østergaard, I. Eshed, M. Hetland, J. Mollenbach Møller, S. Juhi Pedersen, L. Terslev
How well does whole body magnetic resonance imaging agree with whole body ultrasound in the assessment of joint inflammation in rheumatoid arthritis patients
10:50 – ABSTRACT N° OP0143
Alojzija Hocevar (Slovenia)
R. Jese, Z. Rotar, M. Tomsic
Predictors of severe cranial ischemic complications in giant cell arteritis

11:00 – ABSTRACT N° OP0144
Niv Ben-Shabat (Israel)
H. Amitai, A. Cohen, D. Comanesther, S. Tiosano
Mortality in giant cell arteritis patients: a nationwide population-based study

11:10 – ABSTRACT N° OP0145
Diane Marsman (Netherlands)
A. van der Maas, A. den Broeder, F. van den Hoogen, N. den Broeder, N. Boers
Normal versus elevated acute phase reactants in patients with polymyalgia rheumatica: are these different subsets?

11:20 – ABSTRACT N° OP0146
Gulen Hatemi (Turkey)
Efficacy of apremilast for oral ulcers associated with active Behçet’s syndrome over 64 weeks: results from a phase III study

11:30 – ABSTRACT N° OP0147
Isabelle Koné-Paut (France)
KAWAKINRA: a phase IIa multicenter trial to assess the efficacy, and safety of anakinra in patients with intravenous immunoglobulin-resistant Kawasaki disease

10:50 – ABSTRACT N° OP0150
Grant Schultet (United States of America)
T. Do, S. Dhakal, N. Fall, M. Medvedovich, N. Salomonis, A. Grom
Monocyte and macrophage transcriptional phenotypes in systemic juvenile idiopathic arthritis reveal TRIM8 as a mediator of IFNgamma hyperresponsiveness and risk for macrophage activation syndrome

10:50 – ABSTRACT N° OP0151
Klaus Tenbrock (Germany)
MiRNAs contribute to dysregulated ROS metabolism of immune cells in the inflamed joint

11:00 – ABSTRACT N° OP0152
Erdal Sag (Turkey)
S. Demir, M. Nielsen, M. Hvid, E. Turhan, Y. Bilginer, S. Özen, B. Deleuran
Oligoarticular juvenile idiopathic arthritis does not show signs of T cell exhaustion, in spite of increased expression of co-inhibitory receptors

11:10 – ABSTRACT N° OP0153
Jim Jarvis (United States of America)
H. Kessler, E. Tarbell, Y. Park
Broadening our understanding of the genetics of juvenile idiopathic arthritis: interrogation of three dimensional chromatin structures within JIA-associated risk loci

11:20 – ABSTRACT N° OP0154
Emma Dorris (Ireland)
F. Adeeb, D. Lawless, W. Ng, A. Anjum, N. Morgan, E. Cummins, S. Savic, A. Fraser, G. Wilson
A novel RELA truncation in a 3-generation family with Behçet’s disease alters the apoptotic response to inflammatory stimulants

10:15 - 11:45 N101/N102
Abstract session PReS
JOURNEYS FROM BENCH TO BEDSIDE IN PAEDIATRIC RHEUMATOLOGY

Chair(s):
Johannes Roth (Germany)
Lucy Wedderburn (United Kingdom)

10:20 – ABSTRACT N° OP0148
George Robinson (United Kingdom)
A. Radziszewska, C. Wincup, C. Ciurtin, Y. Ioannou, I. Pineda Torra, E. Jury on behalf of Jury Lab
Metabolomics in juvenile-onset SLE: identifying new biomarkers to predict cardiovascular risk

10:30 – ABSTRACT N° OP0149
Jim Jarvis (United States of America)
E. Tarbell, K. Jiang, T. Hennon, L. Holmes, P. Gaffney, T. Liu
CD4+ T cells from children with active juvenile idiopathic arthritis show aberrant chromatin organization and CTCF localization associated with transcriptional abnormalities

10:15 - 11:45 N105/N106
Abstract session HPR
TRANSFORMATIVE CARE: THE FUTURE

Chair(s):
Wilfred F. Peter (Netherlands)
Yeliz Prior (United Kingdom)

10:20 – ABSTRACT N° OP0155-HPR
Ross Wilkie (United Kingdom)
S. Parmar, M. Bucknall
Targets for reducing premature mortality in older adults with osteoarthritis: results from a novel path analysis within a Cox proportional hazards model

10:30 – ABSTRACT N° OP0156-HPR
Zhengping Huang (China)
X. Zhong, Z. Xie, T. Li
The feasibility and effectiveness of telemedicine for knee osteoarthritis in disease management: a randomised control trial
10:30 – ABSTRACT N° OP0157-HPR
Marc De Meulemeester (Belgium)
T. Jansen, G. Petersen, F. Perez-Ruiz
European patient voice in gout survey – subjective satisfaction in gout patients versus objective suboptimal gout care

10:50 – ABSTRACT N° OP0158-HPR
Hayley McBain (United Kingdom)
M. Bezzant, A. Bosworth
The barriers and facilitators to requesting and receiving psychological support for people with rheumatoid arthritis and adults with juvenile idiopathic arthritis

11:00 – ABSTRACT N° OP0159
Arjan de Zwart (Netherlands)
The effect of high-intensity resistance training and vitamin D supplementation on muscle strength in patients with knee osteoarthritis: a randomized controlled trial

11:10 – ABSTRACT N° OP0160-HPR
Else Marit H. Gravãs (Norway)
N. Østerås, R. Nossum, R. Mehl Eide, Å. Klokkeide, K. Hoegh Matre, M. Olsen, Ø. Andreassen, I. Haugen, A. Tvetter, I. Kjeken
Does occupational therapy delay or reduce the proportion of patients who receives thumb carpometacarpal surgery? A randomized controlled trial

11:20 – ABSTRACT N° OP0161-HPR
Ingvild Kjeken (Norway)
A. Tvetter, R. Nossum, R. Mehl Eide, Å. Klokkeide, K. Hoegh Matre, M. Olsen, Ø. Andreassen, N. Osteras
Short-term effect of occupational therapy intervention on hand function and pain in patients with thumb base osteoarthritis – secondary analyses of a randomized controlled trial

11:30 – ABSTRACT N° OP0162-HPR
Valentin Ritschl (Austria)
The need for personalized, non-pharmacological intervention programmes in autoimmune connective tissue disorders: results of a EULAR-funded scoping review with a nested, descriptive meta-analysis

10:15 - 11:45
N111/N112

Abstract session
OTHER ORPHAN DISEASES

Chair(s):
Tilmann Kallinich (Germany)

10:20 – ABSTRACT N° OP0163
Norbert Blank (Germany)
Long-term effectiveness of canakinumab in patients with cryopyrin-associated periodic syndrome

10:30 – ABSTRACT N° OP0164
Feng Huang (China)
Y. Wang, Z. Zhao, J. Zhu, J. Zhang
Leflunomide in combination with glucocorticoids Is superior to conventional glucocorticoids monotherapy in preventing relapse in IgG4-related disease: a randomized, open-label, controlled trial

10:40 – ABSTRACT N° OP0165
Marie Kostine (France)
EULAR recommendations for the diagnosis and the management of rheumatic immune-related adverse events due to cancer immunotherapy

10:50 – ABSTRACT N° OP0166
Masato Tarumi (Japan)
The efficacy of calcineurin inhibitors in patients with Adult-onset Still’s disease: multi-centre historical cohort study

11:00 – ABSTRACT N° OP0167
Emanuel Della Torre (Italy)
E. Rigamonti, C. Perugino, M. Falconi, J. Stone, A. Manfredi, S. Pililai
B lymphocytes directly contribute to tissue fibrosis in IgG4-related disease

11:10 – ABSTRACT N° OP0168
Umut Kalyoncu (Turkey)
Derivation and validation of a new still activity score (SAS)
11:20 – ABSTRACT N° OP0169
D. Prieto-Peña (Spain)
M. Calderón-Goercke, A. Martínez-Meñaca, V. Mora-Cuesta, S. Fernández-Rozas,
D. Iturbe-Fernández, J. Cifrián-Martínez, M. González-Gay, R. Blanco
Long-term survival in lung transplantation for interstitial lung disease associated with connective tissue diseases. Study of 26 cases of a single center

11:30 – ABSTRACT N° OP0170
Andreu Fernandez-Codina (Canada)
B. Pinilla, I. Pinal-Fernandez, C. Feijoo-Masso, M. Lopez-Dupla, E. Fonseca, O. Orozco-Galvez,
F. Martinez-Valle on behalf of Registro Español de Enfermedad Relacionada con la IgG4 (REERIGG4)
Use of the provisional EULAR/ACR IgG4-RD classification criteria in a cohort of Spanish patients

10:15 - 11:45 N115/N116
Joint Session PAR/PReS
FROM CHILD TO ADULT CARE - BREAKING DOWN THE BARRIERS OF TRANSITION

Learning objectives:
- To outline the barriers of transition and potential strategies to overcome them
- To discuss measures and instruments of how improvements can be achieved in daily practice

Chair(s):
Mirjam Kepic (Slovenia)
Berent J. Prakken (Netherlands)

10:20 – ABSTRACT N° SP0041
Stephen Ball (United Kingdom)
Tackling transition: the current landscape, and where we are heading

10:40 – ABSTRACT N° SP0042
Judy Ammerlaan (Netherlands)
From paediatric care to adult care – the needs of young people, and how healthcare professionals can facilitate optimal transition

10:00 – ABSTRACT N° SP0043
Indra Beer (Germany)
My ideal transition

11:20 – ABSTRACT N° OP0171-PARE
Cajsa Helin Hollstrand (Sweden)
K. Nordlund, M. Beermann
The Swedish young rheumatics report – the most urgent matters and the most promising development areas for young people with RMDs in Sweden

11:30 – ABSTRACT N° OP0172-PARE
Mirjam Kepic (Slovenia)
S. Stones, S. Angevare, S. Ainsworth, W. Costello, A. Gruss, A. van de Louw
Working together for children and families living with rheumatic and musculoskeletal diseases: the European network for children with arthritis (ENCA)

10:20 – ABSTRACT N° OP0173
Ignacio Rego-Perez (Spain)
Erosive hand osteoarthritis associates with low occurrence of knee osteoarthritis

10:40 – ABSTRACT N° OP0174
Daniel Prieto-Alhambra (United Kingdom)
E. Burn, J. Weaver, A. Sena, H. Morgan Stewart, P. Ryan
Partial knee replacement is associated with a lower risk of venous thromboembolism and opioid use than total knee replacement but increased risk of long-term revision: a multinational, multi-database, propensity score-matched, cohort analysis including over 280,000 patients

10:50 – ABSTRACT N° OP0175
Christian Roux (France)
S. Ferrero, R. Wittoek, E. Allado, E. Fontas, C. Cruzel, L. Euler-Ziegler, D. Loeuille
Methotrexate in patients with hand osteoarthritis refractory to analgesics: a randomised, double-blind, placebo controlled trial

11:00 – ABSTRACT N° OP0176
Marieke Loef (Netherlands)
W. Damman, R. de Mutsert, F. Rosendaal, M. Kloppenburg
Health-related quality of life in hand osteoarthritis patients from the general population and the outpatient clinic

11:10 – ABSTRACT N° OP0177
Feng Pan (Australia)
J. Tian, S. MaisarahMattap, F. Cicuttini, G. Jones
Association between metabolic syndrome and knee structural change on MRI: a 10.7-year follow-up study

11:20 – ABSTRACT N° SP0044
Christian Roux (France)
C. Rouille, J. Coste, J. Sellam, A. Rat, F. Guillemin
Cardiovascular comorbidities have a deleterious impact on knee osteoarthritis prognosis at 5 years: data from the prospective KHOALA cohort
11:20 – ABSTRACT N° OP0179
Feng Pan (Australia)
J. Tian, I. Munugoda, S. Graves, M. Lorimer, F. Cicuttini, G. Jones
Do distinct pain phenotypes have different risk of knee replacement: a 13.7-year follow-up study?

11:30 – ABSTRACT N° OP0180
Féline Kroon (Netherlands)
M. Korteckaas, A. Boonen, S. Böhringer, M. Reijnierse, F. Rosendaal, N. Riyazi, M. Starmans, F. Turksstra, J. van Zeben, C. Allaart, M. Kloppenburg
Low-dose prednisolone in patients with hand osteoarthritis (HOPE): results from a randomised double-blind placebo-controlled trial

10:15 - 11:45 N107/N108
Abstract session
SYSTEMIC SCLEROSIS, MYOSITIS AND RELATED SYNDROMES - ETIOLOGY, PATHOGENESIS AND ANIMAL MODELS

Chair(s):
Francesco Del Galdo (United Kingdom)
Ellen De Langhe (Belgium)

10:20 – ABSTRACT N° OP0183
Oliver Distler (Switzerland)
Efficacy and safety of riociguat in patients with early diffuse cutaneous systemic sclerosis and interstitial lung disease (SSc-ILD): results from the phase IIB RISE-SSc study

10:30 – ABSTRACT N° OP0181
He Chen (China)
Molecular characterization and stratification of idiopathic inflammatory myopathies: on the basis of skeletal muscle transcriptome study

10:40 – ABSTRACT N° OP0182
Richard Stratton (United Kingdom)
Synthetic peptides targeting CD206 inhibit pathogenic macrophages in systemic sclerosis

10:50 – ABSTRACT N° OP0184
Elena Pachera (Switzerland)
S. Assassi, G. Salazar, M. Frank-Bertoncelj, J. Distler, G. Kania, O. Distler
Proliferative lncRNA H19X: unravelling the effects on chromatin remodeling in systemic sclerosis fibroblasts

11:00 – ABSTRACT N° OP0185
Michal Rudnik (Switzerland)
M. Stellato, P. Błyszczyk, K. Klingel, J. Henes, C. Feghali-Bostwick, O. Distler, G. Kania
Inflammation-dependent decreased expression of CD52 on circulating CD14+ monocytes facilitates adhesion in systemic sclerosis

11:10 – ABSTRACT N° OP0186
Mara Stellato (Switzerland)
M. Rudnik, F. Renoux, P. Błyszczyk, E. Osto, M. Dewenter, P. Seebeck, E. Pachera, O. Distler, G. Kania
LIN-GP38+ stromal cells are key effector cells in myocardial fibrosis and defects of the conduction system

11:20 – ABSTRACT N° OP0187
Olga Koneva (Russian Federation)
L. Ananyeva, L. Garzanova, O. Desinova, O. Ovsyannikova, M. Starovoytova on behalf of Laboratory of microcirculation and inflammation
Rituximab and cyclophosphamide comparison for efficacy and safety in the patients with systemic sclerosis associated with interstitial lung disease

10:15 - 11:45 N109/N110
Abstract session
GENETICS, EPIGENETICS AND IMMUNITY

Chair(s):
Anne Barton (United Kingdom)
Alla Skapenko (Germany)

10:20 – ABSTRACT N° OP0189
John Bowes (United Kingdom)
A. Yarwood, S. Smith, D. Tarasek, W. Thomson on behalf of Childhood Arthritis Prospective Study (CAPS), United Kingdom Juvenile Idiopathic Arthritis Genetics Consortium (UKJIAGC), Childhood Arthritis Response to Medication Study (CHARMS), Biologics for Children with Rheumatic Diseases (BCRD) and BSPAR-Etanercept Study
Genetics of juvenile idiopathic arthritis: the identification of a novel risk locus and clinical subgroup analysis

10:30 – ABSTRACT N° OP0188
Junping Yin (Germany)
X. Wang, X. Yue, G. Riemekasten, X. Yu, F. Petersen
Pathogenicity of functional autoantibodies against AT1R in a mouse model of systemic sclerosis

10:20 – ABSTRACT N° OP0187
Olga Koneva (Russian Federation)
L. Ananyeva, L. Garzanova, O. Desinova, O. Ovsyannikova, M. Starovoytova on behalf of Laboratory of microcirculation and inflammation
Rituximab and cyclophosphamide comparison for efficacy and safety in the patients with systemic sclerosis associated with interstitial lung disease

10:30 – ABSTRACT N° OP0188
Junping Yin (Germany)
X. Wang, X. Yue, G. Riemekasten, X. Yu, F. Petersen
Pathogenicity of functional autoantibodies against AT1R in a mouse model of systemic sclerosis
**GUIDED POSTER TOURS**

Guided poster tours on various topics are taking place during the official poster viewing. For details on the posters presented during the various tours, please refer to the online programme available at [www.congress.eular.org](http://www.congress.eular.org) or the EULAR 2019 Congress Mobile App.

Please note that you need to register to participate in a guided poster tour. The number of participants per tour is limited to 20. Registrations can be made at the poster tours & workshop desk, located in the registration area in Hall 2, on a ‘first-come-first-served’ basis the day of the poster tour.

The poster tours take place at the corresponding ePoster stations located in Hall 10 (Tour T01 on ePoster station 01, T02 on ePoster station 02, etc.)

**Poster tour**

**T01: CYTOKINES AND INFLAMMATORY MEDIATORS - NOVEL MECHANISTIC PATHWAYS IN RHEUMATIC MUSCULOSKELETAL DISEASES – FROM SCIENCE TO CLINICS**

**Chair(s):**
- Timothy R. Radstake (Netherlands)
- Stefano Alivernini (Italy)

**ABSTRACTS N°: THU0006 - THU0019**

**Poster tour**

**T02: RA, THESE ARE EXCITING TIMES..**

**Chair(s):**
- Duncan Porter (United Kingdom)
- Yannick Degboe (United Kingdom)

**ABSTRACTS N°: THU0058 - THU0067**

**Poster tour**

**T03: DO WE HARM WHEN WE IMPROVE? TREATMENT EFFECTS AND COMORBIDITIES IN RHEUMATOID ARTHRITIS**

**Chair(s):**
- Laure Gossec (France)
- Peter Korsten (Germany)

**ABSTRACTS N°: THU0109 - THU0118**
T04: SLE, SJÖGREN'S AND APS - CLINICAL ASPECTS (OTHER THAN TREATMENT) - LUPUS JOURNEY  
**Chair(s):**  
Angela Tincani (Italy)  
Maria Chiara Gerardi (Italy)  
**ABSTRACTS N°:** THU0244 - THU0253

T05: CLINICAL ASPECTS OF AXIAL SPA: ALL YOU WANT TO KNOW, AND LIKELY MORE - PART I  
**Chair(s):**  
Robert B. M. Landewé (Netherlands)  
Miranda van Lunteren (Netherlands)  
**ABSTRACTS N°:** THU0358 - THU0366

T06: OSTEOARTHRITIS: RESEARCH IN MOTION  
**Chair(s):**  
Francis Berenbaum (France)  
Gjis Snijders (Netherlands)  
**ABSTRACTS N°:** THU0412 - THU0421

T07: MUSCULOSKELETAL PAIN; MOLECULES TO MANAGEMENT  
**Chair(s):**  
David Walsh (United Kingdom)  
Alberto Batticciotto (Italy)  
**ABSTRACTS N°:** THU0467-THU0471 & THU0482-THU0486

T08: TRANSLATIONAL SCIENCE AS THE FOUNDATION FOR FUTURE THERAPIES IN PAEDIATRIC RHEUMATOLOGY  
**Chair(s):**  
Fabrizio De Benedetti (Italy)  
**ABSTRACTS N°:** THU0505 - THU0514

T09: HOW CAN WE IMPROVE OUR CARE OF CHILDREN AND YOUNG PEOPLE WITH PAEDIATRIC RHEUMATIC DISORDERS?  
**Chair(s):**  
Coziana Ciurtin (United Kingdom)  
Gerd Horneff (Germany)  
**ABSTRACTS N°:** THU0515-THU0522,THU0594,THU0655

T10: OTHER ORPHAN DISEASES - KNOW RARE DISEASES MUCH BETTER  
**Chair(s):**  
Nemanja Damjanov (Serbia)  
Predrag Ostojic (Serbia)  
**ABSTRACTS N°:** THU0554 - THU0564

T11: DIAGNOSTICS AND IMAGING PROCEDURES - WHAT’S NEW IN IMAGING - MISCELLANEOUS TOPICS  
**Chair(s):**  
Xenofon Baraliakos (Germany)  
Valentin S. Schäfer (Germany)  
**ABSTRACTS N°:** THU0595 - THU0604

T12: HEALTH SERVICES RESEARCH  
**Chair(s):**  
Loreto Carmona (Spain)  
Lucia Silva-Fernández (Spain)  
**ABSTRACTS N°:** THU0623 - THU0632

T13: FURTHERING CLINICAL MANAGEMENT  
**Chair(s):**  
Rikke H. Moe (Norway)  
Rinnie Geenen (Netherlands)  
**ABSTRACTS N°** THU0696-HPR - THU0704-HP
ABSTRACT N° OP0198
C. Kent Kwoh (United States of America)
F. Roemer, L. Sharma, E. Ashbeck, C. Hu, A. Guermazi on behalf of the Biomarkers of Early Arthritis of the Knee (BEAK) Investigators
MRI-detected structural abnormalities and development of incident radiographic knee osteoarthritis over 10 years of follow-up

13:35 - 15:00 HALL 7A
CHALLENGES IN CLINICAL PRACTICE session
CAN DRUGS AND SURGERY HELP PEOPLE WITH JOINT PAIN INCREASE ACTIVITY?

Learning objectives:
- Understand how inactivity causes psychological and physical morbidity, and is a goal in its own right
- Learn how to identify people who might not get back to activity when pathology and pain has been treated
- Learn how to select evidence-based interventions to increase activity

Chair(s):
David Walsh (United Kingdom)
Mikhail Protopopov (Germany)

13:35 – ABSTRACT N° SP0048
Robert B. M. Landewé (Netherlands)
HOT: Advances in treating spondyloarthritis (incl. SpA-like developing into adulthood)

14:15 – ABSTRACT N° SP0047
Philip G. Conaghan (United Kingdom)
New imaging technologies in OA: where are the added values?

14:30 – ABSTRACT N° OP0197
Nidhi Sofat (United Kingdom)
V. Ejindu, C. Heron, L. Assi, A. Kuttapitiya, G. Whitley, S. Koushesh, A. Harrison, F. Howe
Evaluating the relation of structural damage by MRI to clinical pain scores, pain sensitisation and type II collagen degradation in knee osteoarthritis

13:30 - 15:00 HALL 8
Clinical Science session
CAN IMAGING IMPROVE OUTCOME IN OA?

Learning objectives:
- To clarify the place of imaging for defining rapid progressors among knee OA patients
- To explain how imaging could help for demonstrating a structural effect of a potential disease-modifying OA drug
- To know which new imaging technologies are in evaluation for diagnosis and/or prognosis of OA

Chair(s):
Jean-Denis Laredo (France)
Daniel Prieto-Alhambra (United Kingdom)

13:45 – ABSTRACT N° SP0045
Jean-Pierre Raynauld (Canada)
Can imaging predict progressors?
Clinical Science session

**MY JOINTS HURT AND I’M OVERWHELMINGLY TIRED - FATIGUE IN RHEUMATOID ARTHRITIS**

**Learning objectives:**
- To recognise and assess fatigue in adults and adolescents with inflammatory arthritis
- To understand treatment options for fatigue in inflammatory arthritis

**Chair(s):**
Annette van der Helm - van Mil (Netherlands)
Mike O. Becker (Switzerland)

**14:25** – ABSTRACT N° SP0051
Thea Viet Vlieland (Netherlands)
Case 2 discussant: Discussion of how a large proportion of people do not become active after joint replacement despite adequate pain relief, reasons, negative consequences of reduced activity and possible approaches

**13:30 - 15:00**

Basic and Translational Science session

**MOLECULAR FINGERPRINTING**

**Learning objectives:**
- To understand methods that are used in multi-omics research
- To learn what information can be gained from big data analysis for clinical practice

**13:30 - 15:00**

From Bench to Bedside

**DIFFERENT PATHOPHYSIOLOGICAL PATHWAYS IN AXIAL AND PERIPHERAL DISEASE: PERIPHERAL AND AXIAL SPONDYLOARTHRITIS: TO SPLIT OR TO LUMP?**

**Learning objectives:**
- To understand the differences in the underlying pathophysiology of the different rheumatological manifestations of SpA
- To learn how these differences could explain recent results from clinical trials
- To address what this might mean for the treating rheumatologist

**Chair(s):**
Douglas Veale (Ireland)
Jordi Gratacos-Masmitja (Spain)

**13:30 - 14:25**

**13:35** – ABSTRACT N° SP0052
José Antonio P. da Silva (Portugal)
Fatigue in rheumatoid arthritis: what it is and how to assess it?

**13:55** – ABSTRACT N° SP0053
James Galloway (United Kingdom)
How to prevent and manage fatigue in patients with RA

**14:15** – ABSTRACT N° OP0199
Abdulla Watad (Israel)
The human enthesis harbours resident adaptive CD4+ and CD8+ T cells with inducible IL-17A and TNF protein that is pharmacologically suppressed by RORγt and PDE4 inhibitors but not methotrexate in a novel in vitro enthesis model

**14:45** – ABSTRACT N° OP0200
Maria Sokolova (Germany)
A set of inflammatory markers allowing to detect systemic inflammation in psoriatic skin, enthesal and joint disease in the absence of CRP and their link to clinical disease manifestation

**13:30 - 15:00**

**13:30 - 15:00**

**13:35** – ABSTRACT N° OP0201
Ellen Dalen Arnstad (Norway) on behalf of Nordic Study Group of Paediatric Rheumatology (NoSPeR)
Fatigue in juvenile idiopathic arthritis after 18 years of follow-up

**14:15** – ABSTRACT N° OP0202
Wan-fai Ng (United Kingdom)
Effect of RSLV-132 on fatigue in patients with primary Sjögren’s syndrome – results of a phase II randomised, double-blind, placebo-controlled, proof of concept study
Chair(s): Giulio Cavalli (Italy)

13:35 – Ratko Djukanovic (United Kingdom)
Molecular fingerprinting in asthma

13:53 – ABSTRACT N° SP0054
Lars Rogge (France)
Deconvolution of the immune response

14:11 – ABSTRACT N° SP0055
Timothy R. Radstake (Netherlands)
Clinical multi-omics

14:29 – ABSTRACT N° SP0056
Kazuhiro Yamamoto (Japan)
Mapping genes to immune cells

14:47 – ABSTRACT N° OP0203
Remy Pollock (Canada)
R. Machhar, V. Chandran, D. Gladman
Characterizing the epigenomic landscape of psoriasis patients destined to develop psoriatic arthritis

Chair(s): Nele Caeyers (Belgium)
Cornelia van den Ende (Netherlands)

13:35 – Norelee Kennedy (Ireland)
Best drug ever: exercise

13:53 – ABSTRACT N° SP0059
Keegan Knittle (Finland)
Helping people maintain physical activity

14:11 – ABSTRACT N° SP0060
George Metsios (United Kingdom)
Towards optimal intensity

14:29 – Hazel L. Breland (United States of America)
How to make it happen

14:47 – ABSTRACT N° OP0206-HPR
Fabrizio De Benedetti (Italy)
P. Brogan, A. Grom, P. Quartier, R. Schneider, K. De Graaf, P. Jacqm in, M. Ballabio, C. de Min
Emapalumab, an interferon gamma (IFN-Y)-blocking monoclonal antibody, in patients with macrophage activation syndrome (MAS) complicating systemic juvenile idiopathic arthritis (SJIA)
13:30 - 15:00  N111/N112
Clinical Science session

GETTING A GRIP ON THE CO-MORBIDITIES IN GOUT

Learning objectives:
- Comorbidities are important contributors to the pathogenesis of gout and influence treatment options
- The session will give an update of the mechanisms linking gout to co-morbidities

Chair(s):
Alexander So (Switzerland)
Frederic Lioté (France)

13:35 – ABSTRACT N° SP0061
Edward Roddy (United Kingdom)
Gout and associated co-morbidities – relevance to clinical practice

13:55 – ABSTRACT N° SP0062
Mariano Andrés (Spain)
Cardiovascular morbidity and gout - from epidemiology to therapy

14:15 – Miguel Lanaspa (United States of America)
The metabolic syndrome - links to hyperuricemia and gout

14:35 – ABSTRACT N° OP0207
Robert Terkeltaub (United States of America)
Effect of serum urate lowering with allopurinol on blood pressure in young adults

14:45 – ABSTRACT N° OP0208
Angelo Gaffo (United States of America)
N. Dronamraju, S. Johansson, J. Parkinson, E. Johnsson, F. Erlandsson, A. Stack
Urate-lowering therapy with verinurad and febuxostat reduces serum uric acid and albuminuria in hyperuricemic patients with diabetes

13:30 - 15:00  N117/N118
EULAR Projects in Education and Training

CHALLENGING PROJECTS IN EDUCATION AND TRAINING

Learning objectives:
- To get the updated information about new educational activities of EULAR School of Rheumatology
- To learn how to improve teaching skills
- To discuss the ways to improve the collaboration between National Societies and EULAR

Chair(s):
Nemanja Damjanov (Serbia)
Annamaria Iagnocco (Italy)

13:35 – ABSTRACT N° SP0065
Annamaria Iagnocco (Italy)
EULAR Education 2019: new developments and updates

13:45 – ABSTRACT N° SP0066
Loreto Carmona (Spain)
How to improve your teaching skills

14:15 – ABSTRACT N° OP0209-PARE
Nemanja Damjanov (Serbia)
How to improve collaboration between National Societies and EULAR

14:20 Round Table discussion

14:50 Q&A

* In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area, Hall 2
### 13:30 - 15:00  N107/N108

**Practical skills session*  
**CRYSTAL II**

**Learning objectives:**
- The final aim of the session is to provide the attendants with the basics to start synovial fluid analysis by themselves.
- The session will include:
  - A talk on the methods for identification and the characteristics of MSU and CPP crystals to allow it.
  - A practical session with the aid of a tutor looking synovial fluid samples containing crystals and discussion of the questions that may arise.
- It will be very helpful if the attendants refresh the basics of the microscope use before the session.

**Chair(s):**
- Anne-Kathrin Tausche (Germany)
- Eliseo Pascual (Spain)

**13:35 – Eliseo Pascual (Spain)**

*Introductory talk on crystal analysis*

**Tutor(s):**
- Francisca Sivera (Spain)
- José Pimentao (Portugal)
- Francesca Oliviero (Italy)
- Eleonora Norkuviene (Lithuania)

### 14:15 – ABSTRACT N° SP0069

**Ilfita Sahbudin (United Kingdom)**

*How to differentiate minimal disease activity in RA + demo*

### 14:35 – ABSTRACT N° SP0070

**Juhani Koski (Finland)**

*How to perform US-guided interventions + demo*

**Model:**
- Sara Kamp (Denmark)

### 15:00 - 15:30  N109/N110

**Practical skills session*  
**ULTRASOUND BASIC I**

**Learning objectives:**
- Use of ultrasound to better diagnose gout and identify various aspects and localization of gout crystal deposits.
- Diagnostic value of ultrasound in the evaluation of patients with trochanteric pain syndrome.
- Identify the sonographic findings corresponding to minimal disease activity in rheumatoid arthritis.
- Theoretical aspects and practical issues of ultrasound-guided interventions.

**Chair(s):**
- Stephanie Finzel (Germany)
- Maria Stoenoiu (Belgium)

**13:35 – ABSTRACT N° SP0067**

**Sara Nysom (Denmark)**

*How to assess US lesions for gout + demo*

**13:55 – ABSTRACT N° SP0068**

**Ingrid Möller (Spain)**

*US for trochanteric pain syndrome – clinical use + demo*

---

* In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area, Hall 2.
15:30 - 17:00  HALL 8

Clinical Science session
DIAGNOSTIC CHALLENGES IN VASCULITIS

Learning objectives:
To understand the difficulties, problems and solutions in diagnosing vasculitis

Chair(s):
Christian Dejaco (Italy)
Sofia Ramiro (Netherlands)

15:35 – ABSTRACT N° SP0072
Wolfgang Schmidt (Germany)
Imaging in the diagnosis of large vessel vasculitis

15:55 – ABSTRACT N° SP0073
Maria C. Cid (Spain)
Diagnosis of gastrointestinal vasculitis

16:15 – ABSTRACT N° SP0074
Leonard Calabrese (United States of America)
Diagnosis of cerebral vasculitis

16:35 – ABSTRACT N° OP0210
Elisa Fernández (Spain)
I. Monjo, G. Bonilla, C. Plasencia, M. Miranda-Carus, A. Balsa, E. de Miguel
False positives of ultrasound in giant cell arteritis. Some diseases can also have halo sign

16:45 – ABSTRACT N° OP0211
Douwe J Mulder (Netherlands)
H. Hop, M. Sandovici, A. Glaudemans, A. Van Roon, R. Siart, E. Brouwer
Ultrasonography can potentially be the first choice of imaging in suspected extra-cranial GCA

15:30 - 17:00  HALL 7B

From Bench to Bedside
RADIOGRAPHIC PROGRESSION IN ARTHRITIDES: STILL VALID OR A TALE FROM THE PAST!?

Learning objectives:
• To provide a state-of-the-art overview on the topic of structural damage progression in three forms of arthritis, in which such a progression deemed to be important (RA, PsA, axSpA)
• Each presentation should address 3 questions:
  • The natural course of structural damage progression and observed changes over the past 20 years
  • Clinical relevance of progression
  • Evidence for treatment

Chair(s):
Dennis McGonagle (United Kingdom)
Lene Terslev (Denmark)

15:35 – ABSTRACT N° SP0075
Eve Smith (United Kingdom)
Case presenter: Childhood onset of neurolupus

15:45 – Sylvia Kamphuis (Netherlands)
Case discussant

16:03 – ABSTRACT N° SP0076
Lovro Lamot (Canada)
Case presenter: Transition of neurolupus phase into adulthood

16:13 – ABSTRACT N° SP0077
Brigitte Bader-Meunier (France)
Case discussant

16:31 – ABSTRACT N° SP0078
Antonis Fanouriakis (Greece)
Case presenter: Longstanding neuro lupus in adult life

16:41 – Marcello Govoni (Italy)
Case discussant

15:30 - 17:00  HALL 7A

CHALLENGES in Clinical Practice session
HOW TO MANAGE AND TREAT CHILDHOOD ONSET LUPUS?
A MULTIDISCIPLINARY POINT OF VIEW

Learning objectives:
This session will be structured as a curbside consultation ensuring the interactive discussion of different specialists including paediatric and adult rheumatologists and a patient representative

Chair(s):
Alberto Martini (Italy)
Nele Caeyers (Belgium)

15:35 – ABSTRACT N° SP0079
Désirée van der Heijde (Netherlands)
Structural damage progression in RA – does it still matter with improved medical and non-medical treatments

16:00 – ABSTRACT N° SP0080
Denis Poddubnyy (Germany)
Structural damage progression in axSpA

16:25 – ABSTRACT N° SP0081
Philip Helliwell (United Kingdom)
Structural damage progression in PsA
15:30 - 17:00  N103/N104

Clinical Science session

DIFFICULT TO MANAGE SJÖGREN’S SYNDROME AND MYOSITIS

Learning objectives:
To discuss rare manifestations of Sjögren’s syndrome and myositis that can pose challenges in diagnosis, management and treatment

Chair(s):
João E. Fonseca (Portugal)
Chiara Baldini (Italy)

15:35 – Xavier Mariette (France)
Sjögren’s syndrome with cryoglobulinemic vasculitis

15:55 – Roberto Gerli (Italy)
Sjögren’s syndrome with neurological involvement

16:15 – ABSTRACT N° OP0212
Sheila Melchor (Spain)
on behalf of SjögrenSer Project
Digestive involvement in patients with primary Sjögren syndrome from the SjögrenSer Spanish registry

16:25 – ABSTRACT N° SP0082
Albert Selva-O’Callaghan (Spain)
Screening for malignancies in Sjögren syndrome and myositis

16:45 – ABSTRACT N° OP0213
Kohei Karino (Japan)
M. Kono, M. Kono, Y. Fujieda, M. Kato, T. Bohgaki, O. Amengual, K. Oku, S. Yasuda, T. Atsumi
Myofascia-dominant inflammation detected on whole body MRI predicts rapidly progressive interstitial lung disease in patients with dermatomyositis

15:30 - 17:00  N101/N102

Clinical Science session

FRACTURE LIAISON SERVICE: AN OPPORTUNITY FOR RHEUMATOLOGISTS TO FOCUS ON SECONDARY FRACTURE PREVENTION

Learning objectives:
- To learn how to organise a secondary fracture prevention dedicated service (FLS)
- To understand strategies for the identification, assessment, treatment and monitoring of secondary fracture prevention

Chair(s):
Daniel Prieto-Alhambra (United Kingdom)
Sandrine Bours (Netherlands)

15:35 – ABSTRACT N° SP0085
Bo Abrahamsen (Denmark)
Whom to identify and invite to an FLS? Who is that fracture patient?

15:55 – ABSTRACT N° OP0215
Anthony Woolf (United Kingdom)
J. Erwin, D. Enki
The risk of first and subsequent fractures in patients with rheumatoid arthritis in the UK

16:05 – ABSTRACT N° OP0216
Yasser El Miedany (United Kingdom)
M. El Gaafary, M. Toth, W. Hassan, A. Mehanna
Identification and management of patients at increased risk of osteoporotic fracture: implementation of imminent risk factor in standard daily practice for bone mineral density assessment and patient management
16:15 – ABSTRACT N° SP0086
Daniel Prieto-Alhambra (United Kingdom)
Assessment: how to personalize secondary fracture prevention?

16:35 – ABSTRACT N° SP0087
Kassim Javaid Muhammad (United Kingdom)
Treatment: how to implement it and how to monitor adherence?

15:30 - 17:00
N111/N112

Practical skills session*

SCIENTIFIC DATA VISUALISATION: FOCUS ON (POSTER) PRESENTATION

Learning objectives:
• To choose the data visualisation that best fits the data
• To identify the basics of table and graph design
• To choose tables and graphs that tells the story in the data
• To learn about poster design

Chair(s):
Maarten Boers (Netherlands)

15:35 – ABSTRACT N° SP0092
Maarten Boers (Netherlands)
Scientific data visualisation: focus on (poster) presentation

15:30 - 17:00
N105/N106

Health Professionals session
HOW NOT TO SMOKE LIKE A CHIMNEY

Learning objectives:
• To obtain valuable knowledge about the consequences about smoking
• How to support people to stop smoking
• Understand more about how quitting feels

Chair(s):
Ross Wilkie (United Kingdom)
Andrea Marques (Portugal)

15:30 – ABSTRACT N° SP0088
Antonio Naranjo (Spain)
How you know it is smart not to smoke like a chimney

15:48 – ABSTRACT N° SP0089
Helen Harris (United Kingdom)
Consequences of smoking cessation in rheumatology

16:06 – ABSTRACT N° SP0090
Ida Kristiane Roelsgaard (Denmark)
Intensive smoking cessation intervention

16:24 – ABSTRACT N° SP0091
Marios Kouloumas (Cyprus)
How to support yourself quitting smoking

16:47 – ABSTRACT N° OP0217-HPR
Ida Kristiane Roelsgaard (Denmark)
T. Thomsen, M. Østergaard, A. Semb, L. Andersen, B. Esbensen
Evaluation of patients’ experiences of an intensive smoking cessation intervention for people with rheumatoid arthritis

16:15 – ABSTRACT N° SP0094
Tanita-Christina Wilhelmer (Austria)
Diseases on sale - how I deal with all my conditions

16:35 – ABSTRACT N° OP0218-PARE
Wendy Gerhart (Canada)
G. Major, A. Gerhart, M. Walsh
Preventative medicine through identifying and addressing comorbidities of spondyloarthritis (SpA*) to improve patient outcomes through patient organization partnerships and allied healthcare outreach

* In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area, Hall 2
15:30 - 17:00  N117/N118

EULAR Projects in Investigative Rheumatology

BIG DATA AND THE DISRUPTION OF MEDICAL CARE

Learning objectives:

- Gain new insights into genomic medicine and how it is evolving as a discipline and changes medicine
- Learn about approaches for interrogating large datasets to identify molecular classifiers for disease, personalized medicine and novel therapeutic targets
- Acquire new knowledge about the process whereby molecular signatures can be derived from biological samples for diagnostic and prognostic purposes
- Hear about EULAR’s own perspective on Big Data as applied to rheumatology

Chair(s):

Timothy R. Radstake (Netherlands)
Andrew Cope (United Kingdom)

15:35 – Harald Schmidt (Netherlands)
The end of medicine as we know it

15:55 – ABSTRACT N° SP0095
Joanna Kedra (France)
EULAR points to consider on Big Data

16:15 – Kenneth G. C. Smith (United Kingdom)
Cohort-based whole genome sequencing in primary immune deficiency: a trip into genomic space

16:35 – Anke H. Maitland-van der Zee (Netherlands)
Sniffing on breath, from molecular fingerprinting to clinical practice in asthma and cancer

16:55
Discussion

15:30 - 17:00  N109/N110

Practical skills session*

ULTRASOUND ADVANCED I

Learning objectives:

- To deepen knowledge into some practical applications of ultrasound in RMD diseases
- To gain insight into new fields of application of ultrasound in RMD clinical practice and research

Chair(s):

Esperanza Naredo (Spain)
Georgios Filippou (Italy)

15:35 – ABSTRACT N° SP0100
David A. Bong (Spain)
US of the hamstring – clinical application + demo

15:55 – Soren Torp-Pedersen (Denmark)
US for diagnosing lumps and bumps – characteristics and differential diagnosis + patient cases

16:15 – ABSTRACT N° SP0101
Andrea Delle Sedie (Italy)
US for assessing lung involvement in rheumatic diseases – clinical use + demo

16:35 – ABSTRACT N° SP0102
Andrew Filer (United Kingdom)
US for synovial biopsies – clinical relevance and safety + demo

Model:

Sara Kamp (Denmark)

---

* In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area, Hall 2
17:30 - 19:00  SOUTH AUDITORIUM

Basic and Translational Science session
FIGHTING AND FIXING: FROM INITIATION TO RESOLUTION OF INFLAMMATION

Learning objectives:
- This session focuses on the kinetic of the inflammatory response
- It covers the initiation and the resolution of inflammation
- The role of macrophages, neutrophils, neutrophil extracellular traps (NETs), and of aggregated NETs in these processes will be discussed

Chair(s):
Patrizia Rovere-Querini (Italy)
Martin Herrmann (Germany)

17:35 – ABSTRACT N° SP0103
Patrizia Rovere-Querini (Italy)
T lymphocytes and innate immune cells balance muscle regeneration and autoimmunity

17:55 – ABSTRACT N° SP0104
Markus Hoffmann (Germany)
The Janus-faced gladiator: neutrophils in sterile inflammation and autoimmunity

18:15 – ABSTRACT N° SP0105
Gerhard Krönke (Germany)
Regulation of autoantibody activity by T cell subsets

18:35 – ABSTRACT N° OP0220
Lucy MacDonald (United Kingdom)
Single-cell transcriptomic and functional analyses reveal novel heterogeneity in pathogenic pathways mediated by human synovial tissue macrophages

18:45 – ABSTRACT N° OP0221
Emmanuel Karouzakis (Switzerland)
Oligomeric S100A4 induces monocyte innate immune memory
09:10 – ABSTRACT No SP0108
Anika Grueneboom (Germany)
LSFM and catching up in joint imaging

09:35 – ABSTRACT No OP0222
Marine Fauny (France)
E. Albuisson, E. Bauer, J. Perrier Cornet, I. Chary Valckenaere, D. Loeuille
Study of vertebral fracture prevalence and scanographic bone attenuation coefficient (SBAC-L1) in patients with rheumatoid arthritis and ankylosing spondylitis vs. controls

09:45 - 10:15
EXHIBITION AND EULAR VILLAGE (HALL 10)
COFFEE BREAK

10:15 - 11:45
HALL 6
WIN & HOT session
PARADIGM SHIFTS IN ARTHRITIDES

Learning objectives:
- To provide an overview on recent changes in treating RA with emphasis on the introduction of bsDMARDs and tsDMARDs and re-evaluation of efficacy and safety aspects and their consequences on individual outcome and societal costs
- To provide an update on the infection related arthritides with consideration of emerging infections and evidence based diagnostic and treatment algorithms

10:20
Gerd R. Burmester (Germany)
WIN: The wind of change in RA: towards ts & bsDMARDs

11:00 – ABSTRACT No SP0109
Robert Schoen (United States of America)
HOT: Diagnosis and treatment of infection related arthritides

10:15 - 11:45
HALL 8
Abstract session
RHEUMATOID ARTHRITIS - BIOLOGICAL DMARDS

Chair(s):
Eduardo Mysler (Argentina)
Janet Pope (Canada)

10:20 – ABSTRACT No OP0223
Yoshiya Tanaka (Japan)
Efficacy and safety of E6011, an anti-fractalkine monoclonal antibody, in MTX-IR patients with rheumatoid arthritis
10:30 – ABSTRACT N° OP0224
Uwe Junker (Switzerland)
R. Finch, A. Sostelly, K. Sue-Ling, A. Blaeuer, G. Duchateau-Nguyen, L. Ukarma, C. Petry, P. Ravva, P. Villiger
Results of a phase 2 study of RG6125, an anti-Cadherin-11 monoclonal antibody, in rheumatoid arthritis patients with an inadequate response to anti-TNFalpha therapy

10:40 – ABSTRACT N° OP0225
Evelyne Vinet (Canada)
Y. St-Pierre, C. Moura, J. Curtis, S. Bernatsky
Serious infections in offspring exposed in utero to non-TNF biologics and tofacitinib

10:50 – ABSTRACT N° OP0226
Teresa Simon (United States of America)
Solid tumour outcomes in patients with RA treated with abatacept and other DMARDs: results from a 10-year international post-approval study

11:00 – ABSTRACT N° OP0227
Jérôme Avouac (France)
Effects of successive switches to different biosimilars infliximab on immunogenicity in chronic inflammatory diseases in daily clinical practice

11:10 – ABSTRACT N° OP0228
Chris Buckley (United Kingdom)
GSK3196165 an investigational anti-GM-CSF monoclonal antibody, improves patient reported outcomes in a phase IIB study of patients with rheumatoid arthritis (RA)

11:20 – ABSTRACT N° OP0229
Andreas Kerschbaumer (Austria)
H. Herkner, J. Smolen, A. Aletaha
Phase II clinical trials systematically overestimate treatment effects of subsequent phase III trials in rheumatoid arthritis

11:30 – ABSTRACT N° OP0230
Giovanni Adami (Italy)
A. Fascio, G. Orsolini, A. Giollo, D. Gatti, M. Rossini
Effectiveness of influenza vaccine in TNF inhibitors treated patients

10:15 - 11:45  HALL 7A

Abstract session
HOW TO TREAT SPA:CHOICES AND OUTCOMES WITH BDMARDS

Chair(s):
Helena Marzo-Ortega (United Kingdom)
Santiago Rodrigues-Manica (Portugal)

10:20 – ABSTRACT N° OP0231
Désirée van der Heijde (Netherlands)
Dual neutralisation of IL-17A and IL-17F with bimekizumab was associated with improvements in patient-reported and quality-of-life outcomes in patients with active ankylosing spondylitis: results from a phase 2B, randomised, double-blind, placebo-controlled, dose-ranging study

10:30 – ABSTRACT N° OP0232
Inna Gaydukova (Russian Federation)
Netakimab reduces the disease activity of radiographic axial spondyloarthritis. Results of ASTERA study

10:40 – ABSTRACT N° OP0234
James Cheng-Chung Wei (Taiwan, Republic of China)
T. Kim, M. Kishimoto, T. Morishige, N. Ogusu, S. Kobayashi
Efficacy and safety of brodalumab, an anti-interleukin-17 receptor a monoclonal antibody, in patients with axial spondyloarthritis: a 16 week results of a phase 3, multicenter, randomized, double-blind, placebo-controlled, dose-ranging study

10:50 – ABSTRACT N° OP0235
Xenofon Baraliakos (Germany)
L. Coates, L. Gossec, S. Jeka, A. Mera Varela, B. Schulz, M. Rissler, A. Das Gupta, C. Perella, E. Pournara
Secukinumab improves axial manifestations in patients with psoriatic arthritis and inadequate response to NSAIDs: primary analysis of the MAXIMISE trial

11:00 – ABSTRACT N° OP0236
Bente Glintborg (Denmark)
Similar one-year treatment retention of originator and biosimilar etanercept. Results of a Nordic collaboration including 1015 Patients with spondyloarthritis
11:10 – ABSTRACT N° OP0237
Adrian Ciurea (Switzerland)
C. Tellenbach, R. Micheroli, K. Buerki, A. Scherer, M. Nissen, P. Zufferey, P. Exer, B. Moeller, D. Kyburz
Interleukin-17 or TNF blockade in patients with axial spondyloarthritis after withdrawal of at least one TNF inhibitor

11:20 – ABSTRACT N° OP0238
Annelies Boonen (Netherlands)
M. Dougados, B. Combe, T. Hunter, B. Zhu, D. Sandoval, L. Bessette, A. Deodhar
Work productivity and activity impairment among patients with active ankylosing spondylitis/radiographic axial spondyloarthritis and treated with ixekizumab for 16 weeks: results from COAST-V and COAST-W

11:30 – ABSTRACT N° OP0233
Mohammad H. Derakhshan (United Kingdom)
L. Dean, G. Jones, G. Macfarlane, S. Siebert, K. Gaffney on behalf of British Society of Spondyloarthritis
The impact of extra-articular manifestations on the choice of TNF Inhibitor in patients with axial spondyloarthritis in the BSRBR-AS register

10:15 - 11:45
N103/N104
Abstract session
SSC AND MYOSITIS – NOVEL THERAPEUTIC OPTIONS

Chair(s):
Christopher Denton (United Kingdom)
Barbara Ruaro (Italy)

10:20 – ABSTRACT N° OP0239
Anna-Maria Hoffmann-Vold (Norway)
Progressive lung fibrosis in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database

10:30 – ABSTRACT N° OP0240
Anniek van Roon (Netherlands)
A. Eman Abdulle, S. van de Zande, A. Van Roon, D. Zhang, R. Bos, H. Bootsma, A. Smit, D. Mulder
Assessment of pulse wave velocity in systemic sclerosis: potential beneficial effects of bosentan on forearm arterial stiffness? An exploratory study

10:40 – ABSTRACT N° OP0241
Victoria Werth (United States of America)
Safety and efficacy of lenabasum in an open-label extension of a phase 2 study of lenabasum in refractory skin-predominant dermatomyositis (DM) subjects

11:50 – ABSTRACT N° OP0242
Kristin Highland (United States of America)
O. Distler, M. Gahlemann, A. Azuma, A. Fischer, M. Mayes, G. Raghu, W. Sauter, M. Girard, V. Kohlbrenner, E. Clerisme-Beaty, S. Stowasser, M. Kuwana, T. Maher on behalf of SENSCIS trial investigators
Safety profile of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and idiopathic pulmonary fibrosis

11:00 – ABSTRACT N° OP0243
Nupoor Acharya (India)
D. Mishra, S. Dhoooria, V. Dhir, S. Jain, S. Sharma
Efficacy of pirfenidone in systemic sclerosis related interstitial lung disease - a randomised controlled trial

11:10 – ABSTRACT N° OP0244
Sheng-Xiao Zhang (China)
H. Sun, J. Wang, Y. Hao, G. Liu, C. Wang, C. Gao, X. Li
Efficacy and safety of low-dose IL-2 in patients with multiple myositis/dermatomyositis

11:20 – ABSTRACT N° OP0245
Dinesh Khanna (United States of America)
Preservation of lung function observed in a phase 3 randomized controlled trial of tocilizumab for the treatment of early SSc
10:30 – ABSTRACT N° OP0247
Margherita Zen (Italy)
F. Saccon, M. Gatto, M. Larosa, F. Benvenuti, L. Iaccarino, A. Doria
**Effect of immunosuppressive drug withdrawal on damage progression and flare occurrence in SLE patients in remission**

10:40 – ABSTRACT N° OP0248
Maria Tektonidou (Greece)
K. Keramiotou, C. Anagnostou, A. Galanos, E. Kataxaki, P. Sfikakis
**The impact of exercise on hand function and quality of life of patients with systemic lupus erythematosus: a randomized controlled trial**

10:50 – ABSTRACT N° OP0249
Leyre Riancho-Zarrabeitia (Spain)
**Antiphospholipid syndrome (APS) in systemic lupus erythematosus (SLE) leads to a more severe disease**

11:00 – ABSTRACT N° OP0250
Jianlin Huang (China)
T. Xie, Q. Shu, J. Yang, Y. Wang, H. Wang, X. Liu, C. Zhao, X. Duan, G. Wang, R. Wu, Y. Hao, Y. Jia, F. Xiao, L. Sun on behalf of SSDM collaboration group
**Influential factors in promoting treat-to-target for systemic lupus erythematosus via empowering patients: a cohort study from China by smart system of disease management (SSDM)**

11:10 – ABSTRACT N° OP0251
Ewa Olech (United States of America)
E. van Rijen, A. Ashrafzadeh, A. Kant, J. Merril
**SLE Patients from North America are older with less serologic activity than other populations. In international clinical trials**

11:20 – ABSTRACT N° OP0252
John Hanly (Canada)
**Neuropathies in systemic lupus erythematosus: results from an international, inception cohort study**

11:30 – ABSTRACT N° OP0253
Marc Scherlinger (France)
J. Sibilia, H. Devilliers, L. Arnaud

10:15 - 11:45  SOUTH AUDITORIUM

**Abstract session PReS**

**TACKLING THE CHALLENGES OF AUTOIMMUNE/AUTOINFLAMMATORY CONDITIONS IN CHILDREN AND YOUNG PEOPLE**

**Chair(s):**
Jelena Vojinovic (Serbia)
Christian Scott (South Africa)

10:20 – ABSTRACT N° OP0254
Helen J. Lachmann (United Kingdom)
**Canakinumab improves patient-reported outcomes in patients with recurrent fever syndromes: results from a phase 3 trial (cluster)**

10:30 – ABSTRACT N° OP0255
Claudia Bracaglia (Italy)
G. Marucci, F. Del Chierico, A. Russo, M. Pardeo, A. Insalaco, G. Prencipe, I. Caiello, P. Dolezalova, S. Fingerhutova, F. De Benedetti, L. Putignani
**Microbiota transplant to control inflammation in a NLRC4-related disease patient with recurrent hemophagocytic lymphohistiocytosis (HLH)**

10:40 – ABSTRACT N° OP0256
Helga Sanner (Norway)
**In medium to long-term juvenile dermatomyositis, proinflammatory and profibrotic cytokines are differently associated with pulmonary involvement in active vs inactive disease**

10:50 – ABSTRACT N° OP0257
Natalia Cabrera (France)
P. Nakhleh, J. Lega, A. Belot
**Childhood-onset monogenic systemic lupus erythematosus not due to complement deficiency: a systematic review of 90 cases**

11:00 – ABSTRACT N° OP0258
Martina Finetti (Italy)
**Lesson from Eurofever registry after the first ten years of enrolment**
11:10 – ABSTRACT N° OP0259
Florian Milatz (Germany)
Overweight and obesity in patients with juvenile idiopathic arthritis enrolled in the German national paediatric rheumatologic database (NPRD)

11:20 – ABSTRACT N° OP0260
Leonardo Oliveira Mendonça (Italy)
S. Signa, C. Matucci Cerinic, E. Toniolo, M. Bustaffa, M. D’Alessandro, S. Volpi, R. Caorsi, M. Gattorno
Vaccination safety and coverage in an Italian cohort of autoinflammatory diseases

10:15 - 11:45
Abstract session EPIDEMIOLOGY

Chair(s):
Kimme Hyrich (United Kingdom)

10:20 – ABSTRACT N° OP0261
Lene Dreyer (Denmark)
T. Kopp, E. Arkema, R. Cordtz, B. Delcoigne, J. Askling
Risk of neurological adverse events during tumour necrosis factor inhibitor treatment for arthritis: a population-based cohort study from DANBIO and ARTIS

10:30 – ABSTRACT N° OP0262
Mohammad H. Derakhshan (United Kingdom)
L. Dean, G. Jones, G. Macfarlane, S. Siebert, K. Gaffney on behalf of British Society of Spondyloarthritis
Factors associated with acute anterior uveitis in patients with axial spondyloarthritis: analysis of the BSRBR-AS register database

10:40 – ABSTRACT N° OP0263
Zara Izadi (United States of America)
M. Gianfrancesco, M. Evans, J. Kay, L. Trupin, G. Schmajuk, M. Petri, J. Yazdany
Hydroxychloroquine dosing in patients with rheumatic disease across the U.S.: data from the rheumatology informatics system for effectiveness (RISE) registry

10:50 – ABSTRACT N° OP0264
Leticia Garcia-Montoya (United Kingdom)
J. Nam, K. Mankia, L. Duquenne, P. Pentony, A. DiMatteo, P. Emery
Refining the primary care CCP+ patient pathway

11:00 – ABSTRACT N° OP0265
Michael Cook (United Kingdom)
S. Verstappen, T. O’Neill
Frailty, disability, and work disability in people with osteoarthritis and rheumatoid arthritis

11:10 – ABSTRACT N° OP0266
Simon Krabbe (Denmark)
K. Grøn, B. Glintborg, F. Mehnert, D. Jarbøl, M. Østergaard, M. Hetland
Risk of hospitalized infection in patients with chronic inflammatory arthritis treated with biological drugs - a matched cohort study

11:20 – ABSTRACT N° OP0267
Georgina Nakafero (United Kingdom)
Inactivated influenza vaccination does not associate with disease flares in autoimmune rheumatic diseases: a self-controlled case series study using data from the clinical practice research datalink

10:15 - 11:45
Abstract session HPR

HPR ABSTRACT SESSION II

Chair(s):
Wilfred Peter (Netherlands)
Mwidimi Ndosi (United Kingdom)

10:20 – ABSTRACT N° OP0268-HPR
Lindsay Bearne (United Kingdom)
The prevalence and impact of fatigue in people with primary antiphospholipid syndrome: a mixed methods study

10:30 – ABSTRACT N° OP0269-HPR
Susan J. Bartlett (Canada)
Patterns of fatigue and predictors of significant improvement in the 1st year of RA: results from the Canadian early arthritis cohort (CATCH)

10:40 – ABSTRACT N° OP0270-HPR
Gamze Arın (Turkey)
E. Ünal, S. Demir, Y. Bilginer, S. Özen
Comparison of the reasons for not going to school between children with juvenile Idiopathic arthritis and their families

10:50 – ABSTRACT N° OP0271-HPR
Rafaela Cavalheiro do Espírito Santo (Brazil)
J. Miranda de Souza Silva, J. Baker, V. Hax, C. Brenol, L. Filippin, P. Lora, R. Xavier
Assessment of muscle mass relative to fat mass and its association with disease activity status and physical functioning in rheumatoid arthritis
11:00 – ABSTRACT N° OP0272-HPR
Karin Niedermann (Switzerland)
A. Rausch, A. Meichtry, B. Walker, R. Braem, A. Ciurea
Fitness status of people with axial spondyloarthritis (AxSpA): first results after implementation of fitness assessments in AxSpA exercise groups

11:10 – ABSTRACT N° OP0273-HPR
Emília Moreira (Brazil)
A. Jones, E. da Silva Lima, F. Jennings, J. Natour
Functional exercise for adults with chronic non-specific low back pain: a randomized controlled trial

11:20 – ABSTRACT N° OP0274-HPR
George E. Fragoulis (Greece)
L. Edelaar, V. Schäfer, J. Schoones, I. Iagnocco, T. Vliet Vlieland, E. Nikiphorou
Development of generic core competences of health professionals in rheumatology: a systematic literature review informing the 2018 EULAR recommendations

10:15 - 11:45
N111/N112
Abstract session
SLE, SJÖGREN’S AND APS - ETIOLOGY, PATHOGENESIS AND ANIMAL MODELS
Chair(s):
Yi Zhao (China)
Patrizia Rovere-Querini (Italy)

10:20 – ABSTRACT N° OP0275
Brittany Fay (United States of America)
M. Scuron, N. Shin, Y. Yang, E. Yue, A. Combs, J. Oliver, F. Thomas, R. Page, E. Huarte, P. Smith
The PI3KΔInhibitor INCB050465 ameliorates salivary gland pathology and reduces autoantibody formation in a murine model of Sjögren’s syndrome

10:30 – ABSTRACT N° OP0276
Davide Lucchesi (United Kingdom)
Dendritic cell-derived IL-27 Regulates the magnitude of inducible ectopic germinal centres but fails to Downmodulate IL-17 production in CD4 T cells from patients with Sjögren’s syndrome

10:40 – ABSTRACT N° OP0277
Anastasia Filia (Greece)
G. Bertsias, N. Panousis, D. Nikolopoulos, E. Dermitzakis, D. Boumpas
RNA sequencing and machine learning techniques predict major organ involvement in patients with systemic lupus erythematosus

10:50 – ABSTRACT N° OP0278
George Tsokos (United States of America)
Biomarker profiling reveals novel mechanistic insights into ustekinumab therapeutic responses in systemic lupus erythematosus

11:00 – ABSTRACT N° OP0279
Elena Pontarini (United Kingdom)
A unique IL-21 signature characterizes lesional and circulating T-follicular helper cells in Sjögren’s syndrome patients with ectopic germinal centres and MALT lymphoma

11:10 – ABSTRACT N° OP0280
Paul Smith (United States of America)
B. Fay, X. He, A. Margulis, Y. Yang, Y. Li, W. Yao, E. Huarte, M. Scuron
The selective JAK1 inhibitor INCB054707 ameliorates cutaneous lesions in a spontaneous murine model of systemic lupus erythematosus

11:30 – ABSTRACT N° OP0282
Enrique Esteve-Valverde (Spain)
Obstetric antiphospholipid syndrome (OAPS) vs. obstetric morbidity related with antiphospholipid antibodies (OMAPS): a survey of 1650 cases from EUROAPS registry

10:15 - 11:45
N115/N116
Abstract session
PARE ABSTRACT SESSION I
Chair(s):
Kate Betteridge (United Kingdom)
Kristijonas Mazuras (Lithuania)

10:15 – Ovidiu Constantinescu (Romania)
Edgar Stene Prize Winning Essay 2019: My ideal employer - work without barriers for people with RMDs
10:25 – ABSTRACT N° OP0283-PARE
Patricia Pennings MSc (Netherlands)
R. Verkaik, H. Kappen, H. Boeije
A Dutch research agenda developed by people with RMDs: what are the main problems people with RMDs face and what are their main wishes for research and development?

10:35 – ABSTRACT N° OP0284-PARE
Nenad Nedić (Serbia)
M. Lapčević
The influence of functional training and psycho-social support

10:45 – ABSTRACT N° OP0285-PARE
Jürgen Clausen (Germany)
R. Dietzel, G. Armbrecht
Sarcopenia in patients with rheumatic diseases

10:55 – ABSTRACT N° OP0286-PARE
Elsa Mateus (Portugal)
C. Cavique, A. Cláudio, M. Carmo, M. Guerreiro, A. Cavaco
Developing a virtual assistant to promote education on osteoarthritis

11:05 – ABSTRACT N° OP0287-PARE
Alice Grosjean (Switzerland)
A. Vieira, C. Bouillot, J. Inga Díaz, M. Oosterbaan, J. Koelwijn-Tukker, I. Lesuisse on behalf of Sjögren Europe Task Force
Setting up a European federation of Sjögren’s syndrome patient associations: how we built up Sjögren Europe in less than one year

11:15 – ABSTRACT N° OP0288-PARE
Laura Lunt (United Kingdom)
S. Shoop-Worrall, S. Khanom, I. Bolger, A. Fantana, M. Short, J. McDonagh
What do young people think about continuous data collection in clinical research and the types of electronic devices?

11:25 – ABSTRACT N° OP0289-PARE
Androulla Phoka Charalambous (Cyprus)
The role of patient organisations on the education and establishment of rheumatology nurse

10:20 – ABSTRACT N° OP0290
Muriel Elhai (Switzerland)
M. Frank-Bertoncelj, K. Klein, O. Distler, C. Ospelt
Hotair is involved in joint patterning by regulating FGFR2, BMP2 and Wnt pathways

10:30 – ABSTRACT N° OP0291
Jérôme Avouac (France)
A. Leblond, S. Pezet, A. Cauvet, C. Casas, J. Pires Da Silva, R. Hervé, L. Semerano, C. Lemaire, Y. Allanoere
Activation of the deacetylase sirtuin-1 counteracts the activated and proangiogenic profile of endothelial cells in rheumatoid arthritis and alleviates experimental arthritis

10:40 – ABSTRACT N° OP0292
Alejandro Ibañez-Costa (Spain)
The helpful eight: key splicing machinery elements in leukocyte subsets may improve the typification of the disease in rheumatoid arthritis patients

10:50 – ABSTRACT N° OP0293
Lisa Patel (United Kingdom)
M. Foster, F. Shen, P. Vink, I. Anderson, L. Jopling, S. Smith, I. Greig, S. Williams
A first-in-class metabolic reprogramming agent, MBS2320, selectively modulates immune cell function and improves osteoid formation and bone protection versus etanercept in the mouse collagen-induced arthritis model

11:00 – ABSTRACT N° OP0294
Harris Perlman (United States of America)
M. Foster, F. Shen, P. Vink, I. Anderson, L. Jopling, S. Smith, I. Greig, S. Williams
A first-in-class metabolic reprogramming agent, MBS2320, selectively modulates immune cell function and improves osteoid formation and bone protection versus etanercept in the mouse collagen-induced arthritis model

11:10 – ABSTRACT N° OP0295
Nikolaos Vlachogiannis (Greece)
A. Gatsiou, K. Stamatelopoulos, M. Tektonidou, P. Sfikakis, K. Stellos
Aberrant adenosine to inosine RNA editing in active rheumatoid arthritis

11:15 – 11:45
N117/N118
RHEUMATOID ARTHRITIS - ETIOLOGY, PATHOGENESIS AND ANIMAL MODELS

Chair(s):
Andrew Cope (United Kingdom)
Juan J. Gomez-Reino (Spain)

11:20 – ABSTRACT N° OP0296
Clément Triaille (Belgium)
N-linked glycans in the variable domain of ACPA-IgG in the development of rheumatoid arthritis

11:30 – ABSTRACT N° OP0297
Alice Grosjean (Switzerland)
A. Vieira, C. Bouillot, J. Inga Díaz, M. Oosterbaan, J. Koelewijn-Tukker, I. Lesuisse on behalf of Sjögren Europe Task Force
Setting up a European federation of Sjögren’s syndrome patient associations: how we built up Sjögren Europe in less than one year

10:15 - 11:45
14 JUNE
NOVEL BIOMARKERS IN RMDS - NEXT STEPS TOWARDS CLINICAL IMPLEMENTATION

Chair(s): Joel van Roon (Netherlands)

10:20 – ABSTRACT N° OP0298
Chenglong Fang (China)
T. Luo
PCSK9 in atherosclerotic inflammation of lupus patients and murine model of lupus with atherosclerosis

10:30 – ABSTRACT N° OP0299
Mustafa Atef Abdel meged Abou-Alfa (Egypt)
R. Abdel Noor, H. Nagy, N. Kotb
Assessment of role of urinary heparanase in lupus nephritis patients and its correlation with disease activity

10:40 – ABSTRACT N° OP0300
Daisy Vedder (Netherlands)
M. Gerritsen, M. Nurmohamed, R. van Vollenhoven, C. Lood
A neutrophil signature is strongly associated with cardiovascular risk in gout

10:50 – ABSTRACT N° OP0301
Rohan Machhar (Canada)
S. Oke, J. Ye, F. Abji, V. Chandran
C-X-C motif chemokine 10 (CXCL10) is a potential biomarker of disease activity in psoriatic arthritis (PsA)

11:00 – ABSTRACT N° OP0302
Suzanne Cole (United Kingdom)
C. Simpson, R. Okoye, M. Griffiths, D. Baeten, S. Shaw, A. Maroo
Mucosal-associated invariant T (MAIT)-cell-derived IL-17A and IL-17F production is IL-23-independent and biased towards IL-17F

11:10 – ABSTRACT N° OP0303
Félix Renaudin (France)
L. Campillo-Gimenez, F. Castelli, F. Fenaille, A. Prignon, C. Combes, M. Cohen Solal, F. Lioté, H. Ea
Monosodium urate and calcium pyrophosphate crystal-induced interleukin 1 production depends on glucose uptake through GLUT1 transporter

11:20 – ABSTRACT N° OP0304
Fernanda Genre (Spain)
Genetic and functional study of omentin regarding cardiovascular risk in axial spondyloarthritis

PUBLIC HEALTH, HEALTH SERVICES RESEARCH, AND HEALTH ECONOMICS

Chair(s): Pedro Machado (United Kingdom)

10:20 – ABSTRACT N° OP0306
Cesar Garriga (United Kingdom)
Geographical variation in patient outcomes of primary knee replacement across clinical commissioning groups: study from “The National Joint Registry of England, Wales, Northern Ireland and the Isle of Man”

10:30 – ABSTRACT N° OP0307
Rachelle Meisters (Netherlands)
Standards of care for rheumatoid arthritis: gaps in implementation experienced by patients and rheumatologists across 33 European countries

10:40 – ABSTRACT N° OP0308
Anna Kernder (Germany)
J. Richter, R. Fischer-Betz, B. Winkler-Rohlfing, M. Schneider, G. Chehab

10:50 – ABSTRACT N° OP0309
Elena Myasoedova (United States of America)
C. Crowson, R. Giblon, D. Schaffer, K. Wright, E. Matteson, J. Davis
Optimization of flare management in patients with rheumatoid arthritis: results of a randomized controlled trial

11:00 – ABSTRACT N° OP0310
Thomas Bo Jensen (Denmark)
D. Bartels, E. Aggerholm Sædder, B. Klintd Poulsen, S. Ejdrup Andersen, M. H Christensen, L. Nielsen, H. Christensen
Implementation of TNF-biosimilars (infliximab and etanercept) in Danish departments of rheumatology
**FRI 14 JUNE 2019 | SCIENTIFIC PROGRAMME | 63**

**11:10 – ABSTRACT N° OP0311**
Milada Cvancarova Smástuen (Norway)
R. Madla, O. Soli, E. Hjelvin
Retrospective analysis of prescription dynamics of etanercept after introduction of biosimilars based on Norwegian prescription database. An interim analysis

**11:20 – ABSTRACT N° OP0312**
Douglas White (United States of America)
M. Evans, T. Johansson, R. Myslinski, J. Yazdany, G. Schmajuk
Variability in biologic prescription patterns for rheumatoid arthritis patients in the American College of Rheumatology informatics system for effectiveness (RISE) registry

**11:30 – ABSTRACT N° OP0313**
Celine van de Laar (Netherlands)
M. Ouende Voshaar, W. Fakhouri, L. Zaremba-Pechmann, F. de Leonardis, I. De La Torre, M. van de Laar
Cost-effectiveness of a JAK1/JAK2-inhibitor vs. a biologic disease-modifying anti-rheumatic drug in a treat-to-target strategy for rheumatoid arthritis

**11:45 - 13:30**
EXHIBITION, EULAR VILLAGE AND POSTER AREAS (HALL 10)
POSTER VIEWING AND LUNCH

For details on the EULAR 2019 posters presentations, please refer to the online programme available at www.congress.eular.org or the EULAR 2019 Congress Mobile App.

**11:50 - 13:30**
POSTER AREA (HALL 10)
GUIDED POSTER TOURS

Guided poster tours on various topics are taking place during the official poster viewing. For details on the posters presented during the various tours, please refer to the online programme available at www.congress.eular.org or the EULAR 2019 Congress Mobile App.

Please note that you need to register to participate in a guided poster tour. The number of participants per tour is limited to 20. Registrations can be made at the poster tours & workshop desk, located in the registration area in Hall 2, on a ‘first-come-first-served’ basis the day of the poster tour.

The poster tours take place at the corresponding ePoster stations located in Hall 10 (Tour F01 on station 01, F02 on station 02, etc...)

**Poster tour**

**F01: GENETICS AND EPIGENETICS**

**Chair(s):**
Caroline Ospelt (Switzerland)
Diane van der Woude (Netherlands)

**ABSTRACTS N°:** FR10001-FRI0009

**Poster tour**

**F02: RHEUMATOID ARTHRITIS – NON-BIOLOGICAL TREATMENTS – UPCOMING SMALL MOLECULE THERAPIES FOR RA**

**Chair(s):**
Alexander So (Switzerland)
James Bluett (United Kingdom)

**ABSTRACTS N°:** FR10129-FRI0138

**Poster tour**

**F03: SLE, SJÖGREN’S AND APS – TREATMENT**

**Chair(s):**
Lai-Shan Tam (Hong Kong (SAR))
Priscilla C. Wong (Hong Kong (SAR))

**ABSTRACTS N°:** FR10173-FRI0182

**Poster tour**

**F04: VASCULITIS**

**Chair(s):**
Hendrik Schulze-Koops (Germany)
Bernhard Hellmich (Germany)

**ABSTRACTS N°:** FR10260-FRI0267

**Poster tour**

**F05: CLINICAL SCIENCE HIGHLIGHTS – SSC AND MYOSITIS**

**Chair(s):**
Ulf Müller-Ladner (Germany)
Marta Aguilar-Zamora (Spain)

**ABSTRACTS N°:** FR10300-FRI0309

**Poster tour**

**F06: UNRAVELLING THE PATHOGENESIS OF SPONDYLOARTHRITIS: A STORY OF GENES, CELLS AND CYTOKINES**

**Chair(s):**
Filip van den Bosch (Belgium)
Dirk Elewaut (Belgium)

**ABSTRACTS N°:** FR10353-FRI0363
F07: MODERN TREATMENTS IN SPA: ABOUT THEIR EFFECT ON RELEVANT DISEASE OUTCOMES

Chair(s): Sofia Ramiro (Netherlands) Clementina López-Medina (France)
ABSTRACTS N°: FRI0372-FRI0381

F08: OSTEOPOROSIS

Chair(s): Piet Geusens (Belgium) Sandrine Bours (Netherlands)
ABSTRACTS N°: FRI0465-FRI0474

F09: CARING FOR CHILDREN AND YOUNG PEOPLE WITH AUTOIMMUNE/AUTOINFLAMMATORY CONDITIONS

Chair(s): Erdal Sag (Turkey) Carine Wouters (Belgium)
ABSTRACTS N°: FRI0533-FRI0542

F10: NEW OPTIONS FOR TREATMENT AND CARE OF CHILDREN AND YOUNG PEOPLE WITH ARTHRITIS

Chair(s): Sebastian Vastert (Netherlands) Margarita Ganeva (Bulgaria)
ABSTRACTS N°: FRI0543-FRI0551

F11: DIAGNOSTICS AND IMAGING PROCEDURES - WHAT'S NEW IN IMAGING IN RA

Chair(s): Xenofon Baraliakos (Germany) Alberto Batticciotto (Italy)
ABSTRACTS N°: FRI0622-FRI0630

F12: EPIDEMIOLOGY AND RISK FACTORS

Chair(s): Alexandre Sepriano (Netherlands) Rene Cordtz (Denmark)
ABSTRACTS N°: FRI0652-FRI0661

F13: LIFESTYLE, EXERCISE

Chair(s): Rikke H. Moe (Norway) Nina Brodin (Sweden)
ABSTRACTS N°: FRI0697-HPR – FRI0701-HPR & FRI0727-HPR – FRI0730-HPR

Special poster tour
POSTER DESIGN TOUR

Learning objectives:
To apply design principles to critically appraise poster design

Chair(s): Maarten Boers (Netherlands)

Meeting point: at the EULAR study groups posters located after meeting point the entrance to Hall 10 on the right

Attendance of the practical skills session “Scientific data visualisation: focus on (poster) presentation” on Thursday at 15:30 in Room N111/N112 is required to attend this special poster tour.

12:00 - 13:30 EPOSTER STATION 14 POSTER AREA (HALL 10)

F14: PARE POSTER TOUR II

Chair(s): Dieter Wiek (Germany) Boriana Boteva (Bulgaria)
ABSTRACTS N°: PARE0011-PARE0020

13:30 - 15:00 HALL 6

WIN N H01 session
SAFETY FIRST! INFECTIOUS COMPLICATIONS AND PREGNANCY ISSUES IN PATIENTS WITH RHEUMATIC DISEASES

Learning objectives:
- To provide a state-of-the-art overview on the current safety considerations related to infectious complications as well as pregnancy issues in the context of the underlying diseases and standard therapy incl. recently introduced treatments
13:30 - 15:00  HALL 7A
Challenges in Clinical Practice session
PREDICTING SHORT-TERM FRACTURE RISK: CAN WE FORESEE THE (CLOSE) FUTURE?

Learning objectives:
- To discuss the validity of existing fracture risk algorithms for short-term (1-2 year) prediction/s
- To learn novel approaches/tools for short term fracture risk prediction

Chair(s):
Piet Geusens (Belgium)

13:35 – ABSTRACT N° SP0114
Nicholas Fuggle (United Kingdom)
Case 1 presenter: Imminent fracture risk: assessment and does it help clinical management

13:45 – ABSTRACT N° SP0115
Cyrus Cooper (United Kingdom)
Case 1 discussant: Imminent fracture risk: assessment and does it help clinical management

14:15 – ABSTRACT N° SP0116
Michael Skjødt (Denmark)
Case 2 presenter: Breaking bad and tragically hip. A case of a missed opportunity after vertebral fracture

14:25 – ABSTRACT N° SP0117
Bo Abrahamsen (Denmark)
Case 2 discussant: Automated (implemented in electronic medical record systems) short-term fracture risk prediction

13:30 - 15:00  HALL 8
Clinical Science session
IMMUNOSUPPRESSION IN SSC – A MATTER OF TIMING!

Learning objectives:
To understand, for which patients immunosuppression is to be chosen and when it should be started

Chair(s):
Ulf Müller-Ladner (Germany)
Cosimo Bruni (Italy)

13:35 – ABSTRACT N° SP0111
Jörg Distler (Germany)
Potential cellular and molecular targets

13:55 – ABSTRACT N° SP0112
Marco Matucci-Cerinic (Italy)
Immunosuppression – one fits all vs. individualized selection?

14:15 – ABSTRACT N° SP0113
Jacob M. van Laar (Netherlands)
Stem cell transplantation – all scientific questions answered?

13:30 - 15:00  HALL 7B
From Bench to Bedside
NEW INSIGHTS IN LUPUS NEPHRITIS (LN)

Learning objectives:
- To identify novel pathogenic mechanisms of LN and possible applications for future treatments
- To discuss the heterogeneity of LN in terms of histological and clinical presentation and implications for the management of patients
- To provide an overview on recent advances in the treatment of LN
- To review the evidence-based approach in the tapering of immunosuppressive drugs in LN patients who are in stable complete remission

Chair(s):
Jane E. Salmon (United States of America)
Dimitrios Boumpas (Greece)

13:35 – Anne Davidson (United States of America)
New pathways in the pathogenesis of LN

13:53 – Dimitrios Boumpas (Greece)
Clinical and histological phenotypes of LN

14:11 – Liz Lightstone (United Kingdom)
Update on the treatment of LN

14:29 – Andrea Doria (Italy)
Can we withdraw corticosteroids and immunosuppressants in LN patients in remission?
Clinical Science session

**N101/N102**

**13:30 - 15:00**

**SOUTH AUDITORIUM**

**Basic and Translational Science session**

**JOINT EULAR - EFIS: COMBATTING OR HARNESSING ILC IN THE BATTLE AGAINST AUTOIMMUNITY**

**Learning objectives:**
- Provide an update about the relevance of ILC for clinical and basic scientists
- Discuss the pros & cons for targeting ILC directly for future therapeutic use

**Chair(s):**
Timo R. Radstake (Netherlands)
Andreas Radbruch (Germany)

**13:35 – ABSTRACT N° SP0121**
Mikael Ebbo (France)
Debate: ILC as innocent bystander

**14:15 – Chiara Romagnani (Germany)**
Debate: ILC as cause of diseases

**13:30 - 15:00**

**N103/N104**

**Clinical Science session**

**OPTIMIZING THE ACCESS TO NEW TREATMENTS FOR RMD PATIENTS**

**Learning objectives:**
- To understand what are the best care pathways for the organisation of care processes in RMD patients
- To increase our knowledge on methods that increase implementation of recommendations for the management of non-pharmacological treatments
- To understand where are the challenges and the hurdles that could delay the access of new treatments and how to fix them

**Chair(s):**
Johannes W. J. Bijlsma (Netherlands)
Dolores Montero (Spain)

**13:35 – ABSTRACT N° SP0118**
Rinie Geenen (Netherlands)
Fibromyalgia; an acceptable diagnosis?

**13:55 – ABSTRACT N° SP0119**
Ernest Choy (United Kingdom)
Searching for pathology; how hard should we look?

**14:15 – ABSTRACT N° SP0120**
Serge Perrot (France)
Personalised treatment for fibromyalgia; the impact of comorbidities

**14:35 – ABSTRACT N° OP0314**
Katarina Aili (Sweden)
P. Campbell, Z. Michaleff, V. Strauss, K. Jordan, A. Breman, P. Croft, S. Bergman
Long-term trajectories of chronic widespread pain: a 21-year prospective cohort latent class analysis

**14:45 – ABSTRACT N° OP0315**
Melissa Holdren (Canada)
Achieving a low disease state within first 3 months in early rheumatoid arthritis results in lower fatigue over 5 years
13:30 - 15:00  N105/N106
Health Professionals session

TEENAGE LOOK IN THE MIRROR (SEXUALITY AND BODY IMAGE MEETING HEALTH CARE)

Learning objectives:
- To learn about the importance of body image and sexuality in young patients
- To learn about how to treat them and meet their needs

Chair(s):
Jette Primdahl (Denmark)
Francoise Alliot Launois (France)

13:35 – ABSTRACT N° OP0318-HPR
Hayley McBain (United Kingdom)
M. Bezzant, A. Bosworth
Is psychological support reaching those in most need? A survey of people with rheumatoid arthritis and adults with juvenile idiopathic arthritis

14:00 – ABSTRACT N° OP0332
Martin Fruth (Germany)
J. Kozik, P. Martin-Seidel, A. Seggewiss, X. Baraliakos, J. Braun
Successful evaluation of a predefined set of anatomic sites in the pelvis of patients with polymyalgia rheumatica showing extracapsular inflammation as visualized by contrast enhanced magnetic resonance imaging

13:30 - 15:00  N110/N111
Practical skills session*

NEW ASSESSMENTS IN CLINICAL PRACTICE

Learning objectives:
- To learn which measures are the best for the assessment of the remission in rheumatoid arthritis in clinical practice
- To learn how to properly assess patients with vasculitis
- To learn about clinical importance of ANA anti-DSF70 antibodies

Chair(s):
Thomas Dörner (Germany)
Annamaria Iagnocco (Italy)

13:35 – ABSTRACT N° SP0124
Annamaria Iagnocco (Italy)
Which measures to use to assess remission in rheumatoid arthritis

13:55 – ABSTRACT N° SP0125
Raashid Luqmani (United Kingdom)
How to assess patient with suspected vasculitis

14:15 – ABSTRACT N° SP0126
Johan Rönnelid (Sweden)
Clinical importance of ANA anti-DSF70 antibodies

14:35 – ABSTRACT N° OP0319
Georgios Filippou (Italy)
Diagnostic accuracy of ultrasound in calcium pyrophosphate deposition disease: preliminary results of the OMERACT US in CPPD sub-group

14:45 – ABSTRACT N° OP0320
Martin Fruth (Germany)
J. Kozik, P. Martin-Seidel, A. Seggewiss, X. Baraliakos, J. Braun
Successful evaluation of a predefined set of anatomic sites in the pelvis of patients with polymyalgia rheumatica showing extracapsular inflammation as visualized by contrast enhanced magnetic resonance imaging

* In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area, Hall 2
SCIENTIFIC PROGRAMME | FRIDAY 14 JUNE 2019

14:30 – ABSTRACT N° OP0321-PARE
Mitchell Silva (Belgium)
N. Caeyers
A novel approach to reach patients for educational purposes - virtual conference ReumaNet

14:45 – ABSTRACT N° OP0322-PARE
Nique Lopuhää (Netherlands)
M. Feith, S. De Jong
Grassroots campaign for Dutch RMD-friendly municipalities

13:30 - 15:00 N107/N108
Practical skills session*
CAPILLAROSCOPY II

Learning objectives:
- Links with other techniques investigating the skin sickness and the peripheral blood flow in scleroderma patients will be reported
- The predictive and prognostic role of capillaroscopy in scleroderma will be explained and documented
- Learners at the end of the session will have understood when a capillaroscopic pattern is pathologic and what to do
- Learners will observe on live patients how the nailfold capillaroscopic analysis is done and will discuss with the tutors the diagnosis

Chair(s):
Alberto Sulli (Italy)
Ariane Herrick (United Kingdom)

13:35 – ABSTRACT N° SP0130
Vanessa Smith (Belgium)
Standardisation of normal versus abnormal and pathological capillaroscopic images

13:45 – ABSTRACT N° SP0131
Ariane Herrick (United Kingdom)
Reliability in the last 10 years: capillaroscopic characteristics versus instrumental detection

13:55 – Maurizio Cutolo (Italy)
Nailfold capillaroscopy realistically detect the links between progression of microvascular pathological damage and clinical symptom

14:05 – ABSTRACT N° SP0132
Francesca Ingegnoli (Italy)
Methods and tools for quantization of capillaroscopic morphological changes

14:15 – Lindsay Bearne (United Kingdom)
What we are brilliant at; PT perspective

13:30 - 15:00 N117/N118
EULAR Projects in Health Professionals
JEWELS IN THE CROWN OF HEALTH PROFESSIONALS

Learning objectives:
- To learn about recent findings from the EULAR Project on core competencies
- To know what different health professionals are especially brilliant at
- To ease multidisciplinary collaboration

Chair(s):
Heidi A. Zangi (Norway)
Hana Smurova (Czech Republic)

13:35 – ABSTRACT N° SP0137
Thea Vliet Vlieland (Netherlands)
Core competencies

13:55 – ABSTRACT N° SP0138
Ingvild Kjeken (Norway)
What we are brilliant at; OT perspective

14:15 – ABSTRACT N° SP0139
Ricardo Ferreira (Portugal)
What we are brilliant at; nursing perspective

14:35 – Lindsay Bearne (United Kingdom)
What we are brilliant at; PT perspective

13:30 - 15:00 N109/N110
Practical skills session*
ULTRASOUND BASIC II

Learning objectives:
- Use of ultrasound to better diagnose gout and identify various aspects and localization of gout crystal deposits
- Diagnostic value of ultrasound in the evaluation of patients with trochanteric pain syndrome
- Identify the sonographic findings corresponding to minimal disease activity in rheumatoid arthritis
- Theoretical aspects and practical issues of ultrasound-guided interventions

Chair(s):
Maria Stoenoiu (Belgium)
Stephanie Finzel (Germany)

13:35 – ABSTRACT N° SP0133
Sara Nysom (Denmark)
How to assess US lesions for gout + demo

* In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area, Hall 2
13:55 – ABSTRACT Nº SP0134
Ingrid Möller (Spain)
US for trochanteric pain syndrome – clinical use + demo

14:15 – ABSTRACT Nº SP0135
Ilfita Sahbudin (United Kingdom)
How to differentiate minimal disease activity in RA + demo

14:35 – ABSTRACT Nº SP0136
Juhani Koski (Finland)
How to perform US-guided interventions + demo

Model:
Sara Kamp (Denmark)

15:00 - 15:30
EXHIBITION AND EULAR VILLAGE (HALL 10)
COFFEE BREAK

15:30 - 17:00
HALL 8
Clinical Science session
OVERDIAGNOSIS AND OVERTREATMENT IN INFLAMMATORY ARTHRITIS

Learning objectives:
- Getting insight into what over-diagnosis and overtreatment means in medicine and whether it exists in rheumatology
- Discussing to what extent modern imaging and biomarkers may add to the risk of over-diagnosis and over-treatment
- Exploring how modern treatment concepts in rheumatology such as early intervention, window of opportunity and treat-to-target may lead to overtreatment and how this can be avoided

Chair(s):
Leonard Calabrese (United States of America)
José Antonio P. da Silva (Portugal)

15:35 – ABSTRACT Nº OP0323
Mariana Luis (Portugal)
L. Brites, A. Prata, T. Santiago, J. da Silva, C. Duarte
Usefulness of universal antinuclear antibodies testing in early arthritis referrals

16:00 – ABSTRACT Nº SP0141
Duncan Porter (United Kingdom)
Does imaging lead to overdiagnosis and overtreatment?

16:15 – ABSTRACT Nº SP0140
Michael Beresford (United Kingdom)
HOT: Management of juvenile idiopathic arthritis 2019 and beyond

16:35 – ABSTRACT Nº SP0141
Joan Bathon (United States of America)
Is treat-to-target a recipe for overtreatment?

15:30 - 17:00
HALL 6
WIN & HOT session
NEW INSIGHTS INTO JIA AND AUTOINFLAMMATORY DISEASES

Learning objectives:
- A dedicated session to enhance communication between paediatric and adults rheumatologists
- To provide an overview on best management of juvenile idiopathic arthritis, an outlook for new treatment possibilities and JIA outcome with a focus on adults
- Recent advances in the diagnosis and treatment of autoinflammatory diseases will be discussed in the context of new insights into the underlying pathogenic mechanisms. These diseases are a prime example how rheumatologists in charge of paediatric and adults patients have witnessed substantial progress recently

15:35 – ABSTRACT Nº SP0140
Michael Beresford (United Kingdom)
HOT: Management of juvenile idiopathic arthritis 2019 and beyond

16:15 – Raphaela Goldbach-Mansky (United States of America)
WIN: Diagnosis and treatment of autoinflammatory diseases

15:30 - 17:00
HALL 7A
Challenges in Clinical Practice session
THE MULTIPLE RHEUMATOLOGICAL FACES OF PSA (OR PSA IS MORE THAN JUST POLY-ARTHRITIS? - CONSEQUENCES FOR MANAGEMENT IN DAILY PRACTICE)

Learning objectives:
To understand the difficulties in translating the clinical trial results (in predominantly polyarticular disease) to making management decisions in individual PsA patients

Chair(s):
Oliver FitzGerald (Ireland)
Eduardo Collantes Estevez (Spain)
15:35 – ABSTRACT N° SP0142
William Tillett (United Kingdom)
Case 1 presenter: A patient with persisting mono/oligo-arthritis (either at start or remaining after treatment of poly-articular disease)

15:45 – ABSTRACT N° SP0143
Laura C. Coates (United Kingdom)
Case 1 discussant: How is tackling oligo-articular disease different from polyarthritis? Can we use trial results from poly-articular PsA in a patient with mono/oligo-arthritis?

16:15 – ABSTRACT N° SP0144
Philippe Carron (Belgium)
Case 2: Solitary enthesitis as a therapeutic challenge

16:25 – ABSTRACT N° SP0145
Dirk Elewaut (Belgium)
Case 2 discussant: Enthesitis and the concept of mechanical stress

15:30 - 17:00
SOUTH AUDITORIUM

Clinical Science session
REPRODUCTIVE ISSUES IN RHEUMATOLOGY

Learning objectives:
- To highlight the shift in paradigm about the beneficial effects of pregnancy on disease activity of chronic arthritis
- To provide practical messages for counselling of women with rheumatic diseases who need to approach assisted reproduction techniques
- To discuss the implications of active disease and drugs on the fertility of men affected by rheumatic diseases

Chair(s):
Frauke Förger (Switzerland)
Antonio Brucato (Italy)

15:35 – ABSTRACT N° SP0148
Laura Andreoli (Italy)
Does pregnancy really ameliorate disease activity of women with chronic arthritis? Old beliefs vs new paradigms

15:53 – ABSTRACT N° SP0149
Nathalie Costedoat-Chalumeau (France)
Assisted reproduction techniques: what can we tell to women with rheumatic diseases?

16:11 – ABSTRACT N° SP0150
Monika Østensen (Norway)
The impact of rheumatic diseases and anti-rheumatic drugs on male fertility in adult and young people

16:29 – Marie Wahren-Herlenius (Sweden)
How to manage pregnancies at risk of neonatal lupus

16:47 – ABSTRACT N° OP0326
Yvette Meißner (Germany)
Development of a standardized minimal core data set for pregnancy registers in rheumatology – results of a EULAR task force

15:30 - 17:00
HALL 7B

From Bench to Bedside
CANNABIS FOR ARTHRITIS: HYPE OR HOPE?

Learning objectives:
- To understand the mechanisms of action of cannabinoids on pain pathways
- To be able to assess the benefits and the risks of cannabinoids for treating arthritis
- To understand how ethical issues can influence the decisions of both clinicians and patients

Chair(s):
Francis Berenbaum (France)
David Walsh (United Kingdom)

15:35 – David Finn (Ireland)
The science of cannabinoids

15:55 – ABSTRACT N° SP0146
Serge Perrot (France)
Benefits of cannabis to your joints: hype or hope?

16:15 – ABSTRACT N° SP0147
Steve Alexander (United Kingdom)
Ethical issues in medical cannabis use

16:35 – ABSTRACT N° OP0324
Martina Winklmayr (Austria)
M. Gaisberger, J. Fuchs, M. Kittl, M. Ritter, M. Jakab
Cannabidiol elevates intracellular calcium and induces apoptosis in human articular chondrocytes

16:45 – ABSTRACT N° OP0325
Robert Spiera (United States of America)
Safety and efficacy of lenabasum in an open-label extension of a phase 2 study in diffuse cutaneous systemic sclerosis subjects (DCSSC)

15:30 - 17:00
HALL 7B

Basic and Translational Science session
THE FUTURE OF THERAPEUTIC STRATEGIES

Learning objectives:
- To learn about novel treatment approaches
- To understand the advantages of cutting-edge treatment approaches
**Chair(s):**
Erwin Van Spil (Netherlands)
Meghna Jani (United Kingdom)

**15:35 – ABSTRACT N° SP0151**
Marcel Karperien (Netherlands)
Microfabrication technologies for cartilage repair

**16:00 – ABSTRACT N° SP0152**
Matthew Peak (United Kingdom)
3D printed drugs

**16:25 – Rafael J. Yáñez-Muñoz (United Kingdom)**
Possibilities of therapeutic gene editing in monogenic and polygenic disease

**16:50 – ABSTRACT N° OP0327**
Anna-Maria Hoffmann-Vold (Norway)
Fecal microbiota transplantation in systemic sclerosis: a double-blind, placebo-controlled randomized pilot trial

**15:30 - 17:00 N101/N102**
Paediatric rheumatology session

**CALMING THE CYTOKINE STORM IN CHILDREN AND ADULTS**

**Learning objectives:**
- To raise awareness of the importance of understanding and knowing how to manage the impact of an uncontrolled cytokine storm in systemic autoimmune/autoinflammatory diseases in children and adults
- To understand the pathophysiology of the cytokine storm that leads to clinical manifestations as macrophage activation syndrome (MAS), and how this has informed therapeutic approaches in paediatric rheumatic disorders
- To raise awareness of the importance of diagnosis and to understanding the therapeutic approach to treating MAS in children and young people and addressing the patient’s needs
- To raise awareness of the uncontrolled cytokine storm occurring in adult patients and to update currently available treatment options, patient needs, and translation of scientific observations into clinical practice in adults

**Chair(s):**
Lovro Lamot (Canada)
Sebastian Vastert (Netherlands)

**15:35 – Alexei Grom (United States of America)**
Pathophysiology informing therapy in MAS: what we’ve learned in paediatric practice

**15:55 – Anna Carin Horne (Sweden)**
Calming the storm in children

**16:15 – ABSTRACT N° SP0153**
Jan van Laar (Netherlands)
Calming the storm in adult MAS/HLH in rheumatic disorders

**16:35 – ABSTRACT N° OP0328**
Mao Mizuta (Japan)
Comparison of serum cytokine profile in macrophage activation syndrome among different background rheumatic diseases in children

**16:45 – ABSTRACT N° OP0329**
Roberta Faccio (United States of America)
S. Mahajan, Z. Yang, E. Mellins
PLCGAMMA2/TMEM178 dependent pathway in myeloid cells modulates the pathogenesis of cytokine storm syndrome

**15:30 - 17:00 N105/N106**
Health Professionals session

**KNOW YOUR METHODS!**
**INTERACTIVE DISCUSSION**

**Learning objectives:**
- To obtain knowledge about the methods behind evidence-based knowledge within the field of rheumatology
- To understand and discuss more about how and when to use different kind of methods

**Chair(s):**
Tanja Stamm (Austria)
Thea Vliet Vlieland (Netherlands)

**15:35 – Josef S. Smolen (Austria)**
Why we need HPR research

**15:55 – ABSTRACT N° SP0154**
Romualdo Ramos (Austria)
Reasons for qualitative research for HPR

**16:15 – ABSTRACT N° SP0155**
Mwidimi Ndosi (United Kingdom)
Reasons for quantitative research for HPR

**16:35**
Voting
MISSING DATA IN CLINICAL RESEARCH: TO IMPUTE OR NOT TO IMPUTE, THAT IS THE QUESTION

**Learning objectives:**
- To understand:
  - The various types of missing data in clinical research (e.g. MCAR, MAR, MNAR)
  - The various strategies to handle missing data and consequences in interpretation of the results of each strategy (e.g. single imputation, multiple imputation)
- When it’s appropriate and when it’s not to perform a specific imputation method (e.g. too scarce available data to inform complex imputation strategies)
- How to best collect clinical data and minimise the issue of missing data

**Chair(s):**
Alexandre Sepriano (Netherlands)
Loreto Carmona (Spain)

**15:35** – ABSTRACT N° SP0156
Stian Lydersen (Norway)
Missing data: is it all the same?

**15:45** – ABSTRACT N° SP0157
Loreto Carmona (Spain)
Pro session: Imputation is a powerful analytical tool, when appropriately used

**16:05** – ABSTRACT N° SP0158
Maxime Dougados (France)
Con session: Prepare your data collection well: Imputation does not replace ‘real data’

**16:25** – Loreto Carmona (Spain)
Summary Pros and Cons

**16:35**
Active audience participation

**16:45**
Session summary

DON’T PANIC – ROUND TABLE DISCUSSION ON RISK PERCEPTION

**Learning objectives:**
- How physicians/HPRs perceive the patients’ risk and communicate it
- Finding solutions to overcome the gap in risk perceptions

**Chair(s):**
Neil Betteridge (United Kingdom)

**15:30 - 17:00**
N111/N112

The Young Rheumatologist

**REMISSION - THE HOLY GRAIL? LOOKING ACROSS DISEASES**

**Learning objectives:**
- To review remission in three diseases
- Remission is the announced objective in inflammatory diseases, however, many questions remain

**Chair(s):**
Sofia Ramiro (Netherlands)
Bernard Combe (France)

**15:35** – ABSTRACT N° SP0162
Daniel Aletaha (Austria)
Remission in RA: does the definition matter?

**15:55** – Pedro Machado (United Kingdom)
Remission in axSpa: how to define it and relevance

**15:30 - 17:00**
N115/N116

PARF session

**REMAINING DATA IN CLINICAL RESEARCH: TO IMPUTE OR NOT TO IMPUTE, THAT IS THE QUESTION**

**Learning objectives:**
- To understand:
  - The various types of missing data in clinical research (e.g. MCAR, MAR, MNAR)
  - The various strategies to handle missing data and consequences in interpretation of the results of each strategy (e.g. single imputation, multiple imputation)
- When it’s appropriate and when it’s not to perform a specific imputation method (e.g. too scarce available data to inform complex imputation strategies)
- How to best collect clinical data and minimise the issue of missing data

**Chair(s):**
Alexandre Sepriano (Netherlands)
Loreto Carmona (Spain)

**15:35** – ABSTRACT N° SP0159
Timothy R. Radstake (Netherlands)
What do we know – what shall we do – what do we tell

**15:40** – Filip van den Bosch (Belgium)
Predict the future? - Finding the right information balance

**15:45** – Codruta Zabalan (Romania)
The right decision relies on sharing information and team work

**15:50** – ABSTRACT N° SP0160
Ricardo Ferreira (Portugal)
Disease remission: do we aim for the same thing?

**15:55** – ABSTRACT N° SP0161
Simon Stones (United Kingdom)
Looking for a needle in a haystack: helping young people to make sense of evidence-based health care

**16:00**
Round Table discussion

**16:40**
Audience Q&A

**15:30 - 17:00**
N117/N118

EULAR Projects in Epidemiology and Health Services

**REMAINING DATA IN CLINICAL RESEARCH: TO IMPUTE OR NOT TO IMPUTE, THAT IS THE QUESTION**

**Learning objectives:**
- To understand:
  - The various types of missing data in clinical research (e.g. MCAR, MAR, MNAR)
  - The various strategies to handle missing data and consequences in interpretation of the results of each strategy (e.g. single imputation, multiple imputation)
- When it’s appropriate and when it’s not to perform a specific imputation method (e.g. too scarce available data to inform complex imputation strategies)
- How to best collect clinical data and minimise the issue of missing data

**Chair(s):**
Alexandre Sepriano (Netherlands)
Loreto Carmona (Spain)

**15:35** – ABSTRACT N° SP0156
Stian Lydersen (Norway)
Missing data: is it all the same?

**15:45** – ABSTRACT N° SP0157
Loreto Carmona (Spain)
Pro session: Imputation is a powerful analytical tool, when appropriately used

**16:05** – ABSTRACT N° SP0158
Maxime Dougados (France)
Con session: Prepare your data collection well: Imputation does not replace ‘real data’

**16:25** – Loreto Carmona (Spain)
Summary Pros and Cons

**16:35**
Active audience participation

**16:45**
Session summary

**15:30 - 17:00**
N115/N116

PARF session

**DON’T PANIC – ROUND TABLE DISCUSSION ON RISK PERCEPTION**

**Learning objectives:**
- How physicians/HPRs perceive the patients’ risk and communicate it
- Finding solutions to overcome the gap in risk perceptions

**Chair(s):**
Neil Betteridge (United Kingdom)

**15:35** – ABSTRACT N° SP0162
Daniel Aletaha (Austria)
Remission in RA: does the definition matter?

**15:55** – Pedro Machado (United Kingdom)
Remission in axSpa: how to define it and relevance

**15:30 - 17:00**
N117/N118

EULAR Projects in Epidemiology and Health Services

**REMAINING DATA IN CLINICAL RESEARCH: TO IMPUTE OR NOT TO IMPUTE, THAT IS THE QUESTION**

**Learning objectives:**
- To understand:
  - The various types of missing data in clinical research (e.g. MCAR, MAR, MNAR)
  - The various strategies to handle missing data and consequences in interpretation of the results of each strategy (e.g. single imputation, multiple imputation)
- When it’s appropriate and when it’s not to perform a specific imputation method (e.g. too scarce available data to inform complex imputation strategies)
- How to best collect clinical data and minimise the issue of missing data

**Chair(s):**
Alexandre Sepriano (Netherlands)
Loreto Carmona (Spain)

**15:35** – ABSTRACT N° SP0156
Stian Lydersen (Norway)
Missing data: is it all the same?

**15:45** – ABSTRACT N° SP0157
Loreto Carmona (Spain)
Pro session: Imputation is a powerful analytical tool, when appropriately used

**16:05** – ABSTRACT N° SP0158
Maxime Dougados (France)
Con session: Prepare your data collection well: Imputation does not replace ‘real data’

**16:25** – Loreto Carmona (Spain)
Summary Pros and Cons

**16:35**
Active audience participation

**16:45**
Session summary

**15:30 - 17:00**
N115/N116

PARF session

**DON’T PANIC – ROUND TABLE DISCUSSION ON RISK PERCEPTION**

**Learning objectives:**
- How physicians/HPRs perceive the patients’ risk and communicate it
- Finding solutions to overcome the gap in risk perceptions

**Chair(s):**
Neil Betteridge (United Kingdom)
16:45 – ABSTRACT N° OP0331
Signe Møller-Bisgaard (Denmark)
Magnetic resonance imaging tenosynovitis and osteitis are independent predictors of radiographic and MRI damage progression in rheumatoid arthritis patients in clinical remission

15:30 - 17:00  N107/N108
Practical skills session*
LABORATORY COURSE - FROM THE CLINIC TO THE LAB AND BACK (FROM TRANSLATION TO PRESCRIPTION)

Learning objectives:
- This session will provide an interactive forum for colleagues with interest in the rheumatology lab
- State of the art and new lab parameters and decision methods will be discussed for three main sections:
  - arthritides
  - connective tissue diseases including antiphospholipid syndrome
  - vasculitides

Chair(s):
Gerd R. Burmester (Germany)
Thomas Dörner (Germany)

15:35 – ABSTRACT N° SP0164
Thomas Dörner (Germany)
ANA diagnostic and antiphospholipid syndrome (APS) as inherited coagulation disorder

16:00 – Pierre Miossec (France)
Vasculitis, systemic autoimmunity

16:25 – ABSTRACT N° SP0165
Eugen Feist (Germany)
New trends in biomarkers in inflammatory joint disease

15:30 - 17:00  N109/N110
Practical skills session*
ULTRASOUND ADVANCED II

Learning objectives:
- To deepen knowledge into some practical applications of ultrasound in RMD diseases
- To gain insight into new fields of application of ultrasound in RMD clinical practice and research

Chair(s):
Claire Harris (United Kingdom)
The new complement therapeutics

15:30 - 17:00  N107/N108
Practical skills session*
LABORATORY COURSE - FROM THE CLINIC TO THE LAB AND BACK (FROM TRANSLATION TO PRESCRIPTION)

Learning objectives:
- To understand how complement regulates immunity
- To recognise complement as a therapeutic target
- To learn about complement as an intracellular mediator

Chair(s):
Iain McInnes (United Kingdom)
John Isaacs (United Kingdom)

15:35 – ABSTRACT N° SP0164
Thomas Dörner (Germany)
ANA diagnostic and antiphospholipid syndrome (APS) as inherited coagulation disorder

16:00 – Pierre Miossec (France)
Vasculitis, systemic autoimmunity

16:25 – ABSTRACT N° SP0165
Eugen Feist (Germany)
New trends in biomarkers in inflammatory joint disease

15:30 - 17:00  N109/N110
Practical skills session*
ULTRASOUND ADVANCED II

Learning objectives:
- To deepen knowledge into some practical applications of ultrasound in RMD diseases
- To gain insight into new fields of application of ultrasound in RMD clinical practice and research

Chair(s):
Georgios Filippou (Italy)
Esperanza Naredo (Spain)

15:35 – ABSTRACT N° SP0166
David Andrew Bong (Spain)
US of the hamstring – clinical application + demo

15:55 – Søren Torp-Pedersen (Denmark)
US for diagnosing lumps and bumps – characteristics and differential diagnosis + patient cases

16:15 – ABSTRACT N° SP0167
Andrea Delle Sedie (Italy)
US for assessing lung involvement in rheumatic diseases – clinical use + demo

16:35 – ABSTRACT N° SP0168
Andrew Filer (United Kingdom)
US for synovial biopsies – clinical relevance and safety + demo

Model:
Sara Kamp (Denmark)

17:30 - 19:00  SOUTH AUDITORIUM
Basic and Translational Science session
COMPLEMENT AND AUTOIMMUNITY - EMERGING THERAPEUTIC OPPORTUNITIES

Learning objectives:
- To understand how complement regulates immunity
- To recognise complement as a therapeutic target
- To learn about complement as an intracellular mediator

Chair(s):
V. Michael Holers (United States of America)
Claire Harris (United Kingdom)

17:35 – ABSTRACT N° SP0169
Marina Botto (United Kingdom)
Complement and lupus in the young and the old

18:00 – ABSTRACT N° SP0170
V. Michael Holers (United States of America)
Is complement a critical ingredient in the development of RA?

18:25 – ABSTRACT N° SP0171
Claire Harris (United Kingdom)
The new complement therapeutics

18:50 – ABSTRACT N° OP0332
Elisa Assirelli (Italy)
L. Pulsetelli, P. Dolzani, O. Addimanda, G. Lisignoli, E. Mariani, R. Meliconi
Complement factor expression and activation in osteoarthritis joint compartments

* In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area, Hall 2
SCIENTIFIC PROGRAMME
SATURDAY
15 JUNE 2019

08:06 – ABSTRACT N° LB0004
Stanley B. Cohen (United States of America)
J. Pope, B. Harraoui, F. Irazoque-Palazuelos,
M. Korkosz, A. Diehl, J. Rivas, T. Lukic, S. Liu,
L. Stockert, N. Ikunni, E. Keystone
Methotrexate withdrawal in patients with rheumatoid arthritis who achieve low disease activity with tofacitinib modified-release 11 mg once daily + methotrexate: a randomised non-inferiority phase 3B/4 study

08:12 – ABSTRACT N° LB0005
Philip J. Mease (United States of America)
J. Smolen, F. Behrens, P. Nash, S. Liu Leage,
L. Lingnan, H. Tahir, M. Gooderham, E. Krishnan,
P. Emery, S. Pillai, P. Helliwell
Multicentre, randomised, open-label, assessor-blinded, parallel-group head-to-head comparison of the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naive to biologic disease-modifying anti-rheumatic drugs: 24-week results

08:18 – ABSTRACT N° LB0006
Philip J. Mease (United States of America)
R. Landewé, P. Rahman, H. Tahir, A. Singhal,
E. Boettcher, S. Navarra, A. Readie, S. Mpfou,
E. Delicha, L. Pricop, D. van der Heijde
Subcutaneous secukinumab 300mg and 150mg provides sustained inhibition of radiographic progression in psoriatic arthritis over 2 years: results from the phase 3 FUTURE-5 trial

08:24 – ABSTRACT N° LB0007
Francis Berenbaum (France)
F. Blanco, A. Guermazi, E. Vignon, K. Miki,
T. Yamabe, L. Viktrup, R. Junor, W. Carey, M. Brown,
K. Verburg, C. West
Subcutaneous tanezumab for osteoarthritis pain: a 24-week phase 3 study with a 24-week follow up

08:30 – ABSTRACT N° LB0008
Vivian Bykerk (United States of America)
W. Rigby, J. Buckner, L. Bridges, M. Nys, S. Gao,
M. Polinsky, A. Johnsen, N. Ray
The effect of HLA-DRB1 risk alleles on the clinical efficacy of abatacept and adalimumab in seropositive biologic-naive patients with early, moderate-to-severe RA: data from a head-to-head single-blinded trial

08:36 – ABSTRACT N° LB0009
Mark C. Genovese (United States of America)
N. Gaylis, D. Sikes, A. Kivitz, D. Horowitz, C. Peterfy,
Y. Levine, D. Chernoff
First-in-human study of novel implanted vagus nerve stimulation device to treat rheumatoid arthritis

08:42 – ABSTRACT N° LB0010
L. M. Verhoef (Netherlands)
N. den Broeder, R. Thurlings, W. van der Laan,
W. van der Weele, M. Kok, H. Bernelot Moens,
T. Woodworth, B. van den Bent, F. van den Hoogen,
A. den Broeder
Ultra-low doses of rituximab for retreatment of rheumatoid arthritis: a randomised controlled non-inferiority trial
08:48 – ABSTRACT N° LB0011
Athimalaipet Ramanan (United Kingdom)
A. Dick, A. Jones, A. McKay, C. Guly, B. Hardwick, R. Lee, M. Smyth, M. Beresford
A phase II single arm (adaptive design) trial of tocilizumab in anti-TNF refractory patients with JIA-associated uveitis (APTITUDE trial)

08:54 – ABSTRACT N° LB0012
Saira Sheikh (United States of America)
Headline results for a phase 4, 52-week, randomised, double-blind, placebo-controlled study to assess adverse events of special interest (AESI) in adults with active, autoantibody-positive systemic lupus erythematosus (SLE) receiving belimumab

09:00 - 10:50 HALL 7A
EULAR Projects in Clinical Affairs

EULAR PROJECTS IN CLINICAL AFFAIRS

Learning objectives:
- To learn, how development of new and updated EULAR recommendations is being performed
- To learn, how difficult-to-treat rheumatic diseases such as Sjögren’s syndrome and large vessel vasculitis are being treated in an evidence-based manner
- To learn, how the various aspects of diagnosis and management of antiphospholipid syndrome are handled in an evidence-based manner

Chair(s):
Thomas Huizinga (Netherlands)
Ulf Müller-Ladner (Germany)

09:00 – ABSTRACT N° SP0189
Antonis Fanouriakis (Greece)
Update on EULAR recommendations for the management of SLE

09:18 – ABSTRACT N° SP0190
Manuel Ramos-Casals (Spain)
Sjögren’s management recommendations 2019

09:36 – ABSTRACT N° SP0191
Maria Tektonidou (Greece)
Management of adult APS: recommendations from an EULAR task force

09:54 – ABSTRACT N° SP0192
Bernhard Hellmich (Germany)
Update of the EULAR recommendations large vessel vasculitis management

10:12 – Laure Gossec (France)
Update of the EULAR recommendation on PsA

10:30 – Josef S. Smolen (Austria)
Update of the EULAR recommendations on RA

09:00 - 10:30 HALL 7B
Challenges in Clinical Practice session

LIGHTS AT BOTH ENDS OF THE TUNNEL? ADVANCES IN GI INVOLVEMENT IN SSC

Learning objectives:
To understand the problems and solutions of GI involvement in SSC

Chair(s):
Jacob M. van Laar (Netherlands)

09:05 – Rucsandra Dobrota (Switzerland)
Case 1 presenter: Traffic jam in all sections – GI dysfunction from oral to anal

09:15 – Carina Mihai (Romania)
Case 1 discussant: Keep it moving: prokinetics from top to bottom

09:45 – ABSTRACT N° SP0172
Kristina Clark (United Kingdom)
Case 2 presenter: Always at the edge: severe GI complications

09:55 – ABSTRACT N° SP0173
Christopher Denton (United Kingdom)
Case 2 discussant: Immunosuppression or antibiotics – when to choose what?

09:00 - 10:50 HALL 7A
EULAR Projects in Clinical Affairs

09:00 - 10:30 N103/N104
WIN & HOI session

PAIN MANAGEMENT @2019

Learning objectives:
- To provide an update on recent insights in the mechanisms of pain in the context of rheumatic diseases differentiating inflammatory related and unrelated conditions and potential treatment pathways at different stages of development
- Give an overview on pain management in patients with arthritides
- Benefit/risk assessment of certain modalities will be discussed incl. potential interaction with DMARDs and insights into the relation of pain treatment and outcome

09:05 – Stefan Bergman (Sweden)
HOT: Arthritis pain management pathways

09:45 – David Walsh (United Kingdom)
WIN: How to stop the train of pain in RMDs?
09:00 - 10:30   SOUTH AUDITORIUM

Basic and Translational Science session

NOVEL AUTOANTIBODIES IN RMD: A NEVER-ENDING QUEST?

Learning objectives:
- To understand the role of autoantibodies in disease pathogenesis
- To learn about autoantibodies in various RMDs

Chair(s):
Diane van der Woude (Netherlands)
Paul Studenic (Austria)

09:05 – ABSTRACT N° SP0174
Luis Munoz (Germany)
Advances in the detection of pathogenic autoantibodies in SLE

09:25 – ABSTRACT N° SP0175
Rene Toes (Netherlands)
Post-translational modifications of antibodies: where there’s smoke there’s fire

09:45 – ABSTRACT N° SP0176
Sasa Cucnik (Slovenia)
Pathogenic antibodies in phospholipid syndrome

10:05 – ABSTRACT N° OP0333
Theresa Kisel (Netherlands)
K. van Schie, L. Hafkenscheid, A. Lundquist, H. Scherer, H. Kokkonen, R. Toes, S. Rantapää Dahlqvist
Rising ACPA IGG variable domain glycosylation predicts a disease associated with an increase in autoantibody levels and the development of rheumatoid arthritis

10:15 – ABSTRACT N° OP0334
Ewa Olech (United States of America)
E. van Rijen, A. Kant, A. Ashrafzadeh, J. Merrill
What serologic profiling provides optimal entry criteria for systemic lupus erythematosus clinical trials?

09:00 - 10:30   N105/N106

Basic and Translational Science session

LESSONS LEARNED FROM CHECKPOINT INHIBITORS

Learning objectives:
- To understand the impact of checkpoint inhibition on the different cells of the immune system and the microbiome
- To see pathways that are modulated by checkpoint inhibition

Chair(s):
Alla Skapenko (Germany)
Thierry Saeverbeke (France)

09:05 – ABSTRACT N° SP0177
David Pisetsky (United States of America)
Impact of checkpoint inhibitors on B cells

09:25 – Hendrik Schulze-Koops (Germany)
Impact of checkpoint inhibitors on T cells

09:45 – Beth Helmink (United States of America)
Checkpoint inhibitor and the microbiome

10:05 – ABSTRACT N° OP0335
Alexandra Filippopoulou (Greece)
D. Daoussis, P. Kraniotis, S. Theodoraki, R. Argiriadi, T. Makatsoris, A. Koutras, A. Solomou, H. Kalofonos, S. Liossis
A prospective clinical and MRI study of immune checkpoint inhibitor (ICI)-induced musculoskeletal manifestations myo-fasciitis and not synovitis is the prominent imaging finding

10:15 – ABSTRACT N° OP0336
Marie Kostine (France)
Commonly used drugs in rheumatology may alter anti-tumoral response to immune checkpoint inhibitors

09:00 - 10:30   N101/N102

Basic and Translational Science session

ORTHOTIC TREATMENT: IS IT IN OR OUT?

Learning objectives:
To learn about the state of the art of orthotic devices within the field of Rheumatic and Musculoskeletal Diseases (RMDs) and gain knowledge about different types of orthoses to facilitate participation

Chair(s):
Valentin Ritschl (Austria)
Wilfred F. Peter (Netherlands)

09:05 – ABSTRACT N° SP0178
Martin van der Esch (Netherlands)
Lower limb orthoses

09:23 – ABSTRACT N° SP0179
Nina Osteras (Norway)
Orthoses and assistive devices for the hand

09:41 – ABSTRACT N° SP0180
Jim Woodburn (United Kingdom)
Foot orthoses in RA

09:59 – Michael Callaghan (United Kingdom)
The value of orthoses to help people move?
09:00 - 10:30  N115/N116

PARE session

WORKSHOP: #CONNECTTODAY AND TOMORROW: THE CAMPAIGNING CONTINUES

Learning objectives:
- To inspire delegates to implement awareness campaigns in their own country
- To share best practices of successful national awareness campaigns and Don’t Delay Connect Today activities

Chair(s):
Nele Caeyers (Belgium)
Marios Kouloumas (Cyprus)

09:05 – Nemanja Damjanov (Serbia)
No delay, let’s act today SPOT EARLY – the Serbian version of #connecttoday

09:10 – ABSTRACT N° SP0184
Maria Ekroth (Finland)
Don’t Delay, Connect Today in Finland: a video to promote early diagnosis

09:15 – ABSTRACT N° SP0185
Jolanta Grygielska (Poland)
Don’t Delay, Connect Today in twelve videos: how to get early diagnosis of RMD’s on the table in Poland

09:20 – ABSTRACT N° SP0186
Mary Vella (Malta)
What do GP’s know about RMD’s? #connecttoday in Malta

10:15 – ABSTRACT N° OP0337-HPR
Hilda Oliveira (Brazil)
A. Jones, F. Jennings, M. Vassalli, A. Rosenfeld, J. Natour
Effectiveness of customized insoles in patients with Morton’s neuroma: a randomized, controlled, double-blind clinical trial
09:00 - 10:30  N117/N118
Paediatric rheumatology session
TACKLING INFLAMMATORY BONE DISORDERS IN CHILDREN AND ADULTS

Learning objectives:
- To raise awareness of inflammatory bone disorders, especially CNO/CRMO and SAPHO, amongst paediatric and adult rheumatologists
- To update on the molecular pathophysiology of these disorders, disease biomarkers and candidates for target-directed treatment
- To understand the presentation, clinical course and outcomes of CNO/CRMO across a lifetime, including SAPHO syndrome
- To update currently available treatment options, patient needs, and translation of scientific observations into clinical practice

Chair(s):
Klaus Tenbrock (Germany)
Anna Surace (United Kingdom)

09:05 – ABSTRACT N° SP0187
Christian Hedrich (United Kingdom)
Pathophysiology and therapeutic consequences of auto-inflammatory bone disorders

09:30 – Polly Ferguson (United States of America)
CRMO/CNO: diagnosis and clinical management from bench to bedside

09:55 – ABSTRACT N° SP0188
Gunter Assmann (Germany)
SAPHO – an adult perspective

10:20 – ABSTRACT N° OP0342
Melissa Oliver (United States of America)
E. Wu, R. Naden, M. Hollander, P. Ferguson, F. Dedeoglu, S. Özen, Y. Zhao
Identifying candidate items towards the development of classification criteria for chronic nonbacterial osteomyelitis (CNO) and chronic recurrent multifocal osteomyelitis (CRMO)

10:30 - 12:00  POSTER AREA (HALL 10)
GUIDED POSTER TOURS

Guided poster tours on various topics are taking place during the official poster viewing. For details on the posters presented during the various tours, please refer to the online programme available at www.congress.eular.org or the EULAR 2019 Congress Mobile App.

Please note that you need to register to participate in a guided poster tour. The number of participants per tour is limited to 20. Registrations can be made at the poster tours & workshop desk, located in the registration area in Hall 2, on a “first-come-first-served” basis the day of the poster tour.

The poster tours take place at the corresponding ePoster stations located in Hall 10 (Tour S01 on ePoster station 01, S02 on ePoster station 02, etc...)

Poster tour
S01: ADAPTIVE IMMUNITY IN RHEUMATIC DISEASES

Chair(s):
Hendrik Schulze-Koops (Germany)
Andrew Cope (United Kingdom)

ABSTRACTS N°: SAT0001-SAT0008

Poster tour
S02: RHEUMATOID ARTHRITIS - BIOLOGICAL DMARDS

Chair(s):
Gerd R. Burmester (Germany)
Eduardo Mysler (Argentina)

ABSTRACTS N°: SAT0120-SAT0130

Poster tour
S03: SLE, SJÖGREN’S AND APS: THE AUTOIMMUNITY CLUB

Chair(s):
Angela Tincani (Italy)
Chiara Bazzani (Italy)

ABSTRACTS N°: SAT0172-SAT0181

Poster tour
S04: SURPRISING AND INNOVATIVE – SSC AND MYOSITIS

Chair(s):
Ulf Müller-Ladner (Germany)
Martin Greco (Spain)

ABSTRACTS N°: SAT0252-SAT0261
Poster tour
S05: CLINICAL ASPECTS OF AXIAL SPA: ALL YOU WANT TO KNOW, AND LIKELY MORE - PART II
Chair(s):
Robert B. M. Landewé (Netherlands)
Philippe Carron (Belgium)
ABSTRACTS N°: SAT0305-SAT0313

Poster tour
S06: PSORIATIC ARTHRITIS: OLD AND NEW DRUGS TACKLING THE DIFFERENT MANIFESTATIONS OF PSORIATIC DISEASE
Chair(s):
Filip van den Bosch (Belgium)
Casper Webers (Netherlands)
ABSTRACTS N°: SAT0360-SAT0370

Poster tour
S07: CRYSTALS
Chair(s):
Alexander So (Switzerland)
Abhishek Abhishek (United Kingdom)
ABSTRACTS N°: SAT0402-SAT0411

Poster tour
S08: INFECTION-RELATED RHEUMATIC DISEASES
Chair(s):
John Isaacs (United Kingdom)
Faye Cooles (United Kingdom)
ABSTRACTS N°: SAT0453-SAT0462

Poster tour
S09: CLINICAL CHALLENGES IN PAEDIATRIC RHEUMATOLOGY
Chair(s):
Helen Foster (Malaysia)
Silvia Federici (Italy)
ABSTRACTS N°: SAT0476-SAT0485

Poster tour
S10: DIAGNOSTICS AND IMAGING PROCEDURES - WHAT’S NEW IN IMAGING IN SPA
Chair(s):
Xenofon Baraliakos (Germany)
Manouk de Hooge (Belgium)
ABSTRACTS N°: SAT0525-SAT0533

Poster tour
S11: IMPROVING OUR STUDIES: RESEARCH METHODS IN EPIDEMIOLOGY, HEALTH SERVICES, AND OUTCOME VALIDATION
Chair(s):
Loreto Carmona (Spain)
Diederik De Cock (Belgium)
ABSTRACTS N°: SAT0555-SAT0629

Poster tour
S12: EPIDEMIOLOGY AND RISK FACTORS - DRUG SAFETY AND REGISTRIES
Chair(s):
Daniel Prieto-Alhambra (United Kingdom)
Helena Florez (Spain)
ABSTRACTS N°: SAT0592-SAT0601

Poster tour
S13: VALIDATION OF OUTCOME MEASURES AND BIOMARKERS IN RMDS
Chair(s):
Timothy R. Radstake (Netherlands)
ABSTRACTS N°: SAT0630-SAT0642

Poster tour
S14: HOW TO IMPROVE YOUR EDUCATION
Chair(s):
Nemanja Damjanov (Serbia)
Tatjana Radnic (Serbia)
ABSTRACTS N°: SAT0676-SAT0685
12:00 - 13:30  HALL 7A

WIN & HOT session

SKIN AND EYE MANIFESTATIONS IN RHEUMATIC DISEASES

Learning objectives:
- A dedicated session to enhance communication and understanding between rheumatologists and dermatologists as well as ophthalmologists
- To provide an update for rheumatologists on recent insights and the management of skin manifestations in rheumatic diseases including potential side effects of newer therapeutics
- Diseases with a characteristic skin affection such as PsA or SLE but also infrequent manifestations will be covered
- Evidence based diagnostic and treatment approaches for uveitis and other eye complications will be provided for treating rheumatologists, including an outlook of ongoing research

12:05 – Athimalaiptet Ramanan (United Kingdom)
**HOT: Uveitis and other eye complications in rheumatology**

12:45 – ABSTRACT N° SP0193
Annegret Kuhn (Germany)
**WIN: Skin and rheumatic diseases**

12:00 - 13:30  N103/N104

Clinical Science session

TO IMAGE OR NOT TO IMAGE IN SPONDYLOARTHRITIS?

Learning objectives:
- To get insight into pitfalls of imaging for the diagnosis in SpA, with a particular focus on false positives of imaging and importance of interpretation of the clinical context
- To learn about the utility of imaging in monitoring the disease and treatment, which imaging techniques, when and what for
- To review data on other relevant imaging techniques other than conventional X-rays and MRI in SpA

Chair(s):
Pascal Claudepierre (France)
Manouk de Hooge (Belgium)

12:05 – ABSTRACT N° SP0194
Floris A. van Gaalen (Netherlands)
*When and how to use and not use imaging for diagnosis?*

12:25 – ABSTRACT N° SP0195
Xenofon Baraliakos (Germany)
*Imaging in disease and treatment monitoring – does it matter?*
12:00 - 13:30  SOUTH AUDITORIUM

Clinical Science session

NOVEL TREATMENTS AND OLD CHALLENGES: WHERE DO WE STAND IN THE MANAGEMENT OF ANTIPHOSPHOLIPID SYNDROME

Learning objectives:
- To identify novel pathogenic pathways and associated targeted treatments in obstetric antiphospholipid syndrome
- To update the state of the art on the effectiveness and safety of direct oral anticoagulants in patients with vascular antiphospholipid syndrome
- To discuss the evidence- and expert opinion-based EULAR recommendations for the management of both childhood-onset and adult antiphospholipid syndrome

Chair(s):
Maria Moraes-Fontes (Portugal)
Ian N. Bruce (United Kingdom)

12:05 – ABSTRACT N° SP0200
Jane E. Salmon (United States of America)
Targeted treatments: what’s on the horizon for obstetric antiphospholipid syndrome?

12:22 – Vittorio Pengo (Italy)
Why do direct oral anticoagulants not work in antiphospholipid syndrome?

12:39 – Tadej Avcin (Slovenia)
Management of paediatric APS: recommendations from an EULAR task force

12:56 – ABSTRACT N° SP0201
Ricard Cervera (Spain)
Catastrophic APS treatment guidelines

13:13 – Stéphane Zuily (France)
Update on the new antiphospholipid syndrome classification criteria development

12:00 - 13:30  N101/N102

Clinical Science session

HOW LOW SHOULD YOU GO?
WHAT IS THE RELEVANT TARGET IN T2T IN RHEUMATOID ARTHRITIS?

Learning objectives:
- To understand the patient perspective of remission
- To recognise different levels of remission and their possible importance

Chair(s):
Duncan Porter (United Kingdom)
Georg Schett (Germany)

12:05 – ABSTRACT N° SP0202
Laure Gossec (France)
What does remission mean for physicians?

12:25 – Sofia Ramiro (Netherlands)
What does remission mean for imaging and biomarkers in RA?

12:45 – ABSTRACT N° SP0203
Ruth Williams (United Kingdom)
What does remission mean for patients?

13:05 – ABSTRACT N° OP0345
Debbie Boeters (Netherlands)
L. Burgers, R. Toes, A. van der Helm - van Mil
Does immunological remission, defined as disappearance of autoantibodies, occur with current treatment strategies? A long-term follow-up study in rheumatoid arthritis patients who achieved a sustained DMARD-free status

13:15 – ABSTRACT N° OP0346
Fan Xiao (Hong Kong (SAR))
J. Griffith, L. Tam
MRI of the wrist in early rheumatoid arthritis after 1-year treat-to-target strategy

12:00 - 13:30  N105/N106

Health Professionals session

BEHAVIOUR CHANGE IN FIBROMYALGIA

Learning objectives:
- To gain knowledge about recent developments in fibromyalgia
- To understand how to help people with fibromyalgia and understand better how it feels

Chair(s):
Andrea Domjan (Hungary)
Caroline Flurey (United Kingdom)

12:05 – ABSTRACT N° SP0200
Jane E. Salmon (United States of America)
Targeted treatments: what's on the horizon for obstetric antiphospholipid syndrome?

12:22 – Vittorio Pengo (Italy)
Why do direct oral anticoagulants not work in antiphospholipid syndrome?

12:39 – Tadej Avcin (Slovenia)
Management of paediatric APS: recommendations from an EULAR task force

12:56 – ABSTRACT N° SP0201
Ricard Cervera (Spain)
Catastrophic APS treatment guidelines

13:13 – Stéphane Zuily (France)
Update on the new antiphospholipid syndrome classification criteria development

12:05 – ABSTRACT N° SP0202
Laure Gossec (France)
What does remission mean for physicians?

12:25 – Sofia Ramiro (Netherlands)
What does remission mean for imaging and biomarkers in RA?

12:45 – ABSTRACT N° SP0203
Ruth Williams (United Kingdom)
What does remission mean for patients?

13:05 – ABSTRACT N° OP0345
Debbie Boeters (Netherlands)
L. Burgers, R. Toes, A. van der Helm - van Mil
Does immunological remission, defined as disappearance of autoantibodies, occur with current treatment strategies? A long-term follow-up study in rheumatoid arthritis patients who achieved a sustained DMARD-free status

13:15 – ABSTRACT N° OP0346
Fan Xiao (Hong Kong (SAR))
J. Griffith, L. Tam
MRI of the wrist in early rheumatoid arthritis after 1-year treat-to-target strategy

12:05 – ABSTRACT N° SP0200
Jane E. Salmon (United States of America)
Targeted treatments: what's on the horizon for obstetric antiphospholipid syndrome?

12:22 – Vittorio Pengo (Italy)
Why do direct oral anticoagulants not work in antiphospholipid syndrome?

12:39 – Tadej Avcin (Slovenia)
Management of paediatric APS: recommendations from an EULAR task force

12:56 – ABSTRACT N° SP0201
Ricard Cervera (Spain)
Catastrophic APS treatment guidelines

13:13 – Stéphane Zuily (France)
Update on the new antiphospholipid syndrome classification criteria development

12:00 - 13:30  N101/N102

Clinical Science session

HOW LOW SHOULD YOU GO?
WHAT IS THE RELEVANT TARGET IN T2T IN RHEUMATOID ARTHRITIS?

Learning objectives:
- To understand the patient perspective of remission
- To recognise different levels of remission and their possible importance

Chair(s):
Duncan Porter (United Kingdom)
Georg Schett (Germany)
12:00 - 13:30 N111/N112

The Young Rheumatologist
HOW TO BUILD A CLINICAL SCIENTIST

Learning objectives:
- To present data about knowledge and skills that are needed to be mastered by future clinical scientist
- To learn about mental health challenges associated with clinical scientist career

Chair(s):
Marloes van Onna (Netherlands)
Victoria Navarro-Compán (Spain)

12:05 – Iain McInnes (United Kingdom)
Difficulties are part of brilliant careers

12:20 – ABSTRACT N° SP0205
Annet van Royen (Netherlands)
Science carrier and mental health

12:35 – Johannes W. J. Bijlsma (Netherlands)
Alternative career choices can be a real bonus

12:50
Round table discussion

12:00 - 13:30 N115/N116

PARE session
RESTLESS LIVES: MANAGING FATIGUE, SLEEP AND PAIN

Learning objectives:
- To tackle fatigue as a misunderstood problem of RMD patients with great impact on their lives
- To create awareness for possible relations between dyssomnia, pain, fatigue in RMDs patients
- To discuss coping techniques to improve sleep quality

Chair(s):
Tanita-Christina Wilhelmer (Austria)
Louise Bennett (United Kingdom)

12:05 – ABSTRACT N° SP0206
Tanja Lange (Germany)
Links between sleep quality and immunity in RMDs

12:25 – ABSTRACT N° SP0207
Eivind Skarpsno (Norway)
Physical activity, chronic musculoskeletal pain and insomnia

12:45 – ABSTRACT N° SP0208
Savia de Souza (United Kingdom)
Understanding the impact of pain, sleep and fatigue on patients lives

13:05 – ABSTRACT N° OP0347-PARE
Lene Mandrup Thomsen (Denmark)
The influence of pain on sleep problems, mental health and use of strong painkillers among patients with arthritis

13:15 – ABSTRACT N° OP0348-PARE
Santos Castañeda (Spain)
J. Negrón, M. Navarro Rubio, J. Baquero Ubeda, L. Carmona
Face arthritis: what situations affect emotionally the patient with rheumatoid arthritis and how to resolve them effectively

12:00 - 13:30 N117/N118

EULAR Projects in Musculoskeletal Imaging
EULAR PROJECTS IN MUSCULOSKELETAL IMAGING

Learning objectives:
- To get updated of the recent projects of ESCMI that have been recently finished
- To get informed about newest developments in the field of imaging in axSpA by submitted scientific abstracts

Chair(s):
Espen Haavardsholm (Norway)
Esperanza Naredo (Spain)

12:05 – ABSTRACT N° SP0209
Maria-Antonietta d’Agostino (France)
EULAR recommendations for reporting in MSK ultrasound studies

12:25 – ABSTRACT N° SP0210
Peter Mandl (Austria)
Implementation and role of modern musculoskeletal imaging (US, MRI and PET) in rheumatological practice in Europe - a EULAR survey

12:45 – ABSTRACT N° SP0211
Ingrid Möller (Spain)
Development of a standardized training model for ultrasound-guided synovial biopsy’s in small and large joints

13:05 – ABSTRACT N° OP0349
Søren A. Just (Denmark)
J. Andersen, J. Pedersen, M. Laursen, K. Holtz, J. Grauslund, T. Savarimuthu
Neural networks for automated scoring of joint disease activity on doppler ultrasound images

13:15 – ABSTRACT N° OP0350
Samiha Ismail (United Kingdom)
N. Purkayastha, P. Taylor, C. Pitzalis, S. Kelly
Ultrasound power doppler semi-quantitative scoring, is it time we moved to a red pixel density algorithmic program to determine true treatment response?
13:45 - 14:45  HALL 7A

Highlight session

CLINICAL BASIC TRANSLATIONAL HIGHLIGHT SESSION

Learning objectives:
- A dedicated debriefing session to highlight key contributions of basic/translational science and clinical science sections
- In 2019, both contributions will have a particular combined focus on paediatric and adult rheumatology highlights

Chair(s):
Thomas Dörner (Germany)
John Isaacs (United Kingdom)

13:50 – Tadej Avcin (Slovenia)
Basic and translational highlights

14:15 – Loreto Carmona (Spain)
Clinical highlights

13:45 - 14:45  N115/N116

PARE session

PARE HIGHLIGHT SESSION

Learning objectives:
To provide an overview of learning and outcomes from the 2019 congress from health professionals and the scientific perspectives, and the first feedback from the PARE delegates

Chair(s):
Dieter Wiek (Germany)
Nele Caeyers (Belgium)

13:50 – ABSTRACT N° SP0213
Alexandre Sepriano (Netherlands)
Highlights from the Scientific programme

14:15 – ABSTRACT N° SP0214
Bente Appel Esbensen (Denmark)
Highlights from the HPR programme

13:45 - 14:45  N105/N106

Health Professionals session

HPR HIGHLIGHT SESSION

Learning objectives:
- To sum up hot topics and take-home messages from the EULAR Congress 2019
- To know more about which abstracts to read on your way home

Chair(s):
Erika Mosor (Austria)
Jenny de la Torre-Aboki (Spain)

14:00 – Victoria Romero Pazos (Spain)
PARE highlights

14:15 – ABSTRACT N° SP0212
Daniel Aletaha (Austria)
Highlights from the scientific programme

14:30 – Nina Brodin (Sweden)
Highlights from the HPR programme
EULAR PROJECTS IN PAEDIATRIC RHEUMATOLOGY

Learning objectives:
- Update on key EULAR Projects in Paediatric Rheumatology – progress and next steps. These will focus on the following:
  - Addressing the challenges of developing the next generation of translational scientists and leaders in paediatric rheumatology
  - Paediatric rheumatology faces many challenges across the globe. Tackling these to ensure equity of access to care is critical for children and young people affected by these disorders
  - Developing a robust evidence base to underpin advancements in care for children across the world faces specific challenges that as an international community we need to consider

Chair(s):
Angelo Ravelli (Italy)

14:20 – Johannes Roth (Germany)
Fostering the next generation of translational researchers

14:40 – ABSTRACT N° SP0020
Christian Scott (South Africa)
The global challenge and opportunity for paediatric rheumatology

15:00 – Helen Foster (Malaysia)
Project abstract 1: Paediatric task force global musculoskeletal health

15:10 – ABSTRACT N° SP0021
Nicolino Ruperto (Italy)
Delivering future global research challenges in paediatric rheumatology

15:30 – ABSTRACT N° SP0022
Lovro Lamot (Canada)
Project abstract 2: EMERGE – helping deliver our worldwide goals

15:45 - 16:15
EXHIBITION AND EULAR VILLAGE (HALL 10)
COFFEE BREAK

16:15 - 17:45
SOUTH AUDITORIUM

Abstract session PReS
JIA: FROM NEW HORIZONS OF TREATMENT TO PERSPECTIVES OF CURRENT ONES

Chair(s):
Dirk Foell (Germany)
Gabriella Giancane (Italy)

16:15
Introduction by Chairs

16:25 – ABSTRACT N° OP0055
Pierre Quartier (France)
Efficacy of canakinumab, on a reduced dose or a prolonged dose interval without concomitant corticosteroids and methotrexate, in patients with systemic juvenile idiopathic arthritis

16:35 – ABSTRACT N° OP0056
Hermine Brunner (United States)
Maintenance of clinical response in individual children with juvenile idiopathic arthritis treated with subcutaneous abatacept

16:45 – ABSTRACT N° OP0057
Manuela Pardeo (Italy)
Early treatment with anakinra in systemic juvenile idiopathic arthritis

16:55 – ABSTRACT N° OP0058
Roline Krol (Netherlands)
Development of inflammatory bowel disease during treatment with etanercept in patients with juvenile idiopathic arthritis
17:05 – ABSTRACT N° OP0059
Andrea Uva (Italy)
L. Rava’, H. Jadoun, A. Aquilani, F. Basta, R. Nicolai, F. De Benedetti, S. Magni-Manzoni
Periarticular glucocorticoid injections: delineating their use in juvenile idiopathic arthritis

17:15 – ABSTRACT N° OP0060
Jens Klotsche (Germany)
Safety profile of etanercept in long-term use in patients with juvenile idiopathic arthritis (JIA)

17:25 – ABSTRACT N° OP0061
Kirsten Minden (Germany)
Consumer perspective on paediatric rheumatology care and service delivery: results from an early juvenile idiopathic arthritis (JIA) cohort study

10:30 – ABSTRACT N° OP0149
Jim Jarvis (United States of America)
E. Tarbell, K. Jiang, T. Hennon, L. Holmes, P. Gaffney, T. Liu
CD4+ T cells from children with active juvenile idiopathic arthritis show aberrant chromatin organization and CTCF localization associated with transcriptional abnormalities

10:40 – ABSTRACT N° OP0150
Grant Schulert (United States of America)
T. Do, S. Dhakal, N. Fall, M. Medvedovich, N. Salomonis, A. Grom
Monocyte and macrophage transcriptional phenotypes in systemic juvenile idiopathic arthritis reveal TRIM8 as a mediator of IFNγ hyperresponsiveness and risk for macrophage activation syndrome

10:50 – ABSTRACT N° OP0151
Klaus Tenbrock (Germany)
MiRNAs contribute to dysregulated ROS metabolism of immune cells in the inflamed joint

11:00 – ABSTRACT N° OP0152
Erdal Sag (Turkey)
S. Demir, M. Nielsen, M. Hvid, E. Turhan, Y. Bilginer, S. Özen, B. Deleuran
Oligoarticular juvenile idiopathic arthritis does not show signs of T cell exhaustion, in spite of increased expression of co-inhibitory receptors

11:10 – ABSTRACT N° OP0153
Jens Klotsche (Germany)
Safety profile of etanercept in long-term use in patients with juvenile idiopathic arthritis (JIA)

11:20 – ABSTRACT N° OP0154
Emma Dorris (Ireland)
F. Adeeb, D. Lawless, W. Ng, A. Anjum, N. Morgan, E. Cummins, S. Savic, A. Fraser, G. Wilson
A novel RELA truncation in a 3-generation family with Behcet’s disease alters the apoptotic response to inflammatory stimuli

17:05 – ABSTRACT N° OP0059
Andrea Uva (Italy)
L. Rava’, H. Jadoun, A. Aquilani, F. Basta, R. Nicolai, F. De Benedetti, S. Magni-Manzoni
Periarticular glucocorticoid injections: delineating their use in juvenile idiopathic arthritis

17:15 – ABSTRACT N° OP0060
Jens Klotsche (Germany)
Safety profile of etanercept in long-term use in patients with juvenile idiopathic arthritis (JIA)

17:25 – ABSTRACT N° OP0061
Kirsten Minden (Germany)
Consumer perspective on paediatric rheumatology care and service delivery: results from an early juvenile idiopathic arthritis (JIA) cohort study

10:30 – ABSTRACT N° OP0149
Jim Jarvis (United States of America)
E. Tarbell, K. Jiang, T. Hennon, L. Holmes, P. Gaffney, T. Liu
CD4+ T cells from children with active juvenile idiopathic arthritis show aberrant chromatin organization and CTCF localization associated with transcriptional abnormalities

10:40 – ABSTRACT N° OP0150
Grant Schulert (United States of America)
T. Do, S. Dhakal, N. Fall, M. Medvedovich, N. Salomonis, A. Grom
Monocyte and macrophage transcriptional phenotypes in systemic juvenile idiopathic arthritis reveal TRIM8 as a mediator of IFNγ hyperresponsiveness and risk for macrophage activation syndrome

10:50 – ABSTRACT N° OP0151
Klaus Tenbrock (Germany)
MiRNAs contribute to dysregulated ROS metabolism of immune cells in the inflamed joint

11:00 – ABSTRACT N° OP0152
Erdal Sag (Turkey)
S. Demir, M. Nielsen, M. Hvid, E. Turhan, Y. Bilginer, S. Özen, B. Deleuran
Oligoarticular juvenile idiopathic arthritis does not show signs of T cell exhaustion, in spite of increased expression of co-inhibitory receptors

11:10 – ABSTRACT N° OP0153
Jens Klotsche (Germany)
Safety profile of etanercept in long-term use in patients with juvenile idiopathic arthritis (JIA)

11:20 – ABSTRACT N° OP0154
Emma Dorris (Ireland)
F. Adeeb, D. Lawless, W. Ng, A. Anjum, N. Morgan, E. Cummins, S. Savic, A. Fraser, G. Wilson
A novel RELA truncation in a 3-generation family with Behcet’s disease alters the apoptotic response to inflammatory stimuli

20:00 - 22:00
ESPLANADE (HALL 6)
NETWORKING PLATFORM

PReS PROGRAMME
THURSDAY
13 JUNE 2019

10:15 - 11:45
N101/N102
Abstract session PReS
JOURNEYS FROM BENCH TO BEDSIDE IN PAEDIATRIC RHEUMATOLOGY

Chair(s):
Johannes Roth (Germany)
Lucy Wedderburn (United Kingdom)

10:20 – ABSTRACT N° OP0148
George Robinson (United Kingdom)
A. Radziszewska, C. Wincup, C. Ciurtin, Y. Ioannou, I. Pineda Torra, E. Jury on behalf of Jury Lab
Metabolomics in juvenile-onset SLE: identifying new biomarkers to predict cardiovascular risk

10:30 – ABSTRACT N° OP0149
Jim Jarvis (United States of America)
E. Tarbell, K. Jiang, T. Hennon, L. Holmes, P. Gaffney, T. Liu
CD4+ T cells from children with active juvenile idiopathic arthritis show aberrant chromatin organization and CTCF localization associated with transcriptional abnormalities

10:40 – ABSTRACT N° OP0150
Grant Schulert (United States of America)
T. Do, S. Dhakal, N. Fall, M. Medvedovich, N. Salomonis, A. Grom
Monocyte and macrophage transcriptional phenotypes in systemic juvenile idiopathic arthritis reveal TRIM8 as a mediator of IFNγ hyperresponsiveness and risk for macrophage activation syndrome

10:50 – ABSTRACT N° OP0151
Klaus Tenbrock (Germany)
MiRNAs contribute to dysregulated ROS metabolism of immune cells in the inflamed joint

11:00 – ABSTRACT N° OP0152
Erdal Sag (Turkey)
S. Demir, M. Nielsen, M. Hvid, E. Turhan, Y. Bilginer, S. Özen, B. Deleuran
Oligoarticular juvenile idiopathic arthritis does not show signs of T cell exhaustion, in spite of increased expression of co-inhibitory receptors

11:10 – ABSTRACT N° OP0153
Jens Klotsche (Germany)
Safety profile of etanercept in long-term use in patients with juvenile idiopathic arthritis (JIA)

11:20 – ABSTRACT N° OP0154
Emma Dorris (Ireland)
F. Adeeb, D. Lawless, W. Ng, A. Anjum, N. Morgan, E. Cummins, S. Savic, A. Fraser, G. Wilson
A novel RELA truncation in a 3-generation family with Behcet’s disease alters the apoptotic response to inflammatory stimuli

10:15 - 11:45
N115/N116
Joint Session PReS/PReS
FROM CHILD TO ADULT CARE - BREAKING DOWN THE BARRIERS OF TRANSITION

Learning objectives:
- To outline the barriers of transition and potential strategies to overcome them
- To discuss measures and instruments of how improvements can be achieved in daily practice
Chair(s): Mirjam Kepic (Slovenia) Berent J. Prakken (Netherlands)

10:20 – ABSTRACT N° SP0041
Stephen Ball (United Kingdom)
Tackling transition: the current landscape, and where we are heading

10:40 – ABSTRACT N° SP0042
Judy Ammerlaan (Netherlands)
From paediatric care to adult care – the needs of young people, and how healthcare professionals can facilitate optimal transition

11:00 – ABSTRACT N° SP0043
Indra Beer (Germany)
My ideal transition

11:20 – ABSTRACT N° OP0171-PARE
Cajsa Helin Hollstrand (Sweden)
K. Nordlund, M. Beermann
The Swedish young rheumatics report – the most urgent matters and the most promising development areas for young people with RMDs in Sweden

11:30 – ABSTRACT N° OP0172-PARE
Mirjam Kepic (Slovenia)
S. Stones, S. Angevare, S. Ainsworth, W. Costello, A. Gruss, A. van de Louw
Working together for children and families living with rheumatic and musculoskeletal diseases: the European network for children with arthritis (ENCA)

11:45 - 13:30
EXHIBITION, EULAR VILLAGE AND POSTER AREAS (HALL 10)
POSTER VIEWING AND LUNCH

For details on the EULAR 2019 posters presentations, please refer to the online programme available at www.congress.eular.org or the EULAR 2019 Congress Mobile App.

11:50 - 13:30
POSTER AREA (HALL 10)
GUIDED POSTER TOURS

For details on the posters presented during the tours, please refer to the online programme available at www.congress.eular.org or the EULAR 2019 Congress Mobile App.

Please note that you need to register to participate in a guided poster tour. The number of participants per tour is limited to 20. Registrations can be made at the poster tours & workshop desk, located in the registration area in Hall 2, on a ‘first-come-first-served’ basis the day of the poster tour.

The poster tours take place at the corresponding ePoster stations located in Hall 10 (Tour T08 on ePoster station 08, T09 on ePoster station 09)

Poster tour PReS
T08: TRANSLATIONAL SCIENCE AS THE FOUNDATION FOR FUTURE THERAPIES IN PAEDIATRIC RHEUMATOLOGY
Chair(s): Fabrizio De Benedetti (Italy)
ABSTRACTS N°: THU0505 - THU0514

Poster tour PReS
T09: HOW CAN WE IMPROVE OUR CARE OF CHILDREN AND YOUNG PEOPLE WITH PAEDIATRIC RHEUMATIC DISORDERS?
Chair(s): Coziana Ciurtin (United Kingdom) Gerd Horneff (Germany)
ABSTRACTS N°: THU0515-THU0522,THU0594, THU0655

13:30 - 15:00
N101/N102
Paediatric rheumatology session
ADULTS ARE JUST GROWN UP CHILDREN! DISCUSS

Learning objectives:
To challenge our paradigms of rheumatology in paediatric and adult practice

Chair(s): Michael Beresford (United Kingdom) Eve Smith (United Kingdom)

13:35 – ABSTRACT N° SP0057
Berent J. Prakken (Netherlands)
Everything starts in childhood!

13:55 – ABSTRACT N° SP0058
Iain McInnes (United Kingdom)
Growing up changes everything!

14:15 – Sophie Ainsworth (United Kingdom)
You must get it right for us!
14:35 – ABSTRACT N° OP0204  
Fabrizio De Benedetti (Italy)  
P. Brogan, A. Grom, P. Quartier, R. Schneider, K. De Graaf, P. Jacqmin, M. Ballabio, C. de Min  
Emapalumab, an interferon gamma (IFN-Y)-blocking monoclonal antibody, in patients with macrophage activation syndrome (MAS) complicating systemic juvenile idiopathic arthritis (SJIA)

14:45 – ABSTRACT N° OP0205  
Veronica Moshe Bergonzo (Israel)  
Live attenuated vaccines in paediatric rheumatic diseases are safe: multicentre, retrospective data collection

15:00 - 15:30  
EXHIBITION AND EULAR VILLAGE (HALL 10)  
COFFEE BREAK

PReS PROGRAMME  
FRIDAY  
14 JUNE 2019

10:15 - 11:45  
SOUTH AUDITORIUM  
Abstract session PReS  
TACKLING THE CHALLENGES OF AUTOIMMUNE/AUTOINFLAMMATORY CONDITIONS IN CHILDREN AND YOUNG PEOPLE

10:20 – ABSTRACT N° OP0254  
Helen J. Lachmann (United Kingdom)  
Canakinumab improves patient-reported outcomes in patients with recurrent fever syndromes: results from a phase 3 trial (cluster)

10:30 – ABSTRACT N° OP0255  
Claudia Bracaglia (Italy)  
G. Marucci, F. Del Chierico, A. Russo, M. Pardeo, A. Insalaco, G. Prencipe, I. Caiello, P. Dolezalova, S. Fingerhutova, F. De Benedetti, L. Putignani  
Microbiota transplant to control inflammation in a NLRC4-related disease patient with recurrent hemophagocytic lymphohistiocytosis (HLH)

10:40 – ABSTRACT N° OP0256  
Helga Sanner (Norway)  
In medium to long-term juvenile dermatomyositis, proinflammatory and profibrotic cytokines are differently associated with pulmonary involvement in active vs inactive disease

10:50 – ABSTRACT N° OP0257  
Natalia Cabrera (France)  
P. Nakhleh, J. Lega, A. Belot  
Childhood-onset monogenic systemic lupus erythematosus not due to complement deficiency: a systematic review of 90 cases

11:00 – ABSTRACT N° OP0258  
Martina Finetti (Italy)  
Lesson from Eurofever registry after the first ten years of enrolment

11:10 – ABSTRACT N° OP0259  
Florian Milatz (Germany)  
Overweight and obesity in patients with juvenile idiopathic arthritis enrolled in the German national paediatric rheumatologic database (NPRD)

11:20 – ABSTRACT N° OP0260  
Leonardo Oliveira Mendonca (Italy)  
S. Signa, C. Matucci Cerinic, E. toniolo, M. Bustaffa, M. D’Alessandro, S. Volpi, R. Caorsi, M. Gattorno  
Vaccination safety and coverage in an Italian cohort of autoinflammatory diseases

11:45 - 13:30  
EXHIBITION, EULAR VILLAGE AND POSTER AREAS (HALL 10)  
POSTER VIEWING AND LUNCH

For details on the EULAR 2019 posters presentations, please refer to the online programme available at www.congress.eular.org or the EULAR 2019 Congress Mobile App.
GUIDED POSTER TOURS

For details on the posters presented during the tours, please refer to the online programme available at www.congress.eular.org or the EULAR 2019 Congress Mobile App.

Please note that you need to register to participate in a guided poster tour. The number of participants per tour is limited to 20. Registrations can be made at the poster tours & workshop desk, located in the registration area in Hall 2, on a ‘first-come-first-served’ basis the day of the poster tour.

The poster tours take place at the corresponding ePoster stations located in Hall 10 (Tour F09 on ePoster station 09, F10 on ePoster station 10)

**Poster tour PReS**

**F09: CARING FOR CHILDREN AND YOUNG PEOPLE WITH AUTOIMMUNE/AUTOINFLAMMATORY CONDITIONS**

**Chair(s):**
Erdal Sag (Turkey)  
Carine Wouters (Belgium)

ABSTRACTS N°: FRI0533-FRI0542

**Poster tour PReS**

**F10: NEW OPTIONS FOR TREATMENT AND CARE OF CHILDREN AND YOUNG PEOPLE WITH ARTHRITIS**

**Chair(s):**
Sebastian Vastert (Netherlands)  
Margarita Ganeva (Bulgaria)

ABSTRACTS N°: FRI0543-FRI0551

**NEW INSIGHTS INTO JIA AND AUTOINFLAMMATORY DISEASES**

**Learning objectives:**
- A dedicated session to enhance communication between paediatric and adults rheumatologists
- To provide an overview on best management of juvenile idiopathic arthritis, an outlook for new treatment possibilities and JIA outcome with a focus on adults
- Recent advances in the diagnosis and treatment of autoinflammatory diseases will be discussed in the context of new insights into the underlying pathogenic mechanisms. These diseases are a prime example how rheumatologists in charge of paediatric and adults patients have witnessed substantial progress recently

**15:35 – ABSTRACT N° SP0140**
Michael Beresford (United Kingdom)  
**HOT: Management of juvenile idiopathic arthritis 2019 and beyond**

**16:15 – Raphaela Goldbach-Mansky**  
(United States of America)  
**WIN: Diagnosis and treatment of autoinflammatory diseases**

**CALMING THE CYTOKINE STORM IN CHILDREN AND ADULTS**

**Learning objectives:**
- To raise awareness of the importance of understanding and knowing how to manage the impact of an uncontrolled cytokine storm in systemic autoimmune/autoinflammatory diseases in children and adults
- To understand the pathophysiology of the cytokine storm that leads to clinical manifestations as macrophage activation syndrome (MAS), and how this has informed therapeutic approaches in paediatric rheumatic disorders
- To raise awareness of the importance of diagnosis and to understanding the therapeutic approach to treating MAS in children and young people and addressing the patient’s needs
- To raise awareness of the uncontrolled cytokine storm occurring in adult patients and to update currently available treatment options, patient needs, and translation of scientific observations into clinical practice in adults

**Chair(s):**
Lovro Lamot (Canada)  
Sebastian Vastert (Netherlands)

**15:35 – Alexei Grom (United States of America)**  
**Pathophysiology informing therapy in MAS: what we’ve learned in paediatric practice**

**15:55 – Anna Carin Horne (Sweden)**  
**Calming the storm in children**

**16:15 – ABSTRACT N° SP0153**
Jan van Laar (Netherlands)  
**Calming the storm in adult MAS/HLH in rheumatic disorders**
PReS PROGRAMME
SATURDAY
15 JUNE 2019

09:00 - 10:30
N117/N118
Paediatric rheumatology session
TACKLING INFLAMMATORY BONE DISORDERS IN CHILDREN AND ADULTS

Learning objectives:
- To raise awareness of inflammatory bone disorders, especially CNO/CRMO and SAPHO, amongst paediatric and adult rheumatologists
- To update on the molecular pathophysiology of these disorders, disease biomarkers and candidates for target-directed treatment
- To understand the presentation, clinical course and outcomes of CNO/CRMO across a lifetime, including SAPHO syndrome
- To update currently available treatment options, patient needs, and translation of scientific observations into clinical practice

Chair(s):
Klaus Tenbrock (Germany)
Anna Surace (United Kingdom)

09:05 – ABSTRACT N° SP0187
Christian Hedrich (United Kingdom)
Pathophysiology and therapeutic consequences auto-inflammatory bone disorders

09:30 – Polly Ferguson (United States of America)
CRMO/CNO: diagnosis and clinical management from bench to beside

10:30 - 12:00
EXHIBITION, EULAR VILLAGE AND POSTER AREAS (HALL 10)
POSTER VIEWING AND COFFEE BREAK

For details on the EULAR 2019 posters presentations, please refer to the online programme available at www.congress.eular.org or the EULAR 2019 Congress Mobile App.

11:50 - 13:30
EPOSTER STATION 09
POSTER AREA (HALL 10)
GUIDED POSTER TOUR

For details on the posters presented during the tour, please refer to the online programme available at www.congress.eular.org or the EULAR 2019 Congress Mobile App.

Please note that you need to register to participate in a guided poster tour. The number of participants per tour is limited to 20. Registrations can be made at the poster tours & workshop desk, located in the registration area in Hall 2, on a ‘first-come-first-served’ basis the day of the poster tour.

Poster tour PReS
S09: CLINICAL CHALLENGES IN PAEDIATRIC RHEUMATOLOGY

Chair(s):
Helen Foster (Malaysia)
Silvia Federici (Italy)

ABSTRACTS N°: SAT0476-SAT0485
HPR PROGRAMME
WEDNESDAY
12 JUNE 2019

13:00 - 14:00
EULAR 2019 OPENING PLENARY SESSION

14:15 - 15:45
N115/N116
Health Professionals session
HEALTH PROFESSIONAL WELCOME SESSION

Learning objectives:
- To learn about recent EULAR HPR achievements
- To prepare for the congress sessions from different angles
- To outline collaboration with PreS

Chair(s):
Milena Gobbo Montoya (Spain)
Rikke H. Moe (Norway)

14:20 – Annette de Thurah (Denmark)
HPR news over the last year

14:40 – ABSTRACT N° SP0018
Maria Bergström (Sweden)
What you shouldn’t miss from the HPR programme as a clinician

15:00 – Marco Testa (Italy)
What you shouldn’t miss from the programme from a research perspective

15:20 – ABSTRACT N° SP0019
Jeannette Cappon (Netherlands)
PReS HPR: Don’t delay, collaborate today

15:45 - 16:15
EXHIBITION AND EULAR VILLAGE (HALL 10)
COFFEE BREAK

16:15 - 17:45
N115/N116
Health Professionals session
REHABILITATION;
OPENING PANDORA’S BOX

Learning objectives:
- State of the art of rehabilitation within the field of rheumatic and musculoskeletal diseases (RMDs)
- To obtain knowledge about the challenges of measuring the outcome of rehabilitation

Chair(s):
Mathilda Bjork (Sweden)
Eda Tonga (Turkey)

16:20 – ABSTRACT N° SP0031
Ann Bremander (Sweden)
News in the world of rehabilitation

16:35 – ABSTRACT N° SP0032
Alison Hammond (United Kingdom)
How to measure rehabilitation

16:50 – Turid Nygaard Dager (Norway)
How to organize interdisciplinary rehabilitation

17:05 – ABSTRACT N° SP0033
Thea Vliet Vlieland (Netherlands)
Rheumatological rehabilitation, what’s next

17:20 – ABSTRACT N° OP0079-HPR
Juliane Stöcker (Netherlands)
J. Spierings, M. Vonk, F. van den Hoogen, M. Nijhuis-van der Sanden, J. Staal, T. Satink, C. van den Ende on behalf of ARCH
Non-pharmacological care in systemic sclerosis: opening the black box

18:15 - 19:45
N105/N106
Health Professionals session
THE RIDDLE OF ADHERENCE

Learning objectives:
- To learn about adherence and important facilitating factors
- To obtain knowledge about screening tools and what to prioritise in clinical care

Chair(s):
Yeliz Prior (United Kingdom)
Fernando Estevez-Lopez (Spain)

18:20 – Robert Horne (United Kingdom)
Adherence and beliefs about medication

18:45 – Ailsa Bosworth (United Kingdom)
Patient perspectives on adherence to medication

19:10 – ABSTRACT N° SP0038
Bart van den Bemt (Netherlands)
Factors important for medical adherence

19:35 – ABSTRACT N° OP0105-HPR
Yomei Shaw (Switzerland)
D. Courvoisier, A. Scherer, A. Ciurea, T. Lehmann, V. Jaeger, U. Walker, A. Finckh
Do mobile apps improve shared decision making and disease management in the rheumatic diseases? An evaluation of apps in a Swiss rheumatology registry

20:00 - 22:00
ESPLANADE (HALL 6)
NETWORKING PLATFORM
HPR PROGRAMME
THURSDAY
13 JUNE 2019

10:15 - 11:45
N105/N106

Abstract session HPR

TRANSFORMATIVE CARE - THE FUTURE

Chair(s):
Wilfred F. Peter (Netherlands)
Yeliz Prior (United Kingdom)

10:20 – ABSTRACT N° OP0155-HPR
Ross Wilkie (United Kingdom)
S. Parmar, M. Bucknall
Targets for reducing premature mortality in older adults with osteoarthritis: results from a novel path analysis within a Cox proportional hazards model

10:30 – ABSTRACT N° OP0156-HPR
Zhengping Huang (China)
X. Zhong, Z. Xie, T. Li
The feasibility and effectiveness of telemedicine for knee osteoarthritis in disease management: a randomised control trial

10:40 – ABSTRACT N° OP0157-HPR
Marc De Meulemeester (Belgium)
T. Jansen, G. Petersen, F. Perez-Ruiz
European patient voice in gout survey – subjective satisfaction in gout patients versus objective suboptimal gout care

10:50 – ABSTRACT N° OP0158-HPR
Hayley McBain (United Kingdom)
M. Bezzant, A. Bosworth
The barriers and facilitators to requesting and receiving psychological support for people with rheumatoid arthritis and adults with juvenile idiopathic arthritis

11:00 – ABSTRACT N° OP0159
Arjan de Zwart (Netherlands)
The effect of high-intensity resistance training and vitamin D supplementation on muscle strength in patients with knee osteoarthritis: a randomized controlled trial

11:10 – ABSTRACT N° OP0160-HPR
Else Marit H. Gravås (Norway)
N. Østerås, R. Nossum, R. Mehl Eide, Å. Klokkeide, K. Hoegh Matre, M. Olsen, Ø. Andreassen, I. Haugen, A. Tveter, I. Kjeken

Does occupational therapy delay or reduce the proportion of patients who receive thumb carpometacarpal surgery? A randomized controlled trial

11:20 – ABSTRACT N° OP0161-HPR
Ingvild Kjeken (Norway)
A. Tveter, R. Nossum, R. Mehl Eide, Å. Klokkeide, K. Hoegh Matre, M. Olsen, Ø. Andreassen, N. Østerås
Short-term effect of occupational therapy intervention on hand function and pain in patients with thumb base osteoarthritis – secondary analyses of a randomized controlled trial

11:30 – ABSTRACT N° OP0162-HPR
Valentin Ritschl (Austria)
The need for personalized, non-pharmacological intervention programmes in autoimmune connective tissue disorders: results of a EULAR-funded scoping review with a nested, descriptive meta-analysis

11:45 - 13:30
EXHIBITION, EULAR VILLAGE AND POSTER AREAS (HALL 10)
POSTER VIEWING AND LUNCH

For details on the EULAR 2019 posters presentations, please refer to the online programme available at www.congress.eular.org or the EULAR 2019 Congress Mobile App.

11:50 - 13:30
EPOSTER STATION 13
POSTER AREA (HALL 10)

GUIDED POSTER TOUR

For details on the posters presented during the tour, please refer to the online programme available at www.congress.eular.org or the EULAR 2019 Congress Mobile App.

Please note that you need to register to participate in a guided poster tour. The number of participants per tour is limited to 20. Registrations can be made at the poster tours & workshop desk, located in the registration area in Hall 2, on a ‘first-come-first-served’ basis the day of the poster tour.
**13:30 - 15:00 N105/N106**

**Health Professionals session**

**EXERCISE - MORE THAN A WONDERDRUG**

**Learning objectives:**
To know about recent findings about RMDs and exercise as treatment, to understand more about how to help make it happen

**Chair(s):**
Nele Caeyers (Belgium)
Cornelia van den Ende (Netherlands)

13:35 – Norelee Kennedy (Ireland)
*Best drug ever: exercise*

13:53 – ABSTRACT N° SP0059
Keegan Knittle (Finland)
*Helping people maintain physical activity*

14:11 – ABSTRACT N° SP0060
George Metsios (United Kingdom)
*Towards optimal intensity*

14:29 – Hazel L. Breland (United States of America)
*How to make it happen*

14:47 – ABSTRACT N° OP0206-HPR
Silje Halvorsen Sveaas (Norway)
H. Solveig Dagfinrud, M. Johansen, E. Pedersen, A. Bilberg
*Beneficial long-term effect of a supervised exercise program on physical activity level in patients with axial spondyloarthritis: 12 months follow-up of a multicenter randomized controlled trial*

**15:30 - 17:00 N105/N106**

**Health Professionals session**

**HOW NOT TO SMOKE LIKE A CHIMNEY**

**Learning objectives:**
- To obtain valuable knowledge about the consequences about smoking
- How to support people to stop smoking
- Understand more about how quitting feels

**Chair(s):**
Ross Wilkie (United Kingdom)
Andrea Marques (Portugal)

15:30 – ABSTRACT N° SP0088
Antonio Naranjo (Spain)
*How you know it is smart not to smoke like a chimney*

15:48 – ABSTRACT N° SP0089
Helen Harris (United Kingdom)
*Consequences of smoking cessation in rheumatology*

16:06 – ABSTRACT N° SP0090
Ida Kristiane Roelsgaard (Denmark)
*Intensive smoking cessation intervention*

16:24 – ABSTRACT N° SP0091
Marios Kouloumas (Cyprus)
*How to support yourself quitting smoking*
11:00 – ABSTRACT N° OP0272-HPR
Karin Niedermann (Switzerland)
A. Rausch, A. Meichtry, B. Walker, R. Braem, A. Ciurea
Fitness status of people with axial spondyloarthritis (AxSpA): first results after implementation of fitness assessments in AxSpA exercise groups

11:10 – ABSTRACT N° OP0273-HPR
Emilia Moreira (Brazil)
A. Jones, E. da Silva Lima, F. Jennings, J. Natour
Functional exercise for adults with chronic non-specific low back pain: a randomized controlled trial

11:20 – ABSTRACT N° OP0274-HPR
George E. Fragoulis (Greece)
L. Edelaar, V. Schäfer, J. Schoones, A. Iagnocco, T. Vliet Vlieland, E. Nikiphorou
Development of generic core competences of health professionals in rheumatology: a systematic literature review informing the 2018 EULAR recommendations

11:45 - 13:30
EXHIBITION, EULAR VILLAGE AND POSTER AREAS (HALL 10)
POSTER VIEWING AND LUNCH
For details on the EULAR 2019 posters presentations, please refer to the online programme available at www.congress.eular.org or the EULAR 2019 Congress Mobile App.

11:50 - 13:30
EPOSTER STATION 13
POSTER AREA (HALL 10)
GUIDED POSTER TOUR
For details on the posters presented during the tour, please refer to the online programme available at www.congress.eular.org or the EULAR 2019 Congress Mobile App.

Please note that you need to register to participate in a guided poster tour. The number of participants per tour is limited to 20. Registrations can be made at the poster tours & workshop desk, located in the registration area in Hall 2, on a ‘first-come-first-served’ basis the day of the poster tour.
13:30 - 15:00  N105/N106

Health Professionals session

TEENAGE LOOK IN THE MIRROR
(SEXUALITY AND BODY IMAGE MEETING HEALTH CARE)

Learning objectives:
- To learn about the importance of body image and sexuality in young patients
- To learn about how to treat them and meet them

Chair(s):
Jette Primdahl (Denmark)
Francoise Alliot Launois (France)

13:35 – Emily Matheson (United Kingdom)
Body image, what you talk about with your patients

14:00 – Jelena Vojinovic (Serbia)
Beauty is only skin deep

14:25 – Joachim Sagen (Norway)
You are not alone

14:50 – ABSTRACT N° OP0318-HPR
Hayley Mc Bain (United Kingdom)
M. Bezzant, A. Bosworth
Is psychological support reaching those in most need? A survey of people with rheumatoid arthritis and adults with juvenile idiopathic arthritis

13:30 - 15:00  N117/N118

EULAR Projects in Health Professionals

JEWELS IN THE CROWN OF HEALTH PROFESSIONALS

Learning objectives:
- To learn about recent findings from the EULAR Project on core competencies
- To know what different health professionals are especially brilliant at
- To ease multidisciplinary collaboration

Chair(s):
Heidi A. Zangi (Norway)
Hana Smucrova (Czech Republic)
HPR PROGRAMME
SATURDAY
15 JUNE 2019

09:00 - 10:30
N105/N106
Health Professionals session
ORTHOTIC TREATMENT: IS IT IN OR OUT?

Learning objectives:
To learn about the state of the art of orthotic devices within the field of Rheumatic and Musculoskeletal Diseases (RMDs) and gain knowledge about different types of orthoses to facilitate participation

Chair(s):
Valentin Ritschl (Austria)
Wilfred F. Peter (Netherlands)

09:05 – ABSTRACT N° SP0178
Martin van der Esch (Netherlands)
Lower limb orthoses

09:23 – ABSTRACT N° SP0179
Nina Osteras (Norway)
Orthoses and assistive devices for the hand

09:41 – ABSTRACT N° SP0180
Jim Woodburn (United Kingdom)
Foot orthoses in RA

09:59 – Michael Callaghan (United Kingdom)
The value of orthoses to help people move?

10:17 – ABSTRACT N° OP0337-HPR
Hilda Oliveira (Brazil)
A. Jones, F. Jennings, M. Vassalli, A. Rosenfeld, J. Natour
Effectiveness of customized insoles in patients with Morton’s neuroma: a randomized, controlled, double-blind clinical trial

12:00 - 13:30
N105/N106
Health Professionals session
BEHAVIOUR CHANGE IN FIBROMYALGIA

Learning objectives:
- To gain knowledge about recent developments in fibromyalgia
- To understand how to help people with fibromyalgia and understand better how it feels

Chair(s):
Andrea Domjan (Hungary)
Caroline Flurey (United Kingdom)

12:05 – ABSTRACT N° SP0204
Yeliz Prior (United Kingdom)
Case 1 presentation: Facilitating behaviour change in fibromyalgia: a case study from the UK

12:15 – Steven Carless (United Kingdom)
Case 1 discussant: Attending fibromyalgia self-management programme

12:45 – Johanna Vriezekolk (Netherlands)
Case 2 presentation: Increasing physical activity in fibromyalgia: a case study from the Netherlands

12:55
Open discussion with the audience

13:45 - 14:45
N105/N106
Health Professionals session
HPR HIGHLIGHT SESSION

Learning objectives:
- To sum up hot topics and take-home messages from the EULAR Congress 2019
- To know more about which abstracts to read on your way home

Chair(s):
Erika Mosor (Austria)
Jenny de la Torre-Aboki (Spain)

14:00 – Victoria Romero Pazos (Spain)
PARE highlights

14:15 – ABSTRACT N° SP0212
Daniel Aletaha (Austria)
Highlights from the scientific programme

14:30 – Nina Brodin (Sweden)
Highlights from the HPR programme

For details on the EULAR 2019 posters presentations, please refer to the online programme available at www.congress.eular.org or the EULAR 2019 Congress Mobile App.
PARE PROGRAMME
WEDNESDAY 12 JUNE 2019

13:00 - 14:00
HALL 6
EULAR 2019 OPENING PLENARY SESSION

14:15 - 15:45
N105/N106
PARE session
WHAT’S NEW: LATEST NEWS ON BIOLOGICAL TREATMENT

Learning objectives:
To inform about the latest news on biologicals and the latest advances in treatment

Chair(s):
Johannes W. J. Bijlsma (Netherlands)
Jürgen Clausen (Germany)

14:33 – ABSTRACT N° SP0014
Jonathan Kay (United States of America)
The latest news on biosimilars treatment

14:51 – Tore K. Kvien (Norway)
To switch or not to switch?

15:09 – ABSTRACT N° OP0012
Marion Pons (France)
S. Chevret, K. Briot, M. d’Agostino, C. Roux, M. Dougados, A. Moltó
Effectiveness of TNFI after a first switch is lower in patients with early axial spondyloarthritis: a longitudinal analysis of the DESIR cohort

15:27 – ABSTRACT N° OP0013-PARE
Laurence Carton (France)
C. Cardon, F. Alliot Launois, G. Chales, B. Liesse, L. Grange on behalf of PATIENT’s of AFLAR
AFLAR’s – French league against rheumatism – position and patient information action about biosimilar medicines in France

15:45 - 16:15
EXHIBITION AND EULAR VILLAGE (HALL 10)
COFFEE BREAK

16:15 - 17:45
N105/N106
PARE session
BRINGING DIGITAL HEALTH CARE SOLUTIONS TO PATIENTS

Learning objectives:
• To present digital health care solutions
• To outline measures to guarantee patient safety and data protection

Chair(s):
Simon Stones (United Kingdom)
Victoria Romero Pazos (Spain)

16:30 – ABSTRACT N° SP0027
Paul Studenic (Austria)
E-health redefines the relationship between patients with RMDs and health care professionals

16:45 – ABSTRACT N° SP0028
Aurelie Najm (France)
What should mobile health applications for RMD patients be like?

17:00 – ABSTRACT N° SP0029
Corinna Elling-Audersch (Germany)
RheVital: controlling your disease activity with an app

17:15 – ABSTRACT N° SP0030
Susanne Karlfeldt (Sweden)
Developing e-health solutions for patients with patients

17:30 – ABSTRACT N° OP0070-PARE
Tinja Saarela (Finland)
Geocaching as an encouragement for being active

17:45 - 18:45
EXHIBITION AND EULAR VILLAGE (HALL 10)
COFFEE BREAK

20:00 - 22:00
ESPLANADE (HALL 6)
NETWORKING PLATFORM
PARE PROGRAMME
THURSDAY
13 JUNE 2019

10:15 - 11:45  N115/N116
Joint Session PARE/PReS
FROM CHILD TO ADULT CARE - BREAKING DOWN THE BARRIERS OF TRANSITION

Learning objectives:
- To outline the barriers of transition and potential strategies to overcome them
- To discuss measures and instruments of how improvements can be achieved in daily practice

Chair(s):
Mirjam Kepic (Slovenia)
Berent J. Prakken (Netherlands)

10:20 – ABSTRACT N° SP0041
Stephen Ball (United Kingdom)
Tackling transition: the current landscape, and where we are heading

10:40 – ABSTRACT N° SP0042
Judy Ammerlaan (Netherlands)
From paediatric care to adult care – the needs of young people, and how healthcare professionals can facilitate optimal transition

11:00 – ABSTRACT N° SP0043
Indra Beer (Germany)
My ideal transition

11:20 – ABSTRACT N° OP0171-PARE
Cajsa Helin Hollstrand (Sweden)
K. Nordlund, M. Beermann
The Swedish young rheumatics report – the most urgent matters and the most promising development areas for young people with RMDs in Sweden

11:30 – ABSTRACT N° OP0172-PARE
Mirjam Kepic (Slovenia)
S. Stones, S. Angevare, S. Ainsworth, W. Costello, A. Gruss, A. van de Louw
Working together for children and families living with rheumatic and musculoskeletal diseases: the European network for children with arthritis (ENCA)

12:00 - 13:30  EPOSTER STATION 14
POSTER AREA (HALL 10)
GUIDED POSTER TOUR

For details on the posters presented during the tour, please refer to the online programme available at www.congress.eular.org or the EULAR 2019 Congress Mobile App.

Please note that you need to register to participate in a guided poster tour. The number of participants per tour is limited to 20. Registrations can be made at the poster tours & workshop desk, located in the registration area in Hall 2, on a ‘first-come-first-served’ basis the day of the poster tour.

Poster tour PARE
T14: PARE POSTER TOUR I

Chair(s):
Elsa Mateus (Portugal)
Kristijonas Mazuras (Lithuania)

ABSTRACTS N° PARE0001 - PARE0010

13:30 - 15:00  N115/N116
Joint Session PARE/PReS
TREATMENT IS MORE THAN DRUGS

Learning objectives:
- To show in how far inflammatory processes can be influenced by nutrition
- To outline the various elements of self-management
- To show the psychological impact of RMDs on patients and share support strategies

Chair(s):
Rikke H. Moe (Norway)
Boriana Boteva (Bulgaria)

13:35 – Christian Kessler (Germany)
How natural medicine can help with RMDs

13:53 – ABSTRACT N° SP0063
Elena Philippou (Cyprus)
Nutrition and rheumatic diseases

For details on the EULAR 2019 posters presentations, please refer to the online programme available at www.congress.eular.org or the EULAR 2019 Congress Mobile App.

11:45 - 13:30  EXHIBITION, EULAR VILLAGE AND POSTER AREAS (HALL 10)
POSTER VIEWING AND LUNCH
14:11 – ABSTRACT N° SP0064
Nicole Stefan-Schick (Germany)
Aktiv-hoch-R – combining exercise and fun

14:29 – Erik Taal (Netherlands)
The psychological impact of a rheumatic disease – what help is needed

14:47 – ABSTRACT N° OP0209-PARE
Tiina Hongisto (Finland)
Improving mental wellbeing - coaching peers to use toolkit for mind

15:00 - 15:30
EXHIBITION AND EULAR VILLAGE (HALL 10)
COFFEE BREAK

15:30 - 17:00
N115/N116
PARE session
SHOULD WE WORRY ABOUT ANYTHING ELSE - ALSO YOUNG PEOPLE HAVE MULTI-MORBIDITIES

Learning objectives:
- To raise awareness of common multi-morbidities and how to manage them
- To provide practical information on what to expect from HPs

Chair(s):
Ivan Padjen (Croatia)
Mitchell Silva (Belgium)

15:35 – ABSTRACT N° SP093
Kristien Van der Elst (Belgium)
Managing more than RMDs

15:55 – Raquel Campanilho-Marques (Portugal)
Watch out for more

16:15 – ABSTRACT N° SP094
Tanita-Christina Wilhelmer (Austria)
Diseases on sale - how I deal with all my conditions

16:35 – ABSTRACT N° OP0218-PARE
Wendy Gerhart (Canada)
G. Major, A. Gerhart, M. Walsh
Preventative medicine through identifying and addressing comorbidities of spondyloarthritis (SpA*) to improve patient outcomes through patient organization partnerships and allied healthcare outreach

16:45 – ABSTRACT N° OP0219-PARE
Jeanette Andersen (Denmark)
A. Cornet
Lupus Europe youth panel - what we learned from young people living with lupus

10:15 - 11:45
N115/N116
PARE ABSTRACT SESSION I

Chair(s):
Kate Betteridge (United Kingdom)
Kristijonas Mazuras (Lithuania)

10:15 – Ovidiu Constantinescu (Romania)
Edgar Stene Prize Winning Essay 2019: My ideal employer - work without barriers for people with RMDs

10:25 – ABSTRACT N° OP0283-PARE
Patricia Pennings MSc (Netherlands)
R. Verkaik, H. Kappen, H. Boeije
A Dutch research agenda developed by people with RMDs: what are the main problems people with RMDs face and what are their main wishes for research and development?

10:35 – ABSTRACT N° OP0284-PARE
Nenad Nedić (Serbia)
M. Lapčević
The influence of functional training and psycho-social support

10:45 – ABSTRACT N° OP0285-PARE
Jürgen Clausen (Germany)
R. Dietzel, G. Armbricht
Sarcopenia in patients with rheumatic diseases

10:55 – ABSTRACT N° OP0286-PARE
Elsa Mateus (Portugal)
C. Cavique, A. Cláudio, M. Carmo, M. Guerreiro, A. Cavaco
Developing a virtual assistant to promote education on osteoarthritis

11:05 – ABSTRACT N° OP0287-PARE
Alice Grosjean (Switzerland)
A. Vieira, C. Bouillot, J. Inga Díaz, M. Oosterbaan, J. Koelewijn-Tukker, I. Lesuisse on behalf of Sjögren Europe Task Force
Setting up a European federation of Sjögren’s syndrome patient associations: how we built up Sjögren Europe in less than one year
14 JUNE FRIDAY 14 JUNE 2019

PARE session
THE BENEFITS OF INVOLVING PATIENTS IN HEALTH TECHNOLOGY ASSESSMENT

Learning objectives:
- To explore the European HTA landscape and future developments
- To demonstrate the role of patients in the HTA process

Chair(s):
Marios Kouloumas (Cyprus)
Polina Pchelnikova (Russian Federation)

13:35 – ABSTRACT N° SP0127
Nathalie Bere (United Kingdom)
Patient engagement within the European Medicines Agency

14:00 – ABSTRACT N° SP0128
Virginia Seiffart (Germany)
The various roles of patient participation in HTA by the example of IQWIG

14:15 – ABSTRACT N° SP0129
Souzi Makri (Cyprus)
A patient’s view on patient involvement

14:30 – ABSTRACT N° OP0321-PARE
Mitchell Silva (Belgium)
N. Caeyers
A novel approach to reach patients for educational purposes - virtual conference ReumaNet

14:45 – ABSTRACT N° OP0322-PARE
Nique Lopuhaä (Netherlands)
M. Feith, S. De Jong
Grassroots campaign for Dutch RMD-friendly municipalities

15:00 - 15:30
EXHIBITION AND EULAR VILLAGE (HALL 10)
COFFEE BREAK
### PARE Session

**DON’T PANIC – ROUND TABLE DISCUSSION ON RISK PERCEPTION**

**Learning objectives:**
- How physicians/HPRs perceive the patients’ risk and communicate it
- Finding solutions to overcome the gap in risk perceptions

**Chair(s):**
Neil Betteridge (United Kingdom)

<table>
<thead>
<tr>
<th>Time</th>
<th>Abstract N°</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:35</td>
<td>SP0159</td>
<td>Timothy R. Radstake (Netherlands)</td>
</tr>
<tr>
<td>15:40</td>
<td></td>
<td>Filip van den Bosch (Belgium)</td>
</tr>
<tr>
<td>15:45</td>
<td></td>
<td>Codruta Zabalan (Romania)</td>
</tr>
<tr>
<td>15:50</td>
<td>SP0160</td>
<td>Ricardo Ferreira (Portugal)</td>
</tr>
<tr>
<td>15:55</td>
<td>SP0161</td>
<td>Simon Stones (United Kingdom)</td>
</tr>
<tr>
<td>16:00</td>
<td></td>
<td>Round Table discussion</td>
</tr>
<tr>
<td>16:40</td>
<td></td>
<td>Audience Q&amp;A</td>
</tr>
</tbody>
</table>

### PARE Session

**WORKSHOP: #CONNECTTODAY AND TOMORROW: THE CAMPAIGNING CONTINUES**

**Learning objectives:**
- To inspire delegates to implement awareness campaigns in their own country
- To share best practices of successful national awareness campaigns and Don’t Delay Connect Today activities

**Chair(s):**
Nele Caeyers (Belgium)
Marios Kouloumas (Cyprus)

<table>
<thead>
<tr>
<th>Time</th>
<th>Abstract N°</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:05</td>
<td>SP0184</td>
<td>Maria Ekroth (Finland)</td>
</tr>
<tr>
<td>09:10</td>
<td></td>
<td>Timothy R. Radstake (Netherlands)</td>
</tr>
<tr>
<td>09:15</td>
<td>SP0185</td>
<td>Jolanta Grygielska (Poland)</td>
</tr>
<tr>
<td>09:20</td>
<td>SP0186</td>
<td>Mary Vella (Malta)</td>
</tr>
<tr>
<td>09:25</td>
<td>OP0340-PARE</td>
<td>Louise Bennett (United Kingdom)</td>
</tr>
<tr>
<td>09:35</td>
<td>OP0341-PARE</td>
<td>Brian Lynch (Ireland)</td>
</tr>
</tbody>
</table>
13:15 – ABSTRACT N° OP0348-PARE
Santos Castañeda (Spain)
J. Negrón, M. Navarro Rubio, J. Baquero Ubeda, L. Carmona
Face arthritis: what situations affect emotionally the patient with rheumatoid arthritis and how to resolve them effectively

13:45 - 14:45 N115/N116
PARE session
PARE HIGHLIGHT SESSION

Learning objectives:
To provide an overview of learning and outcomes from the 2019 congress from health professionals and the scientific perspectives, and the first feedback from the PARE delegates

Chair(s):
Dieter Wiek (Germany)
Nele Caeyers (Belgium)

12:00 - 13:30 N115/N116
PARE session
RESTLESS LIVES: MANAGING FATIGUE, SLEEP AND PAIN

Learning objectives:
- To tackle fatigue as a misunderstood problem of RMD patients with great impact on their lives
- To create awareness for possible relations between dyssomnia, pain, fatigue in RMDs patients
- To discuss coping techniques to improve sleep quality

Chair(s):
Tanita-Christina Wilhelmer (Austria)
Louise Bennett (United Kingdom)

12:05 – ABSTRACT N° SP0206
Tanja Lange (Germany)
Links between sleep quality and immunity in RMDs

12:25 – ABSTRACT N° SP0207
Eivind Skarpsno (Norway)
Physical activity, chronic musculoskeletal pain and insomnia

12:45 – ABSTRACT N° SP0208
Savia de Souza (United Kingdom)
Understanding the impact of pain, sleep and fatigue on patients lives

13:05 – ABSTRACT N° OP0347-PARE
Lene Mandrup Thomsen (Denmark)
The influence of pain on sleep problems, mental health and use of strong painkillers among patients with arthritis
# EULAR RELATED MEETINGS

By invitation only

## WEDNESDAY, 12 JUNE 2019

<table>
<thead>
<tr>
<th>Start - End</th>
<th>Room</th>
<th>Meeting Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 10:00</td>
<td>A10.05</td>
<td>Clinical Rheumatology – Editorial Board meeting</td>
</tr>
<tr>
<td>08:00 - 09:00</td>
<td>A10.01</td>
<td>ESCCA Business meeting</td>
</tr>
<tr>
<td>08:00 - 09:30</td>
<td>A09.13</td>
<td>ESCIR Business meeting</td>
</tr>
<tr>
<td>08:00 - 12:00</td>
<td>A09.08</td>
<td>PReS Council meeting</td>
</tr>
<tr>
<td>09:00 - 10:00</td>
<td>A10.01</td>
<td>EULAR Recommendations/PTC Methodologists Annual Update meeting</td>
</tr>
<tr>
<td>09:00 - 12:30</td>
<td>S16</td>
<td>IM2 project RTCure meeting – RTCure risk RA registry</td>
</tr>
<tr>
<td>09:00 - 11:00</td>
<td>A10.03</td>
<td>Rheumatology Editorial Board meeting</td>
</tr>
<tr>
<td>10:30 - 12:30</td>
<td>S12/14</td>
<td>GRAPPA Adjacent to EULAR</td>
</tr>
<tr>
<td>11:00 - 12:30</td>
<td>S15</td>
<td>Ankylosing Spondylitis International Federation meeting</td>
</tr>
<tr>
<td>16:00 - 17:00</td>
<td>A10.12</td>
<td>EULAR - UEMS</td>
</tr>
<tr>
<td>18:00 - 20:00</td>
<td>A09.08</td>
<td>ERN ReCONNET meeting</td>
</tr>
<tr>
<td>18:00 - 20:00</td>
<td>A10.07</td>
<td>EULAR Recommendations for the use and interpretation of laboratory diagnostic tests for the management of systemic autoimmune rheumatic diseases</td>
</tr>
<tr>
<td>18:00 - 20:00</td>
<td>A10.03</td>
<td>EuroSpA Collaboration Network, Scientific committee meeting</td>
</tr>
<tr>
<td>18:00 - 20:00</td>
<td>S15</td>
<td>Journal of Scleroderma and Related Disorders Editorial Board meeting</td>
</tr>
<tr>
<td>18:00 - 19:30</td>
<td>A10.08</td>
<td>OMERACT Facilitation working group</td>
</tr>
<tr>
<td>18:00 - 19:00</td>
<td>A10.02</td>
<td>Paediatric Rheumatology Editorial Board meeting</td>
</tr>
<tr>
<td>18:00 - 20:00</td>
<td>A09.13</td>
<td>SC PARE Business meeting</td>
</tr>
<tr>
<td>18:00 - 20:00</td>
<td>A10.01</td>
<td>SLEuro Executive Committee meeting</td>
</tr>
</tbody>
</table>

## THURSDAY, 13 JUNE 2019

<table>
<thead>
<tr>
<th>Start - End</th>
<th>Room</th>
<th>Meeting Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 10:00</td>
<td>S17</td>
<td>ARD and RMD Open Journal Editorial Board meeting</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>A10.04</td>
<td>ATACC-RA Steering Committee meeting</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>S12/14</td>
<td>EMEUNET Business meeting</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>A10.02</td>
<td>EULAR Public Affairs Group meeting</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>S15</td>
<td>EULAR Standing Committee for Musculoskeletal Imaging Business meeting</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>A09.13</td>
<td>EULAR study group for Collaborative Research</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>S16</td>
<td>EULAR Synovitis study group meeting</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>A10.03</td>
<td>HPR Standing Committee</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>A10.05</td>
<td>MyoNet study group</td>
</tr>
<tr>
<td>08:00 - 09:30</td>
<td>A10.08</td>
<td>OMERACT Imaging working group</td>
</tr>
</tbody>
</table>
### THURSDAY, 13 JUNE 2019

<table>
<thead>
<tr>
<th>Start - End</th>
<th>Room</th>
<th>Meeting Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 10:00</td>
<td>A09.08</td>
<td>PReS working Parties</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>A10.07</td>
<td>PReS working Parties</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>N113/N114</td>
<td>PReS working Parties</td>
</tr>
<tr>
<td>08:00 - 09:00</td>
<td>A10.06</td>
<td>Task Force meeting classification criteria for hand osteoarthritis</td>
</tr>
<tr>
<td>09:00 - 10:00</td>
<td>A10.01</td>
<td>ENCA Board meeting</td>
</tr>
<tr>
<td>09:00 - 10:00</td>
<td>A10.06</td>
<td>EULAR study group on Therapeutic Drug Monitoring</td>
</tr>
<tr>
<td>12:00 - 13:00</td>
<td>A10.08</td>
<td>PReS Task Force meetings</td>
</tr>
<tr>
<td>17:00 - 19:00</td>
<td>A09.13</td>
<td>AGORA Board meeting</td>
</tr>
<tr>
<td>17:00 - 18:00</td>
<td>A10.07</td>
<td>Annual business meeting Nonpharm Connective Tissue study group</td>
</tr>
<tr>
<td>18:00 - 19:00</td>
<td>S16</td>
<td>Annual business meeting STOPE study group</td>
</tr>
<tr>
<td>17:00 - 19:00</td>
<td>A10.13</td>
<td>BMC Series Editorial Board Meeting</td>
</tr>
<tr>
<td>17:00 - 19:00</td>
<td>A10.01</td>
<td>EMEUNET Country Liaison meeting</td>
</tr>
<tr>
<td>17:00 - 19:00</td>
<td>S17</td>
<td>ESCEHSR EULAR Business meeting</td>
</tr>
<tr>
<td>17:00 - 18:30</td>
<td>A10.03</td>
<td>ESCET Business meeting</td>
</tr>
<tr>
<td>17:00 - 19:00</td>
<td>A10.05</td>
<td>EULAR study group on Microcirculation in Rheumatic Diseases</td>
</tr>
<tr>
<td>17:00 - 18:00</td>
<td>S16</td>
<td>EULAR Systemic Lupus Erythematosus (SLE) study group meeting</td>
</tr>
<tr>
<td>17:00 - 19:00</td>
<td>S12/S14</td>
<td>EUSTAR Board meeting</td>
</tr>
<tr>
<td>17:00 - 18:30</td>
<td>A10.08</td>
<td>OMERACT Methods working group</td>
</tr>
<tr>
<td>17:00 - 18:30</td>
<td>N113/N114</td>
<td>PReS Annual General meeting</td>
</tr>
<tr>
<td>17:00 - 18:00</td>
<td>A10.02</td>
<td>ATACC-RA Business meeting</td>
</tr>
<tr>
<td>17:00 - 19:00</td>
<td>S15</td>
<td>The NECESSITY IMI project on Sjögren’s syndrome</td>
</tr>
<tr>
<td>17:00 - 19:00</td>
<td>A09.08</td>
<td>Tight COntrol in SpondyloArthritis (TICOSPA): Investigators meeting</td>
</tr>
<tr>
<td>18:00 - 19:00</td>
<td>A10.07</td>
<td>Annual Business meeting foot and ankle study group</td>
</tr>
<tr>
<td>18:00 - 19:00</td>
<td>A10.02</td>
<td>Annual Business meeting WORK Study group</td>
</tr>
</tbody>
</table>

### FRIDAY, 14 JUNE 2019

<table>
<thead>
<tr>
<th>Start - End</th>
<th>Room</th>
<th>Meeting Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 10:00</td>
<td>A10.03</td>
<td>HarmonicSS PAG – Synergies for the future</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>S15</td>
<td>EMEUNET Mentor Mentee meetings</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>A10.02</td>
<td>EULAR PARE CEO Exchange Interim meeting</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>A10.01</td>
<td>EULAR Standing Committee for Health Professionals in Rheumatology (ESCHPR) Business meeting</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>S17</td>
<td>EULAR study group ESSENTIAL Sjögren’s Syndrome</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>A10.07</td>
<td>EULAR study group for Risk Factors for RA</td>
</tr>
<tr>
<td>08:00 - 09:30</td>
<td>A10.08</td>
<td>OMERACT Disease working group</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>S16</td>
<td>PReS Working parties</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>A09.08</td>
<td>PReS Working parties</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>S12/S14</td>
<td>PReS Working parties</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>A10.05</td>
<td>Reliability Exercise of World Scleroderma Foundation (WSF) Skin Ulcer Definition</td>
</tr>
</tbody>
</table>
## FRIDAY, 14 JUNE 2019

<table>
<thead>
<tr>
<th>Start - End</th>
<th>Room</th>
<th>Meeting Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 10:00</td>
<td>A10.06</td>
<td>Scandinavian Society for Rheumatology - Board meeting 2019</td>
</tr>
<tr>
<td>09:00 - 10:00</td>
<td>A09.13</td>
<td>French College of Rheumatology Teachers meeting</td>
</tr>
<tr>
<td>12:00 - 13:00</td>
<td>A10.08</td>
<td>PReS Task Force meetings</td>
</tr>
<tr>
<td>17:00 - 19:00</td>
<td>A10.03</td>
<td>ACTion Council for advancing patient inclusion in rheumatology research</td>
</tr>
<tr>
<td>17:00 - 18:00</td>
<td>A10.07</td>
<td>Annual business meeting Physical activity &amp; Exercise study group</td>
</tr>
<tr>
<td>17:00 - 19:00</td>
<td>S12/S14</td>
<td>ASAS meeting</td>
</tr>
<tr>
<td>17:00 - 19:00</td>
<td>S15</td>
<td>EAPPA Patient Advocacy meeting</td>
</tr>
<tr>
<td>17:00 - 19:00</td>
<td>A9.08</td>
<td>EULAR Epidemiology study group (former RODS)</td>
</tr>
<tr>
<td>17:00 - 19:00</td>
<td>A10.01</td>
<td>First General Assembly Sjögren’s Europe</td>
</tr>
<tr>
<td>17:00 - 19:00</td>
<td>A09.13</td>
<td>IMPACT-RMD Consortium: Implementation of Physical Activity in Clinical Practice meeting</td>
</tr>
<tr>
<td>17:00 - 18:30</td>
<td>A10.08</td>
<td>OMERACT Technical Advisory group</td>
</tr>
<tr>
<td>17:00 - 18:30</td>
<td>S16</td>
<td>PReS working Party Chairs meeting</td>
</tr>
<tr>
<td>17:00 - 19:00</td>
<td>S17</td>
<td>PreS/PRINTO Annual meeting</td>
</tr>
<tr>
<td>17:00 - 19:00</td>
<td>A10.13</td>
<td>PReS Health Professionals</td>
</tr>
<tr>
<td>17:00 - 19:00</td>
<td>A10.06</td>
<td>UEMS Section of Rheumatology meeting</td>
</tr>
<tr>
<td>17:15 - 18:30</td>
<td>A10.02</td>
<td>START_Molecular stratification of patients with giant cell arteritis to tailor glucocorticoid and tocilizumab therapy funded by FOREUM</td>
</tr>
<tr>
<td>18:00 - 19:00</td>
<td>A10.07</td>
<td>EULAR Nurse Research and Strategy group (REST)</td>
</tr>
<tr>
<td>18:00 - 19:00</td>
<td>A10.05</td>
<td>Arthritis Research &amp; Therapy Editorial Board meeting (Section Editors and Associate Editors)</td>
</tr>
</tbody>
</table>

## SATURDAY, 15 JUNE 2019

<table>
<thead>
<tr>
<th>Start - End</th>
<th>Room</th>
<th>Meeting Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00 - 10:30</td>
<td>A09.08</td>
<td>EULAR Standing Committee of Paediatric Rheumatology</td>
</tr>
<tr>
<td>10:45 - 11:45</td>
<td>A10.08</td>
<td>PReS Task Force meetings</td>
</tr>
<tr>
<td>15:00 - 16:30</td>
<td>A10.08</td>
<td>OMERACT Consensus working group</td>
</tr>
<tr>
<td>13:00 - 14:30</td>
<td>N113/N114</td>
<td>EULAR School Advisory Board meeting</td>
</tr>
</tbody>
</table>
A NEW SUBCUTANEOUS FORM OF INFliximab IS ON THE HORIZON

FOR MORE INFORMATION, PLEASE VISIT BOOTH 12

Advanced Therapeutics within Everyone’s Reach

Celltrion Healthcare is committed to delivering innovative and affordable medications to promote patients’ access to advanced therapies.
ABBVIE

1 North Waukegan Road
North Chicago, IL 60064
United States

AbbVie is a global, research and development-based biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook or LinkedIn.

ACCORD HEALTHCARE

Sage House, 319 Pinner Road
HA14HF North Harrow, Middlesex
United Kingdom

www.accord-healthcare.com

Part of the Intas Group, Accord Healthcare is a global pharmaceutical company that operates in over 85 countries worldwide and with broad experience in the development and manufacturing of added value generics, specialty and biopharmaceutical products. Our mission is to improve access to high quality, affordable and innovative healthcare around the world.

Accord is one of the largest suppliers of generic treatments in the UK and across Europe. With over 1000 scientists, Accord Healthcare is a proud innovator and uses its Research and Development capabilities to deliver new therapies through its Added Value Product (AVP) portfolio with the aim of improving the patient experience of healthcare.

Accord has an extensive development team with an in-depth understanding of complex medicines and biosimilars. Added Value Products deliver enhancements over standard medicines, either through new therapeutic uses, better efficacy, safety or tolerability profiles, or in the way the medicines are delivered, with the aim of making the healthcare experience better for both patients and healthcare professionals.

The Accord AVP portfolio focuses on five essential therapeutic areas: Oncology & Haematology, Critical Care, CNS, Autoimmune, Fertility.

AGORA

Avda. Novo Mesoir 2, 4A
CP15190 A Coruña
Spain
www.agora-platform.eu

Agora is a platform of organizations representing people with Rheumatic and Musculoskeletal Diseases in Southern Europe, which has been active since 2011. Agora aims to raise awareness, create a stronger voice for people with RMDs and motivate them to become more active and conscious through its various projects and initiatives. Furthermore, Agora aims in assisting the foundation and development towards user-led organizations of people with RMDs in Southern Europe, as well as promote supportive attitudes towards RMDs and enable patients to live independently and participate fully in society.
ALPINION MEDICAL SYSTEMS CO., LTD

77, Heungan-daero 81beon-gil, Dongan-gu
14117 Anyang-si, Gyeonggi-do
South of Korea
www.alpinion.com

“We are Ultrasound Professionals”

ALPINION Medical Systems was established in 2007 as a true value innovator in the imaging technology field for: diagnostic ultrasound system, therapeutic ultrasound system (HIFU: High Intensity Focused Ultrasound), and advanced piezoelectric and single crystal transducer technologies.

ALPINION exerts its best to widen the market access with quality products as well. Our belief comes from the belief that the qualified medical technology must be shared by all. Initiating from ultrasound business, we have a vision to expand our business scopes vertically and horizontally to deliver real values to customers. We ALPINION, a value innovator in medical industry, are aiming to become the most reliable and trusted company that also offers sustainable values to our customers.

American College of Rheumatology (ACR)

2200 Lake Boulevard, NE
Atlanta, GA 30319
United States
www.rheumatology.org

The American College of Rheumatology (ACR) is an ethically-driven, professional membership organization committed to improving the care of patients with rheumatic disease and advancing the rheumatology subspecialty. Founded in 1934, we are a not-for-profit, global medical society that serves over 9,600 physicians, health professionals, and scientists worldwide.

The ACR supports its members by providing meaningful education, research, advocacy, and practice support.

Amgen

Suurstoffi 22
P.O Box 94
6343 Rotkreuz
Switzerland
www.amgen.com

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit www.amgen.com and follow us on www.twitter.com/amgen

ANKYLOSING SPONDYLITIS INTERNATIONAL FEDERATION (ASIF)

27 Old Gloucester Street
London WC1N 3AX
United Kingdom
www.asif.info

ASIF is a global umbrella organisation established to increase public awareness of Axial Spondyloarthritis and to disseminate knowledge of the disease around the world.

Axial Spondyloarthritis (AxSpA of which AS, Ankylosing Spondylitis is one branch) is a rheumatic inflammatory auto-immune disease primarily affecting the spine and sacroiliac joints, it is also called ‘Morbus Bechterew’ in some European countries.

ASIF has 42 Patient Organisation members 38 countries. Our most recent members are Israel and the Ukraine. We aim to share the most up-to-date knowledge of the disease around the world.

ASIF leads on World AS Day which falls on the first Saturday in May each year.

The Asia Pacific League of Associations for Rheumatology (APLAR), was established in 1963 in Sydney. What began with four founding nations has now increased in scale to include 32 national rheumatology association members. The geographical region covered by APLAR reaches from New Zealand in Oceania to Jordan in the Middle East. The APLAR network of national associations represents 25,000+ rheumatologists.
APLAR strives to propagate and consolidate rheumatology endeavours in the Asia Pacific region. APLAR publishes the APLAR Journal of Rheumatology and organises annually the preeminent English-only rheumatology congress in the Asia-Pacific region. The APLAR congress and journal brings together world-class research and thought-leadership from rheumatologists, internists, orthopaedic surgeons, clinical immunologists, physiatrists, physical and occupational therapists, paediatricians and researchers from allied disciplines on a common platform that facilitates deliberations on all aspects of musculoskeletal diseases.

For more information visit: www.aplar.org

BOOTH N° V22

ASSOCIATION OF WOMEN IN RHEUMATOLOGY

2125 Valleygate Drive
Fayetteville, NC 28304
United States
www.awirgroup.org

Our mission is to promote the science and practice of rheumatology, foster the advancement and education of women in rheumatology, and advocate access to the highest quality health care, and management of patients with rheumatic diseases.

BOOTH N° 43

AURINIA PHARMACEUTICALS INC.

1203 – 4464 Markham Street
V8Z 7X8 Victoria,
British Colombia
Canada
www.auriniapharma.com

Aurinia is a clinical stage biopharmaceutical company focused on developing and commercializing therapies in disease areas of high unmet medical need. We are currently developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN) and focal segmental glomerulosclerosis (FSGS). Additionally, we are advancing voclosporin ophthalmic solution (VOS), a topical formulaion, for the treatment of dry eye syndrome (DES).

BOOTH N° 32

BIOGEN

Neuhofstrasse 30
6340 Baar
Switzerland
www.biogen.com

At Biogen, our mission is clear: we are pioneers in neuroscience. As one of the world’s first global biotechnology companies, Biogen has the leading portfolio to treat multiple sclerosis; introduced the first and only approved treatment for spinal muscular atrophy; and invests in advancing care in neuroscience. Biogen also manufactures and commercializes three anti-TNF biosimilars of advanced biologics in Europe. More than 115’000 patients have been treated with one of those biosimilars, contributing to expanding access to patients and the future of healthcare sustainability having generated estimated healthcare cost savings of >800 million Euro annually across Europe.

BOOTH N° V06

BMJ

BMA House
Tavistock Square
London WC1H 9JP
United Kingdom
www.bmj.com/company

Annals of the Rheumatic Diseases (ARD), a collaboration between EULAR and BMJ, is the #1 journal in rheumatology (with impact factor 12.350) and the flagship in the Essential Rheumatology suite. It’s supported by RMD Open, an open access journal expanding on rheumatic & musculoskeletal diseases, and Lupus Science & Medicine – the 1st lupus-specific open access journal.

The package also comprises of the EULAR Textbook on Rheumatic Diseases, the EULAR textbook on Paediatric Rheumatology, the EULAR textbook on Systemic Sclerosis & the EULAR Textbook on Musculoskeletal Ultrasound in Rheumatology.

BOOTH N° 65

BOEHRINGER INGELHEIM

Binger Strasse 173
55216 Ingelheim am Rhein
Germany
www.boehringer-ingelheim.com

Improving the health of humans and animals is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com
with our industry-leading patient support and access programs. Together, these aspects form the core of our commitment to patients worldwide. For more information, visit www.celgene.com

BOOTH N° 01 + 02

CELLTRION HEALTHCARE CO., LTD.

4F, 19, Academy-ro 51
Yeonsu-gu
22014 Incheon
South Korea
www.celltrionhealthcare.com

Celltrion Healthcare is a global biopharmaceutical company which conducts worldwide marketing and distribution of Celltrion, Inc.’s biosimilars and biologics. Celltrion Healthcare endeavors to offer high-quality, cost-effective and advanced therapeutics for patients in rheumatology, gastroenterology, immunology and oncology.

Celltrion Healthcare has three products approved by EMA: infliximab biosimilar which is the world’s first biosimilar mAb medication for treatment of a number of autoimmune diseases, rituximab biosimilar for treatment of lymphoma, leukemia and autoimmune diseases, and trastuzumab biosimilar for treatment of breast cancer and metastatic gastric cancer.

BOOTH N° 24

BRISTOL-MYERS SQUIBB

3401 Princeton Pike
Lawrenceville,
NJ 08648
United States
www.bms.com

Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing and delivering innovative medicines for patients with serious diseases. Our people are focused on helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience and fibrosis. Through the Bristol-Myers Squibb Foundation, we promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions, giving new hope to some of the world’s most vulnerable people. Each day, our employees around the world work together for patients – it drives everything we do.

BOOTH N° V08

BRITISH SOCIETY FOR RHEUMATOLOGY

Bride House,
18-20 Bride Lane
EC4Y 8EE, London
United Kingdom
www.rheumatology.org.uk

British Society for Rheumatology is the leading UK membership society for rheumatology and musculoskeletal care health professionals. We are member driven, supporting them in delivering the best care, at all stages of the care pathway, improving the lives of children and adults with rheumatic and musculoskeletal disease.

Visit us at stand V08 to learn more about the society, including our conferences, courses, the benefits of membership and our official journals, Rheumatology and Rheumatology Advances in Practice.

Tweet us @Rheumatologyuk and @RheumJnl

BOOTH N° 69

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY

Via Santa Maria 31
56126 Pisa
Italy
www.clinexprheumatol.org

Clinical and Experimental Rheumatology is an international journal focused on the latest developments in rheumatology. Every issue contains original articles, editorials, reviews, case reports and articles on paediatric rheumatology, aimed at updating readers in this complex and growing field.

The journal also publishes regular annual supplements on monothematic topics, facing the most new and controversial aspects in rheumatology, such as Contemporary Advances in Clinical Rheumatology, Vasculitis, Behçet’s disease and Autoinflammatory conditions, Systemic Sclerosis, Fibromyalgia and Sjogren’s syndrome.

BOOTH N° 60 + 84

CELGENE CORPORATION

86 Morris Avenue
NJ 07901, Summit
United States
www.celgene.com

Celgene Corporation (Nasdaq:CELG) is a global biopharmaceutical company that is helping healthcare providers turn incurable cancers into chronic, manageable diseases, as well as manage serious inflammatory conditions through innovative therapies. This dedication to medical progress goes hand-in-hand
ERN RECONNET

Via Roma 67
56126 Pisa
Italy
www.reconnet.ern-net.eu

ERN ReCONNET is the European Reference Network on Rare and Complex Connective Tissue and Musculoskeletal Diseases. ERN ReCONNET involves 26 HCPs from 8 different EU countries and covers: Systemic Sclerosis, Mixed Connective Tissue Diseases, Idiopathic Inflammatory Myopathies, Anti-phospholipid syndrome, Undifferentiated Connective Tissue Diseases, IgG4 related diseases, Relapsing Polychondritis, SLE, Sjögren Syndrome, Ehlers-Danlos Syndromes. ERN ReCONNET aims to improve early diagnosis, patient management and empowerment, care delivery and virtual discussion of clinical cases across Europe.

ELI LILLY AND COMPANY

Lilly Corporate Center
Indianapolis, IN 46285
United States
www.lilly.com

Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. Founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com.

ELMEUNET

Seestrasse 240
8802 Kilchberg
Switzerland
www.eular.org

EMEUNET, the EMerging EULAR NETwork, is an EULAR network of young clinicians and researchers in rheumatology that promotes education and research, developing existing and new collaborations and integrating younger members within all EULAR activities. The main objectives of EMEUNET include the development of a European-wide network of young emerging rheumatologist and rheumatology-oriented researchers, enabling continued excellence in research and promoting and facilitating a comprehensive higher educational platform for all rheumatology trainees across Europe.
to reduce the burden of RMDs on individuals and society and to improve the treatment, prevention and rehabilitation of RMDs. To this end, EULAR fosters excellence in education and research in the field of rheumatology. It promotes the translation of research advances into daily care and fights for the recognition of the needs of people with RMDs by the EU institutions through advocacy action.

EULAR STUDY GROUPS

Seestrasse 240
8802 Kilchberg
Switzerland
www.eular.org

EULAR Study Groups are focus groups; they are located within the sphere of a EULAR Standing Committee that has received EULAR endorsement. These groups independently promote activities/scientific networking without financial support from EULAR. They are open to anyone who is interested in the specific field, and who brings background knowledge in that subject area.

EUROPEAN LUPUS SOCIETY

Via G. Ripamonti 129
20141 Milan
Italy
www.sleuro.org

The European Lupus Society is a non-profit association and pursues the following goals:

• Building up a community of clinicians and researchers interested in SLE with special focus to engage younger physicians in the field
• Promoting and coordinating the organisation of research and educational meetings on SLE and related syndromes
• Promoting equal access to best standard of care for SLE patients across Europe
• Facilitating research projects and clinical trials in SLE

Visit our booth V18 and learn more about the society. Follow us on Facebook & Twitter @SLEuroSociety

EUROPEAN NETWORK FOR CHILDREN WITH ARTHRITIS (ENCA)

www.enca.org

The European Network for Children with Arthritis (ENCA) is a network of national associations working to support children and young people with paediatric rheumatic diseases, and their families. ENCA works closely with the Paediatric Rheumatology European Society (PReS), demonstrating the importance of integrating professional and lived experiences to meet the needs of patients and their families. Together with PReS, ENCA also founded World Young Rheumatic Diseases Day (WORD Day), a new international awareness day launched on March 18th, 2019.
BOOTH N° 80

FIDIA FARMACEUTICI SPA

Via Ponte della Fabbrica 3/A
35031 Abano Terme
Italy

www.fidiapharma.com

Italian developer and leading manufacturer (FDA-approved) of innovative products based on hyaluronic acid (700+ patents), in joint care, wound care, ophthalmology, aesthetics and autologous biological therapy. Products are available in 100 countries, through subsidiaries and partners.

BOOTH N° C4

FOREUM FOUNDATION FOR RESEARCH IN RHEUMATOLOGY

Seestrasse 240
8802 Kilchberg
Switzerland

www.foreum.org

FOREUM Foundation for Research in Rheumatology is an independent non-profit organisation, devoted to promote research in rheumatic and musculoskeletal diseases (RMDs). FOREUM seeks to initiate research of the highest quality and periodically announces calls for research proposals.

FOREUM seeks to raise funds from donors sharing FOREUM’s vision and goals: recognising that research and innovation in this field are crucial for improving prevention and management of RMDs and, hence, the living, working and socio-economic conditions of the more than 120 million people in Europe afflicted by RMDs.

BOOTH N° V26

FOUNDATION ARTHROSE IN PARTNERSHIP WITH MCI BRUSSELS OFFICE

Boulevard du Souverain 280
1160 Brussels
Belgium

www.fondationarthrose.org

The Osteoarthritis Foundation is a private foundation established in July 2015 by health professionals, scientists but also patients. The Foundation is a nonprofit organization mainly devoted to fighting osteoarthritis without neither distinction on grounds of language, region or race nor political, philosophical or religious considerations through educational, scientific, philanthropic and humanitarian initiatives.

Our event: World Osteoarthritis Day Intergenerational Event (WODIES)

the objective of this public and free-of-charge event is to raise awareness and showcase means prevention,
innovations and new advances in treatments around the condition and how it can affect us all. Participants will meet patients, researchers, associations and health care professionals to learn more about osteoarthritis and related illnesses.

**BOOTH N° 19**

**FRESENIUS KABI**

Else-Kröner-Straße 1
61352 Bad Homburg
Germany
www.fresenius-kabi.com

Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. Product portfolio: I.V. generic drugs, infusion therapies, clinical nutrition products and medical devices for administering these products. Fresenius Kabi offers products for collection and processing of blood components and for therapeutic treatment of patient blood by apheresis systems. The company also develops biosimilars with a focus on autoimmune diseases and oncology.

**BOOTH N° V12**

**GISEA/OEG**

Via degli Antichi Pastifici, 17
70056 Molfetta (BA)
Italy
www.gisea.eu

The GISEA registry is an independent database that was established by the Italian Group for the Study of Early Arthritis (GISEA) in 2008, funded by the Italian Association of Rheumatic Patients (ANMAR - ONLUS). In line with the network’s epidemiological strategy, the initial protocol was designed to collect long-term follow-up data concerning patients with rheumatic diseases treated with biological agents in order to investigate the real-world characteristics in terms of disease activity, comorbidities and survival on treatment.

**BOOTH N° 79**

**GRIFOLS**

Av. de la Generalitat 153-159
08174 Sant Cugat. Barcelona
Spain
www.grifols.com

An experienced and trusted partner, Grifols advances patient care with innovative diagnostic solutions that improve disease detection and management and simplify laboratory operations. Today, we empower customers with diagnostic products that span the healthcare continuum – from prevention, screening, diagnosis, and prognosis to disease and treatment monitoring.

Our comprehensive transfusion medicine portfolio is designed to support safety from donation through transfusion. We also offer a growing portfolio of specialized clinical diagnostics designed to detect and monitor treatment of infectious, autoimmune, and neurodegenerative diseases.

With more than 75 years of history, Grifols remains committed to exploring new technologies and developing the breakthrough diagnostic solutions of tomorrow, for healthcare professionals working to ensure the safest and most effective care for patients.

**BOOTH N° 45**

**GILEAD SCIENCE, INC**

333 Lakeside Drive
CA 94404, Foster City
United States
www.gilead.com

Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need. Gilead’s Inflammation R&D team is focused on improving therapeutic options for the treatment of multiple conditions, including Rheumatoid Arthritis and other rheumatic diseases. We are pursuing a comprehensive clinical trial program evaluating novel agents with the goal of advancing the care of patients suffering from inflammatory conditions.
**BOOTH N° 15**

HEMICS

Kanaaldijk 29
5683 CR Best
The Netherlands
www.hemics.com

Hemics is a medical device company active in the field of inflammatory joint diseases. Hemics developed the HandScan, a new non-invasive optical imaging device. It supports rheumatologists in objective assessment of inflammatory status in patients with Rheumatoid Arthritis (RA). The technique is time saving, non-invasive, safe and operator independent, perfectly fitting the workflow in the rheumatologist’s office.

**BOOTH N° 39**

GUNA S.P.A.

Via Palmanova 71
20132 Milan
Italy
www.guna.com

Guna S.p.a. was founded in Milan, Italy, in 1983, with the aim of developing and manufacturing innovative, safe, and effective medicines, with a strong focus on research. Ethical principles are equally important for Guna. The company’s ultimate mission is to spread a human-centered Medicine, in harmony with nature. Today, with 300 employees and distributors in over 30 countries on 4 continents, Guna is one of the world’s most intriguing companies in the field of low dose medicines, medical devices, nutraceuticals and dermocosmeceuticals.

**BOOTH N° 58**

JANSSEN

Turnhoutseweg 30
2340 Beerse
Belgium
www.janssen.com/emea

About the Janssen Pharmaceutical Companies of Johnson & Johnson

At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.

Learn more at www.janssen.com/emea/. Follow us on Twitter: @JanssenEMEA. Janssen Research & Development, LLC is one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
BOOTH N° V05

JAPAN COLLEGE OF RHEUMATOLOGY

2-9-6 Hamamatsuchō, Minato-ku 105-0013 Tokyo Japan
www.eng.ryumachi-jp.com

The Japan College of Rheumatology (JCR) holds the Annual Scientific Meeting every spring and provides a platform for rheumatologists and other specialists to share knowledge on the prevention and treatment of rheumatic diseases. The Meeting welcomes thousands of rheumatologists and researchers from Japan, as well as from the rest of the world.

The JCR publishes its official journal, Modern Rheumatology and Modern Rheumatology Case Reports, which provides information on the latest developments in rheumatic diseases.

BOOTH N° 83

LABORATOIRES EXPANSCIENCE

1 Place des Saisons 92048 Paris La Défense Cedex France
www.expanscience.com

In 2018, Expanscience – a French independently-owned pharmaceutical and dermo-cosmetics laboratory – generated a turnover of €260.9 M, 66.8% of which out of France and employed 1107 people. For more than 60 years, it has built up a solid international reputation as an innovator and a specialist in skin and the treatment of osteoarthritis. Its products are sold in more than 100 countries. It also develops and sells organic active ingredients to be used in cosmetics, worldwide. Expanscience is a “B Corp”, a label awarded to companies that have a positive impact on society and the environment.

BOOTH N° 11

KONICA MINOLTA BUSINESS SOLUTIONS EUROPE GMBH- HEALTHCARE DIVISION

Hoogoorddreef 9 1101 BA Amsterdam The Netherlands www.konicaminolta.eu/healthcare

Since the founding in 1873, Konica Minolta has always focused on innovation and continuously strives to create products and services that bring real benefit to our customers’ lives. Our healthcare portfolio includes Digital Flat Panel Detectors, Integrated and Retrofit X-ray rooms, Ultrasound, CR, Laser Imagers, and Medical Film.

BOOTH N° 78

LCA PHARMACEUTICAL

9, Allée Prométhée 28000 Chartres France
www.lca-pharma.com

LCA Pharmaceutical is expert in design and manufacture of viscoelastic medical devices with sodium hyaluronate. All of our products have a high molecular weight and high concentration and we offer a wide range of products as follow:

- Treatment of 3 weekly intra-articular injections (40mg-2mL);
- Single injection for knee osteoarthritis (75mg/3mL);
- Single injection for hip osteoarthritis (75mg/3mL);
- Small joints injection (20mg/mL);

Two other innovative products are also available with the first combination of chondroitin sulfate and sodium hyaluronate indicated for treatment of osteoarthritis: pain relief and joint function recovery.

- Single injection (60mg NaHA + 60mg CS / 3mL);
- Treatment of 3 weekly intra-articular injections (40mg NaHA + 40mg CS / 2mL)

BOOTH N° 73

LA LETTRE DU RHUMATOLOGUE

44 rue de Prony 75017 Paris France
www.edimark.fr/lettre-rhumatologue

La Lettre du Rhumatologue is a French monthly publication specialized in rheumatology, which editor in chief is Pr. Bernard Combe.

The publication is released in 4.000 copies issued 10 times a year.
LG CHEM

LG Twin Towers
128 Yeoui-daero,
Yeoungdeungpo-gu
07336 Seoul
Korea

www.lgchem.com

LG Chem, the leading chemical company, has strengthened market dominance starting from the Basic Materials & Chemicals business to Energy Solution, IT and Electronic Materials and Life Science area.

Life Sciences Company focuses at four major healthcare services including pharmaceutical, vaccine, medical device and biopharmaceutical.

Based on its own fundamental technology, LG Chem expanded its pipeline to include biosimilars in order to improve patient access to highly effective biological products.

LG Chem will continue to improve the quality of life by providing innovative portfolio of medicines across the world.

LUPUS EUROPE

St. James House
27-43 Eastern Road
RM1 3NH Romford, Essex
United Kingdom

www.lupus-europe.org

Since 1989, LUPUS EUROPE is the umbrella organisation federating national lupus self-help organisations all over Europe. Today it unites 26 members from 24 countries in Europe and represents more than 30,000 patients.

Our Vision is “a fulfilling life for all people with lupus in Europe until we have reached a world without lupus”.

Our Mission is to be the voice of lupus in Europe and to empower the national organisations for people living with lupus. We pursue this through 3 fundamental Strategic Drivers:

1. People with lupus in Europe participate in and benefit from research in lupus
2. Enthusiasm and empowerment to member organizations.
3. LUPUS EUROPE is heard & acting

For more information or collaboration with LUPUS EUROPE, please contact secretariat@lupus-europe.org

MEDAC

Theaterstrasse 6
22880 Wedel
Germany

www.medac.de

medac Gesellschaft für klinische Spezialpräparate mbH

medac is a privately held pharmaceutical company with a growing pharmaceutical and diagnostics business. Medicinal products from medac support doctors and patients throughout the world in overcoming acute and chronic diseases in the indication areas of oncology, haematology, urology and autoimmune disorders. In addition, medac develops and markets special diagnostic test systems.

Since 1970 medac has been committed to unifying therapeutic and diagnostic areas under one roof.

You can find further information about the company and its products at www.medac.de.
COMPANY PROFILES

BOOTH N° 14

MEDI GMBH & CO. KG

Medicusstr. 1
95448 Bayreuth
Germany
www.medi.de

Founded in Germany in 1951, medi GmbH & Co. KG has become one of the world’s leading manufacturers of medical aids. Our orthopaedic assortment consists of supports and braces for the treatment of joint conditions and injuries for all parts of the human body such as back, shoulder/spine, hip, knee, ankle, wrist, elbow or foot. Our full range of premium-quality products are the first choice of many healthcare professionals all across the globe especially for indications like osteoarthritis, osteoporosis, cruciate ligament rupture, post-operative shoulder immobilization and much else besides.

BOOTH N° 26B

MYLAN

Building 4, Trident Place, Mosquito Way
AL10 9UL Hatfield, Hertfordshire
United Kingdom
www.mylan.com

Mylan is a global biopharmaceutical company committed to setting new standards in healthcare. With a 20-strong biosimilar portfolio under development across multiple therapy areas, including rheumatology, we continue to support patients living with chronic inflammatory conditions.

Mylan’s belief is that 7 billion people across the globe deserve access to high-quality, affordable medicines and we are committed to helping patients get the treatment they need, delivering better health for a better world.

BOOTH N° V11

MEDITERRANEAN JOURNAL OF RHEUMATOLOGY

387 Mesogheion Ave.
15343 Aghia Paraskevi
Greece
www.mjrheum.org

The Mediterranean Journal of Rheumatology (MJR) is an international peer-reviewed platinum open-access online journal which publishes evidence-based original clinical and translational papers in all fields of rheumatic diseases: its international audience is concentrated in the Mediterranean and neighbouring countries.

The MJR publishes original articles, reviews, guidelines, editorials, case reports, case-based reviews, images in rheumatology, expert interviews and meeting reports, and serves the global rheumatology community, as reflected by its contents and its Advisory and Editorial boards.

BOOTH N° 09

NORDIC PHARMA

254 Boulevard St Germain
75007 Paris
France
www.nordicpharmagroup.com

The Nordic Group is a privately owned, fully integrated, pharmaceutical company with a direct presence in 17 countries. Nordic’s strategy is to focus on creating Added Value for specific unmet medical needs and for the true benefit of the patient and the healthcare stakeholders. With the patient in mind, Nordic has developed products which offer more autonomy and comfort in rheumatic disease management.

BOOTH N° 54

MENARINI GROUP

Via Sette Santi 1
50131 Firenze
Italy
www.menarini.com

Menarini Group is an Italian pharmaceutical company, 12th in Europe out of 5,255 companies, and 36th company in the world out of 20,862 companies, with a turnover of more than 3,6 billion Euro and more than 17,000 employees. Menarini Group has always pursued two strategic objectives: Research and Internationalisation and it is present in the most important therapeutic areas including products for cardiology, rheumatology, gastroenterology, pneumology/antibiotics, diabetology, anti-inflammatory agents/analgesics. With 16 production sites and 6 Research and Development centers, Menarini Group has a strong presence throughout Europe and Asia, Africa, Central and South America. Menarini’s products are available in 136 countries worldwide. For further information please visit www.menarini.com

BOOTH N° 05 + 22

NOVARTIS PHARMA AG

Fabrikstrasse 2
4056 Basel
Switzerland
www.novartis.com

Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 1 billion people globally and we are finding innovative ways to expand access to our latest treatments. Find out more at www.novartis.com.
The OAFI is an independent non-profit OA patient organisation with the aim of working on the prevention and treatment of osteoarthritis (OA), along with the improvement of the quality of life of patients.

OAFI organises educational and social programmes focused on prevention at risk groups such as seniors, sportspeople and women over 45 in order to raise awareness. Also, OAFI promotes the development of new therapies for better treatment of OA and the improvement in quality of life of patients.

The Pan-American League of Associations for Rheumatology (PANLAR) brings together the scientific associations for Rheumatology, health professionals related to rheumatic diseases and rheumatic patient organizations in the Americas. It mission is to stimulate, promote and support research, prevention, treatment and rehabilitation of rheumatic diseases. PANLAR Congresses are the most important events in rheumatology in the Region, being the essential meeting place for rheumatologists and other specialists. In 2020 the Congress will take place in Miami (USA) from 2 to 5 May at the Hyatt Regency.

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products.
Highly accurate university research made it possible to create REGENFLEX PROJECT®, a system developed specifically for degenerative and trauma-caused diseases. Our line helps to: Prevent Degeneration, Diminish Inflammation and Pain, Restore Elasticity and Improve the Mobility of Articulations, Tendons and Muscles. Regenflex Project Products: Regenflex, Regenflex Starter, Regenflex Bio-Plus, Regenflex Gel.

For more information visit our website.

BOOTH N° V27

RHEUMATOLOGY NEWS

9381 Judicial Drive
97 Century Drive
Parsippany NJ 07054
United States
www.mdedge.com/rheumatologynews

Rheumatology News is the leading independent newspaper for the practicing rheumatologist. With specialty-focused news and insightful commentary--in a clear, concise, accessible format--Rheumatology News keeps busy rheumatologists up-to-date on clinical advances that impact their daily practice of medicine. Rheumatology News is published 18X/year and circulates to nearly 8,000 rheumatologists, selected primary care physicians, and NP and PA specialists in rheumatology. All articles are researched, written, and produced by professional medical journalists. Rheumatology News can be found online at www.mdedge.com/rheumatologynews.

BOOTH N° 04

SAMUMED, LLC

9381 Judicial Drive
92121 San Diego, CA
United States
www.samumed.com

Samumed is a leading drug development platform company for tissue-level regeneration. Based on novel discoveries in small molecule-based Wnt pathway modulation, Samumed is currently conducting numerous clinical trials in regenerative medicine, degenerative diseases and oncology.

BOOTH N° 21

SANDOZ INTERNATIONAL GMBH

Industriestrasse 25
83607 Holzkirchen
Germany
www.sandoz.com

Sandoz is a global leader in generic pharmaceuticals and biosimilars. As a division of the Novartis Group,
our purpose is to discover new ways to improve and extend people’s lives. We contribute to society’s ability to support growing healthcare needs by pioneering novel approaches to help people around the world access high-quality medicine. Our broad portfolio, covering all major therapeutic areas, accounted for 2018 sales of USD 9.9 billion. Sandoz is headquartered in Holzkirchen, in Germany’s Greater Munich area.

BOOTH N° 62
SANOFI GENZYME

50 Binney St
MA 02142 Cambridge
United States
www.sanofi.com

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Sanofi, Empowering Life

BOOTH N° 68
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY

INCUBA Navitas, 6th floor,
Inge Lehmanns Gade 10
8000 Aarhus
Denmark
www.scandjrheumatol.se

The Scandinavian Journal of Rheumatology publishes international, peer reviewed, high quality, original reports of clinical and basic research, as well as editorials, review articles and informative case reports covering all aspects of rheumatology.

2017 Impact Factor: 3.021.

Subscriptions include print, online access, and supplements to the Journal.

Published since 1955 by the Scandinavian Society for Rheumatology.

Detailed information is available on our website www.scandjrheumatol.se

BOOTH N° 86
SOBI

At Sobi, we are transforming the lives of people affected by rare diseases. As a specialised international biopharmaceutical company, we provide sustainable access to innovative therapies in the areas of haematology, immunology and specialty care. We bring something rare to rare diseases – a belief in the strength of focus, the power of agility and the potential of the people we are dedicated to serving. The hard work and dedication of our approximately 1050 employees around the globe has been instrumental in our success across Europe, North America, the Middle East, Russia and North Africa, leading to total revenues of SEK 9.1 billion in 2018. Sobi’s share (STO:SOBI) is listed on Nasdaq Stockholm. You can find more information about Sobi at www.sobi.com.

BOOTH N° V10
SOCIETÀ ITALIANA DI REUMATOLOGIA - SIR

Via Turati 40
20121 Milano
Italy
www.reumatologia.it

The Italian Society for Rheumatology (SIR) aim is to develop projects in the field of the rheumatological scientific research, training and health care. SIR encourages any initiative, intended to assist rheumatic patients and to prevent and treat rheumatological diseases.

In these last years, SIR has realized activity of prevention and early diagnosis of rheumatological diseases among the population through campaigns like #ReumaDays - SIR meets the citizens, that allowed SIR to meet the citizens in the Italian squares in order to increase their knowledge on these diseases, and Rheumatological diseases? No thanks! A campaign that allowed rheumatologist specialists to hold special prevention classes, in over 65s in senior centers, to prevent diseases and control their symptoms.
**BOOTH N° 71**

**SPRINGER NATURE**

Tiergartenstr. 17
69121 Heidelberg
Germany
www.springernature.com

Springer Nature is one of the world’s leading global research, educational and professional publishers, home to an array of respected and trusted brands providing quality content through a range of innovative products and services. Springer Nature is the world’s largest academic book publisher, publisher of the world’s most influential journals and a pioneer in the field of open research. The company numbers almost 13,000 staff in over 50 countries and has a turnover of approximately EUR 1.5 billion. Springer Nature was formed in 2015 through the merger of Nature Publishing Group, Palgrave Macmillan, Macmillan Education and Springer Science+Business Media.

Find out more: www.springernature.com

**BOOTH N° V09**

**THE PARTNERSHIP OF TURKISH LEAGUE AGAINST RHEUMATISM (TLAR) AND TURKISH SOCIETY FOR RHEUMATOLOGY (TRD)**

Sisli
34394 Istanbul
Turkey
www.romatoloji.org
www.trasd.org.tr

TURKISH LEAGUE AGAINST RHEUMATISM was established in 1947 by physical medicine and rehabilitation specialists. TLAR became a member of EULAR in 1947, organized the 4th EULAR Congress in Istanbul in 1959. Main activities are Archives of Rheumatology, Congress & Imaging School, School of YoungTLAR, TLAR-Online, e-book, and TLAR-Network projects.

TURKISH SOCIETY FOR RHEUMATOLOGY was founded in 1993 as the representative scientific society for rheumatologists based on internal medicine. It currently has 344 members representing the vast majority of certified rheumatologists in Turkey.

EULAR representation is being carried on by the partnership of TRD and TLAR since 2014.

**BOOTH N° 67**

**THE JOURNAL OF RHEUMATOLOGY PUBLISHING COMPANY LTD.**

365 Bloor Street East, Suite 901
M4W 3L4 Toronto,
Ontario
Canada
www.jrheum.org

The Journal of Rheumatology is an independent, international medical journal founded by Dr. Metro Ogryzlo in 1974. The Journal publishes timely, original, peer-reviewed research articles on clinical subjects in rheumatology and related fields. Accessible in print and online, The Journal of Rheumatology is dedicated to impacting practicing physicians worldwide.

**BOOTH N° 85**

**TILMAN**

Zi Sud, 15
5377 Baillonville
Belgium
www.tilman.be

Tilman is a Belgian pharmaceutical laboratory developing, manufacturing and distributing plant-based medicines for 60 years.

By using industrial equipment in compliance with GMP (Good Manufacturing Practices) pharmaceutical standards, Tilman is one of the most modern phytotherapy laboratories in Europe. Scientific rigour and compliance with the strictest of standards both contribute to the design of medicines with NOC (Notice of Compliance) and a full range of safe and effective products distributed by health professionals in numerous countries all over the world.

**BOOTH N° V17**

**THE LUPUS ACADEMY**

Maasdjik 409
4264 AS Veen
Netherlands
www.lupus-academy.org

The Lupus Academy is a long-term initiative committed to improving patient outcomes in SLE and allied diseases. By providing a highly interactive educational forum, the Lupus Academy is dedicated to sharing best clinical practice through the dissemination and discussion of cutting edge scientific and clinical research.
BOOTH N° 61

UCB

Allée de la Recherche 60
1070 Brussels
Belgium
www.ucb.com

UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people and create value for specific patient populations living with severe diseases in rheumatology, dermatology and neurology.

BOOTH N° V16

WORLD SCLERODERMA FOUNDATION

Elisabethenstrasse 3
4051 Basel
Switzerland
www.worldsclerofound.org

The World Scleroderma Foundation is dedicated to initiating and supporting research in scleroderma in all its aspects in all regions of the world. It is also committed to improving the quality of life for scleroderma sufferers and their families.

To facilitates patient oriented research both independently and in collaboration with other existing organizations and learned societies working in this field.

Support is in the form of project grants, expert advisory panels and knowledge dissemination platforms.

Patient groups as well as allied health professionals will be an integral part of the WSF structure. WSF will liaison with society, industry and government in an open and dynamic fashion. Importantly we will remain independent of regional, political or industrial pressures.

BOOTH N° V25

WCO-IOF-ESCEO 2020 – WORLD CONGRESS ON OSTEOPOROSIS, OSTEOARTHRITIS AND MUSCULOSKELETAL DISEASES

Barcelona International Convention Centre
Plaça de Willy Brandt, 11-14
08019 Barcelona
Spain
www.wco-iof-esceo.org

This worldwide known event is jointly organized every year by the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF). This year, the 2019 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases took place in Paris, France from April 04-07, 2019 and gathered 4000 delegates. This new edition of WCO-IOF-ESCEO aims to continue facilitating effective debate on unresolved clinical and therapeutic dilemmas, supported by evidence-based medicine and expert opinions, on issues in the fields of Osteoporosis, Osteoarthritis, Rheumatoid Arthritis, Muscles, Pain and Joint Diseases.

BOOTH N° 37

XIRALITE GMBH

Robert-Koch-Platz 4
10115 Berlin
Germany
www.xiralite.com

Xiralite GmbH is a medical device company located in the heart of Berlin, Germany. We offer innovative concepts for the diagnosis and therapy of several diseases, thereby providing significantly improved benefits to our customers. Xiralite’s key technology is based on fluorescence optical imaging and our medical imaging devices enable diagnostics of microcirculation disorders. Through this unique technology, alterations of the microcirculation become visible allowing for the identification of different types of rheumatic diseases. Our devices are installed worldwide in clinical practices, hospitals and research institutions.

BOOTH N° 72

WISEPRESS LTD

15 Lyon Road, Merton
SW19 2RL London
United Kingdom
www.wisepress.com

Wisepress.com, Europe’s leading conference bookseller, has a complete range of books and journals relevant to the themes of the meeting. Books can be purchased at the stand or, if you would rather not carry them, posted to you – Wisepress will deliver worldwide. In addition to attending 200 conferences per year, Wisepress has a comprehensive medical and scientific bookshop online with great offers.
ACKNOWLEDGEMENTS

The EULAR 2019 Organising Committee wishes to express its gratitude to all satellite symposia organisers and exhibitors as well as to the following partners:

AbbVie
Mobile app

Gilead
Mobile device support centre
Mobile charging stations

GlaxoSmithKline (GSK)
Mobile charging stations

Novartis
Itinerary planner

Regeneron
Cyber cafés

Pfizer
WIFI
Pocket programme
Fine-tuning the treatment of PsA: focus on the IL-23 pathway

Speakers
Lluís Puig
Georg Schett (Scientific Committee)
Stefan Siebert
Peter Taylor (Scientific Committee)

Thursday 13 June 2019
Rooms N101/N102, IFEMA
Madrid, Spain

Learning objectives
After this meeting, participants should be able to:

- Analyse the impact of targeting the IL-12/23 pathway on psoriatic arthritis management
- Discuss current unmet needs in the management of patients with psoriatic arthritis in the clinic
- Describe the IL-23 pathway and the rationale for targeting this pathway in psoriatic arthritis
- Discuss the recent clinical and mechanistic data on targeting the IL-23 pathway in psoriatic arthritis and consider the impact of these data on clinical practice
- Consider the recent data on targeting the IL-23 pathway in psoriasis and how this relates to the treatment of psoriatic arthritis

Programme

17:30–17:35 Welcome and introduction
Georg Schett (Germany)
Peter Taylor (UK)

17:35–17:50 The promise and delivery of targeting the IL-12/23 pathway
Stefan Siebert (UK)

17:50–18:05 Focus on the IL-23 pathway
Georg Schett (Germany)

18:05–18:20 Targeting IL-23: what could this mean in practice?
Peter Taylor (UK)

18:20–18:35 Experience of targeting IL-23 in dermatology
Lluís Puig (Spain)

18:35–18:55 Panel discussion and Q&A
All faculty

18:55–19:00 Conclusions and close of meeting
Georg Schett (Germany)
Peter Taylor (UK)
## EXHIBITOR’S LIST

**Status as of 1 May 2019**

<table>
<thead>
<tr>
<th>COMPANY</th>
<th>STAND N°</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>COMMERCIAL EXHIBITION – EXHIBITORS’ LIST</strong></td>
<td></td>
</tr>
<tr>
<td>ABBVIE</td>
<td>56 + 59</td>
</tr>
<tr>
<td>ACCORD HEALTHCARE</td>
<td>12</td>
</tr>
<tr>
<td>ALPINION MEDICAL SYSTEMS</td>
<td>77</td>
</tr>
<tr>
<td>AMGEN</td>
<td>08 + 20</td>
</tr>
<tr>
<td>AURINIA PHARMACEUTICALS</td>
<td>43</td>
</tr>
<tr>
<td>BIODEN</td>
<td>32</td>
</tr>
<tr>
<td>BOEHRINGER INGELHEIM</td>
<td>65</td>
</tr>
<tr>
<td>BRISTOL-MYERS SQUIBB</td>
<td>24</td>
</tr>
<tr>
<td>CELGENE</td>
<td>60 + 84</td>
</tr>
<tr>
<td>CELLTRION HEALTHCARE</td>
<td>01 + 02</td>
</tr>
<tr>
<td>CLINICAL AND EXPERIMENTAL RHEUMATOLOGY</td>
<td>69</td>
</tr>
<tr>
<td>CYTOKINE SIGNALLING FORUM</td>
<td>70</td>
</tr>
<tr>
<td>ELLILY AND COMPANY</td>
<td>55</td>
</tr>
<tr>
<td>ESAOTE</td>
<td>75</td>
</tr>
<tr>
<td>EXPANSIENCE</td>
<td>83</td>
</tr>
<tr>
<td>FIDIA FARMACEUTICI</td>
<td>80</td>
</tr>
<tr>
<td>FRESENIUS KABI</td>
<td>19</td>
</tr>
<tr>
<td>GEDEON RICHTER</td>
<td>44</td>
</tr>
<tr>
<td>GILEAD SCIENCE</td>
<td>45</td>
</tr>
<tr>
<td>GLAXOSMITHKLINE</td>
<td>30 + 31</td>
</tr>
<tr>
<td>GRIFOLS</td>
<td>79</td>
</tr>
<tr>
<td>GRUNENTHAL GMBH</td>
<td>41</td>
</tr>
<tr>
<td>HEMICS</td>
<td>39</td>
</tr>
<tr>
<td>IBSA INSTITUT BIOCHIMIQUE</td>
<td>15</td>
</tr>
<tr>
<td>IDAZA SCIENTIFIC</td>
<td>76</td>
</tr>
<tr>
<td>JANSEN</td>
<td>58</td>
</tr>
<tr>
<td>KONICA MINOLTA BUSINESS SOLUTIONS EUROPE</td>
<td>11</td>
</tr>
<tr>
<td>LA LETTRE DU RHUMATOLOGUE</td>
<td>73</td>
</tr>
<tr>
<td>LCA PHARMACEUTICALS</td>
<td>78</td>
</tr>
<tr>
<td>LG CHEM</td>
<td>07</td>
</tr>
<tr>
<td>MEDAC</td>
<td>06</td>
</tr>
<tr>
<td>MEI</td>
<td>14</td>
</tr>
<tr>
<td>MENARINI GROUP</td>
<td>54</td>
</tr>
<tr>
<td>MSD</td>
<td>03 + 25</td>
</tr>
<tr>
<td>MYLAN</td>
<td>26B</td>
</tr>
<tr>
<td>NIKON</td>
<td>76</td>
</tr>
<tr>
<td>NORDIC GROUP</td>
<td>09</td>
</tr>
<tr>
<td>NOVARTIS</td>
<td>05 + 22</td>
</tr>
<tr>
<td>PFEIFFER</td>
<td>26A + 28</td>
</tr>
<tr>
<td>REGENERON</td>
<td>62</td>
</tr>
<tr>
<td>REGEN LAB</td>
<td>13</td>
</tr>
<tr>
<td>REGENYAL LABORATORIES</td>
<td>38</td>
</tr>
<tr>
<td>ROCHE</td>
<td>27A + 27B</td>
</tr>
<tr>
<td>SAMUMED</td>
<td>04</td>
</tr>
<tr>
<td>SANDOZ</td>
<td>21</td>
</tr>
<tr>
<td>SANDOZ GENZYME</td>
<td>62</td>
</tr>
<tr>
<td>SCANDINAVIAN JOURNAL OF RHEUMATOLOGY</td>
<td>68</td>
</tr>
<tr>
<td>SOBI</td>
<td>86</td>
</tr>
<tr>
<td>SPRINGER NATURE</td>
<td>71</td>
</tr>
<tr>
<td><strong>EULAR VILLAGE – EXHIBITORS’ LIST</strong></td>
<td></td>
</tr>
<tr>
<td>AGORA</td>
<td>V14</td>
</tr>
<tr>
<td>AMERICAN COLLEGE OF RHEUMATOLOGY</td>
<td>V01 + V02</td>
</tr>
<tr>
<td>ANKLYOSING SPONDYLITIS FEDERATION (ASIF)</td>
<td>V13</td>
</tr>
<tr>
<td>APLAR 2020</td>
<td>V04</td>
</tr>
<tr>
<td>ASSOCIATION OF WOMEN IN RHEUMATOLOGY</td>
<td>V22</td>
</tr>
<tr>
<td>BMJ</td>
<td>V06</td>
</tr>
<tr>
<td>BRITISH SOCIETY FOR RHEUMATOLOGY</td>
<td>V08</td>
</tr>
<tr>
<td>EMEUNET</td>
<td>C3</td>
</tr>
<tr>
<td>ERN RECONNECT</td>
<td>V11</td>
</tr>
<tr>
<td>EULAR SOCIAL MEDIA WALL</td>
<td>C7</td>
</tr>
<tr>
<td>EULAR EXECUTIVE SECRETARIAT</td>
<td>C1</td>
</tr>
<tr>
<td>EULAR HEALTH PROFESSIONALS IN RHEUMATOLOGY</td>
<td>C6</td>
</tr>
<tr>
<td>EULAR PARE</td>
<td>C5</td>
</tr>
<tr>
<td>EULAR STUDY GROUPS</td>
<td>V28</td>
</tr>
<tr>
<td>EUROPEAN LUPUS SOCIETY</td>
<td>V18</td>
</tr>
<tr>
<td>EUROPEAN NETWORK FOR CHILDREN WITH ARTHRITIS (ENCA)</td>
<td>V07</td>
</tr>
<tr>
<td>EUROPEAN PAIN FOUNDATION (EFIC)</td>
<td>V23</td>
</tr>
<tr>
<td>FORUM FOUNDATION FOR RESEARCH IN RHEUMATOLOGY</td>
<td>C4</td>
</tr>
<tr>
<td>FOUNDATION ARTHROSE</td>
<td>V26</td>
</tr>
<tr>
<td>GISEA/DEC</td>
<td>V12</td>
</tr>
<tr>
<td>HELP POINT FOR SMARTPHONES AND MOBILE DEVICES - EYELED</td>
<td>V25</td>
</tr>
<tr>
<td>JAPAN COLLEGE OF RHEUMATOLOGY</td>
<td>V05</td>
</tr>
<tr>
<td>LUPUS EUROPE</td>
<td>V15</td>
</tr>
<tr>
<td>MEDITERRANEAN JOURNAL OF RHEUMATOLOGY</td>
<td>V11</td>
</tr>
<tr>
<td>OSTEOARTHRITIS FOUNDATION INTERNATIONAL (OAFI)</td>
<td>V26</td>
</tr>
<tr>
<td>PANLAR 2020</td>
<td>V03</td>
</tr>
<tr>
<td>PAIN - PALDIATRIC RHEUMATOLOGY</td>
<td>C2</td>
</tr>
<tr>
<td>REDO-REUMATOLOGHE DONNE</td>
<td>V21</td>
</tr>
<tr>
<td>RHEUMATOLOG NEWS</td>
<td>V27</td>
</tr>
<tr>
<td>SOCIETTA ITALIANA DI REUMATOLOGIA - SIR</td>
<td>V10</td>
</tr>
<tr>
<td>THE LUPUS ACADEMY</td>
<td>V17</td>
</tr>
<tr>
<td>TURKISH LEAGUE AGAINST RHEUMATISM (TLAR)</td>
<td>V09</td>
</tr>
<tr>
<td>TURKISH SOCIETY FOR RHEUMATOLOGY (TRD)</td>
<td>V09</td>
</tr>
<tr>
<td>WCO-IoF-ESCO 2020</td>
<td>V25</td>
</tr>
<tr>
<td>WORLD SCLERODERMA FOUNDATION</td>
<td>V16</td>
</tr>
</tbody>
</table>
**CONGRESS VENUE OVERVIEW PLAN**

**NORTH CONVENTION CENTRE**
- Overflow area
- Related meetings N113/N114
- Sessions N101–N116

**SOUTH CONVENTION CENTRE**
- South auditorium
- Related meetings S12–S17
- Prayer rooms S21–S22

**HALL 9**
- Hospitality suites
- Overflow area

**MEZZANINE 9**
- Hospitality suites A09.01–A09.14
- Related meetings A09.08 & A09.13

**HALL 7**
- Sessions

**MEZZANINE 7**
- First aid
- Hospitality suites A07.01 & A07.02
- Speakers preview, Rooms S01–S03

**NORTH CONVENTION CENTRE**
- Overflow area
- Related meetings N113/N114
- Sessions N101–N116

**SOUTH CONVENTION CENTRE**
- South auditorium
- Related meetings S12–S17
- Prayer rooms S21–S22
HALL 10
Catering, exhibition, posters
Cyber café
EULAR Village

MEZZANINE 10
Related meetings A10.01–A10.15

HALL 8
Sessions

Press centre

HALL 6
Sessions
MEZZANINE 6
Hospitality suite A06.01
Press conferences A06.02

HALL 2
Cloakroom
Registration area
In response to injury or inflammation, cells at the site of pain release a number of biochemical mediators, including prostaglandins, cytokines, and a neurotrophin called nerve growth factor (NGF). NGF plays a key role in driving chronic pain. Excess NGF can change the way nerves signal pain. In the periphery, excess NGF can lead to peripheral and central sensitization, amplifying pain signaling and heightening the perception of pain.

Discover more about what fuels the JAK-STAT pathway

At Gilead, we’re investigating more about the JAK-STAT pathway in proinflammatory cytokine signaling and clinical manifestations of rheumatoid arthritis.

Fuel your knowledge now at learnJAKSTAT.com

Please visit us at EULAR 2019 – BOOTH #45
DISCOVER HOW TO CHANGE THE COURSE OF SEROPOSITIVE RA

VISIT US AT BOOTH 24

Bristol-Myers Squibb

© 2019 Bristol-Myers Squibb Company
427EP1901412 Mar/19